Metal complexes

Abstract
The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, comprising these metal complexes.
Description
RELATED APPLICATIONS

This application is a national stage entry, filed pursuant to 35 U.S.C. § 371, of PCT/EP2015/000043, filed Jan. 13, 2015, which claims the benefit of European Patent Application No. 14000417.7, filed Feb. 5, 2014, which is incorporated herein by reference in its entirety.


The present invention relates to metal complexes which are suitable for use as emitters in organic electroluminescent devices.


In organic electroluminescent devices (OLEDs), the emitting materials employed are increasingly organometallic complexes which exhibit phosphorescence instead of fluorescence (M. A. Baldo et al., Appl. Phys. Left. 1999, 75, 4-6). For quantum-mechanical reasons, an up to four-fold increase in energy and power efficiency is possible using organometallic compounds as phosphorescence emitters. In general, there is still a need for improvement, in particular with respect to efficiency, operating voltage and lifetime, in the case of OLEDs which exhibit triplet emission. This applies, in particular, to OLEDs which emit in the relatively short-wave region, i.e. green and in particular blue.


According to the prior art, the triplet emitters employed in phosphorescent OLEDs are, in particular, iridium and platinum complexes. The iridium complexes employed are, in particular, bis- and tris-ortho-metallated complexes with aromatic ligands, where the ligands are bonded to the metal via a negatively charged carbon atom and a neutral nitrogen atom or via a negatively charged carbon atom and a neutral carbene carbon atom. Examples of such complexes are tris(phenylpyridyl)iridium(III) and derivatives thereof (for example in accordance with US 2002/0034656 or WO 2010/027583). The literature discloses a multiplicity of related ligands and iridium or platinum complexes, such as, for example, complexes with 1- or 3-phenylisoquinoline ligands (for example in accordance with EP 1348711 or WO 2011/028473), with 2-phenylquinolines (for example in accordance with WO 2002/064700 or WO 2006/095943) or with phenylcarbenes (for example in accordance with WO 2005/019373). Platinum complexes are known, for example, from WO 2003/040257. Although good results have already been achieved with metal complexes of this type, further improvements are still desirable here.


The object of the present invention is therefore the provision of novel metal complexes which are suitable as emitters for use in OLEDs. In particular, the object is to provide emitters which exhibit improved properties with respect to efficiency, operating voltage, lifetime, colour coordinates and/or colour purity, i.e. width of the emission band. It is furthermore an object of the present invention to provide metal complexes which have increased oxidation stability, in particular in solution. This is therefore desirable, in particular, since it is known that ortho-metallated iridium complexes in particular are good sensitisers for the generation of singlet oxygen, which is in turn a very aggressive oxidant which is able to attack the metal complexes themselves.


Furthermore, there is still a need for improvement in the case of many metal complexes in accordance with the prior art with respect to the sublimability and solubility. In particular, tris-ortho-metallated complexes frequently have high sublimation temperatures, owing to the high molecular weight, which may in turn result in thermal decomposition during sublimation. In addition, a multiplicity of metal complexes in accordance with the prior art are not sufficiently soluble to enable processing from solution from common organic solvents.


Surprisingly, it has been found that certain metal chelate complexes, described in greater detail below, which contain at least one condensed-on aliphatic 6- or 7-membered ring without benzylic protons achieve this object and are very suitable for use in an organic electroluminescent device. The present invention therefore relates to these metal complexes and to organic electroluminescent devices which comprise these complexes.


EP 1191613 discloses iridium complexes which contain an aliphatic ring condensed onto the coordinating phenyl group of a phenylpyridine ligand. However, the complexes disclosed in this document have high oxidation sensitivity, in particular in solution, meaning that further improvements would be desirable here. Furthermore, improvements with respect to the properties of the complexes on use in an organic electroluminescent device are also still desirable here.


US 2007/0231600 discloses iridium complexes which contain a six-membered ring condensed onto each of the two coordinating aryl or heteroaryl groups. However, compounds containing purely aliphatic six-membered rings without benzylic protons are not disclosed.


K. H. Lee et al. (Journal of Nanoscience and Nanotechnology 2009, 9, 7099-7103) disclose a heteroleptic Ir(ppy)2(acac) complex which contains a condensed-on tetramethylcyclohexane ring. Owing to the frequently shorter lifetime of heteroleptic complexes containing acetylacetonate as co-ligand, tris-ortho-metallated complexes are preferred, since they generally have a longer lifetime. However, the tris-ortho-metallated complexes have the disadvantage that they sublime at higher temperature compared with acetylacetonate complexes owing to the higher molecular weight, which may also result, depending on the precise structure of the complex, in thermal decomposition during sublimation or during vapour deposition during the production of the organic electroluminescent device. Further improvements are therefore desirable here.


The invention thus relates to a compound of the formula (1),

M(L)n(L′)m  formula (1)

which contains a moiety M(L)n of the formula (2):




embedded image



where the following applies to the symbols and indices used:

  • M is iridium or platinum;
  • CyC is an aryl or heteroaryl group having 5 to 18 aromatic ring atoms or a fluorene group, each of which is coordinated to M via a carbon atom and each of which may be substituted by one or more radicals R and each of which is connected to CyD via a covalent bond;
  • CyD is a heteroaryl group having 5 to 18 aromatic ring atoms, which is coordinated to M via a neutral nitrogen atom or via a carbene carbon atom and which may be substituted by one or more radicals R and which is connected to CyC via a covalent bond;
  • R is on each occurrence, identically or differently, H, D, F, Cl, Br, I, N(R1)2, CN, NO2, OH, COOH, C(═O)N(R1)2, Si(R1)3, B(OR1)2, C(═O)R1, P(═O)(R1)2, S(═O)R1, S(═O)2R1, OSO2R1, a straight-chain alkyl, alkoxy or thioalkoxy group having 1 to 20 C atoms or an alkenyl or alkynyl group having 2 to 20 C atoms or a branched or cyclic alkyl, alkoxy or thioalkoxy group having 3 to 20 C atoms, each of which may be substituted by one or more radicals R1, where one or more non-adjacent CH2 groups may be replaced by R1C═CR1, C≡C, Si(R1)2, C═O, NR1, O, S or CONR1 and where one or more H atoms may be replaced by D, F, Cl, Br, I or CN, or an aromatic or heteroaromatic ring system having 5 to 60 aromatic ring atoms, which may in each case be substituted by one or more radicals R1, or an aryloxy or heteroaryloxy group having 5 to 40 aromatic ring atoms, which may be substituted by one or more radicals R1, or an aralkyl or heteroaralkyl group having 5 to 40 aromatic ring atoms, which may be substituted by one or more radicals R1, or a diarylamino group, diheteroarylamino group or arylheteroarylamino group having 10 to 40 aromatic ring atoms, which may be substituted by one or more radicals R1; two adjacent radicals R here may also form a mono- or polycyclic, aliphatic, aromatic or heteroaromatic ring system with one another;
  • R1 is on each occurrence, identically or differently, H, D, F, Cl, Br, I, N(R2)2, CN, NO2, Si(R2)3, B(OR2)2, C(═O)R2, P(═O)(R2)2, S(═O)R2, S(═O)2R2, OSO2R2, a straight-chain alkyl, alkoxy or thioalkoxy group having 1 to 20 C atoms or an alkenyl or alkynyl group having 2 to 20 C atoms or a branched or cyclic alkyl, alkoxy or thioalkoxy group having 3 to 20 C atoms, each of which may be substituted by one or more radicals R2, where one or more non-adjacent CH2 groups may be replaced by R2C═CR2, C≡C, Si(R2)2, C═O, NR2, O, S or CONR2 and where one or more H atoms may be replaced by D, F, Cl, Br, I, CN or NO2, or an aromatic or heteroaromatic ring system having 5 to 60 aromatic ring atoms, which may in each case be substituted by one or more radicals R2, or an aryloxy or heteroaryloxy group having 5 to 40 aromatic ring atoms, which may be substituted by one or more radicals R2, or an aralkyl or heteroaralkyl group having 5 to 40 aromatic ring atoms, which may be substituted by one or more radicals R2, or a diarylamino group, diheteroarylamino group or arylheteroarylamino group having 10 to 40 aromatic ring atoms, which may be substituted by one or more radicals R2; two or more adjacent radicals R1 here may form a mono- or polycyclic, aliphatic ring system with one another;
  • R2 is on each occurrence, identically or differently, H, D, F or an aliphatic, aromatic and/or heteroaromatic hydrocarbon radical having 1 to 20 C atoms, in which, in addition, one or more H atoms may be replaced by F; two or more substituents R2 here may also form a mono- or polycyclic, aliphatic ring system with one another;
  • L′ is, identically or differently on each occurrence, a bidentate ligand which is bonded to M via one carbon atom and one nitrogen atom or via two carbon atoms;
  • n is 1, 2 or 3 for M=iridium and is 1 or 2 for M=platinum;
  • m is 0, 1 or 2 for M=iridium and is 0 or 1 for M=platinum;


    CyC and CyD here may also be linked to one another via a group selected from C(R1)2, C(R1)2—C(R1)2, NR1, O or S;


    a plurality of ligands L here may also be linked to one another or L may be linked to L′ via a single bond or a divalent or trivalent bridge and thus form a tetradentate or hexadentate ligand system;


    characterised in that CyD and/or CyC contain two adjacent carbon atoms, each of which is substituted by radicals R, where the respective radicals R, together with the C atoms, form a ring of the following formula (3):




embedded image



where R1 and R2 have the meanings given above, the dashed bonds indicate the linking of the two carbon atoms in the ligand, and furthermore:

  • A is, identically or differently on each occurrence, C(R1)2, O, S, NR3 or C(═O), with the proviso that two heteroatoms in the group -(A)p- are not bonded directly to one another;
  • R3 is, identically or differently on each occurrence, a straight-chain alkyl or alkoxy group having 1 to 20 C atoms, a branched or cyclic alkyl or alkoxy group having 3 to 20 C atoms, each of which may be substituted by one or more radicals R2, where one or more non-adjacent CH2 groups may be replaced by R2C═CR2, C≡C, Si(R2)2, C═O, NR2, O, S or CONR2 and where one or more H atoms may be replaced by D or F, or an aromatic or heteroaromatic ring system having 5 to 24 aromatic ring atoms, which may in each case be substituted by one or more radicals R2, or an aryloxy or heteroaryloxy group having 5 to 24 aromatic ring atoms, which may be substituted by one or more radicals R2, or an aralkyl or heteroaralkyl group having 5 to 24 aromatic ring atoms, which may be substituted by one or more radicals R2; two radicals R3 which are bonded to the same carbon atom may form an aliphatic or aromatic ring system with one another here and thus form a spiro system; furthermore, R3 may form an aliphatic ring system with an adjacent radical R or R1;
  • p is, identically or differently on each occurrence, 2 or 3.


The presence of a moiety of the formula (3), i.e. a condensed-on aliphatic six- or seven-membered ring, is essential to the invention. As is evident from the above-mentioned formula (3), the 6- or 7-membered ring formed by the four C atoms and the groups A contains no benzylic protons, since R3 is not equal to hydrogen. In the structure of the formula (3) depicted above and the further embodiments of this structure mentioned as preferred, a double bond is formally depicted between the two carbon atoms. This represents a simplification of the chemical structure, since these two carbon atoms are bonded into the aromatic or heteroaromatic system of the ligand and the bond between these two carbon atoms is thus formally between the bond order of a single bond and that of a double bond. The drawing-in of the formal double bond should thus not be interpreted as limiting for the structure, but instead it is apparent to the person skilled in the art that this means an aromatic bond.


“Adjacent carbon atoms” here means that the carbon atoms are bonded directly to one another. Furthermore, “adjacent radicals” in the definition of the radicals means that these radicals are bonded to the same carbon atom or to adjacent carbon atoms.


If adjacent radicals in the structures according to the invention form an aliphatic ring system, it is then preferred for this aliphatic ring system to contain no acidic benzylic protons. This can be achieved by the carbon atoms of the aliphatic ring system which are bonded directly to an aryl or heteroaryl group being fully substituted and not containing any bonded hydrogen atoms. This can furthermore also be achieved by the carbon atoms of the aliphatic ring system which are bonded directly to an aryl or heteroaryl group being the bridgeheads of a bi- or polycyclic structure. The protons bonded to bridgehead carbon atoms are, owing to the spatial structure of the bi- or polycycle, significantly less acidic than benzylic protons on carbon atoms which are not bonded in a bi- or polycyclic structure and for the purposes of the present invention are regarded as non-acidic protons.


An aryl group in the sense of this invention contains 6 to 40 C atoms; a heteroaryl group in the sense of this invention contains 2 to 40 C atoms and at least one heteroatom, with the proviso that the sum of C atoms and heteroatoms is at least 5. The heteroatoms are preferably selected from N, O and/or S. An aryl group or heteroaryl group here is taken to mean either a simple aromatic ring, i.e. benzene, or a simple heteroaromatic ring, for example pyridine, pyrimidine, thiophene, etc., or a condensed aryl or heteroaryl group, for example naphthalene, anthracene, phenanthrene, quinoline, isoquinoline, etc.


An aromatic ring system in the sense of this invention contains 6 to 60 C atoms in the ring system. A heteroaromatic ring system in the sense of this invention contains 1 to 60 C atoms and at least one heteroatom in the ring system, with the proviso that the sum of C atoms and heteroatoms is at least 5. The heteroatoms are preferably selected from N, O and/or S. An aromatic or heteroaromatic ring system in the sense of this invention is intended to be taken to mean a system which does not necessarily contain only aryl or heteroaryl groups, but instead in which, in addition, a plurality of aryl or heteroaryl groups may be interrupted by a non-aromatic unit (preferably less than 10% of the atoms other than H), such as, for example, a C, N or O atom or a carbonyl group. Thus, for example, systems such as 9,9′-spirobifluorene, 9,9-diarylfluorene, triarylamine, diaryl ether, stilbene, etc., are also intended to be taken to be aromatic ring systems in the sense of this invention, as are systems in which two or more aryl groups are interrupted, for example, by a linear or cyclic alkyl group or by a silyl group. Furthermore, systems in which two or more aryl or heteroaryl groups are bonded directly to one another, such as, for example, biphenyl or terphenyl, are likewise intended to be taken to be an aromatic or heteroaromatic ring system.


A cyclic alkyl, alkoxy or thioalkoxy group in the sense of this invention is taken to mean a monocyclic, bicyclic or polycyclic group.


For the purposes of the present invention, a C1- to C40-alkyl group, in which, in addition, individual H atoms or CH2 groups may be substituted by the above-mentioned groups, is taken to mean, for example, the radicals methyl, ethyl, n-propyl, i-propyl, cyclopropyl, n-butyl, i-butyl, s-butyl, t-butyl, cyclobutyl, 2-methylbutyl, n-pentyl, s-pentyl, tert-pentyl, 2-pentyl, neopentyl, cyclopentyl, n-hexyl, s-hexyl, tert-hexyl, 2-hexyl, 3-hexyl, neohexyl, cyclohexyl, 1-methylcyclopentyl, 2-methylpentyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, cycloheptyl, 1-methylcyclohexyl, n-octyl, 2-ethylhexyl, cyclooctyl, 1-bicyclo[2.2.2]octyl, 2-bicyclo[2.2.2]octyl, 2-(2,6-dimethyl)octyl, 3-(3,7-dimethyl)octyl, adamantyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 1,1-dimethyl-n-hex-1-yl, 1,1-dimethyl-n-hept-1-yl, 1,1-dimethyl-n-oct-1-yl, 1,1-dimethyl-n-dec-1-yl, 1,1-dimethyl-n-dodec-1-yl, 1,1-dimethyl-n-tetradec-1-yl, 1,1-dimethyl-n-hexadec-1-yl, 1,1-dimethyl-n-octa-dec-1-yl, 1,1-diethyl-n-hex-1-yl, 1,1-diethyl-n-hept-1-yl, 1,1-diethyl-n-oct-1-yl, 1,1-diethyl-n-dec-1-yl, 1,1-diethyl-n-dodec-1-yl, 1,1-diethyl-n-tetradec-1-yl, 1,1-diethyl-n-hexadec-1-yl, 1, -diethyl-n-octadec-1-yl, 1-(n-propyl)cyclohex-1-yl, 1-(n-butyl)cyclohex-1-yl, 1-(n-hexyl)cyclohex-1-yl, 1-(n-octyl)-cyclohex-1-yl and 1-(n-decyl)cyclohex-1-yl. An alkenyl group is taken to mean, for example, ethenyl, propenyl, butenyl, pentenyl, cyclopentenyl, hexenyl, cyclohexenyl, heptenyl, cycloheptenyl, octenyl, cyclooctenyl or cyclooctadienyl. An alkynyl group is taken to mean, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl or octynyl. A C1- to C40-alkoxy group is taken to mean, for example, methoxy, trifluoromethoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy or 2-methylbutoxy.


An aromatic or heteroaromatic ring system having 5-60 aromatic ring atoms, which may also in each case be substituted by the radicals mentioned above and which may be linked to the aromatic or heteroaromatic ring system via any desired positions, is taken to mean, for example, groups derived from benzene, naphthalene, anthracene, benzanthracene, phenanthrene, benzophenanthrene, pyrene, chrysene, perylene, fluoranthene, benzofluoranthene, naphthacene, pentacene, benzopyrene, biphenyl, biphenylene, terphenyl, terphenylene, fluorene, spirobifluorene, dihydrophenanthrene, dihydropyrene, tetrahydropyrene, cis- or trans-indenofluorene, cis- or trans-monobenzoindenofluorene, cis- or trans-dibenzoindenofluorene, truxene, isotruxene, spirotruxene, spiroisotruxene, furan, benzofuran, isobenzofuran, dibenzofuran, thiophene, benzothiophene, isobenzothiophene, dibenzothiophene, pyrrole, indole, isoindole, carbazole, indolocarbazole, indenocarbazole, pyridine, quinoline, isoquinoline, acridine, phenanthridine, benzo-5,6-quinoline, benzo-6,7-quinoline, benzo-7,8-quinoline, phenothiazine, phenoxazine, pyrazole, indazole, imidazole, benzimidazole, naphthimidazole, phenanthrimidazole, pyridimidazole, pyrazinimidazole, quinoxalinimidazole, oxazole, benzoxazole, naphthoxazole, anthroxazole, phenanthroxazole, isoxazole, 1,2-thiazole, 1,3-thiazole, benzothiazole, pyridazine, benzopyridazine, pyrimidine, benzopyrimidine, quinoxaline, 1,5-diazaanthracene, 2,7-diazapyrene, 2,3-diazapyrene, 1,6-diazapyrene, 1,8-diazapyrene, 4,5-diazapyrene, 4,5,9,10-tetraazaperylene, pyrazine, phenazine, phenoxazine, phenothiazine, fluorubin, naphthyridine, azacarbazole, benzocarboline, phenanthroline, 1,2,3-triazole, 1,2,4-triazole, benzotriazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 1,3,5-triazine, 1,2,4-triazine, 1,2,3-triazine, tetrazole, 1,2,4,5-tetrazine, 1,2,3,4-tetrazine, 1,2,3,5-tetrazine, purine, pteridine, indolizine and benzothiadiazole.


Preference is given to compounds of the formula (1), characterised in that they are uncharged, i.e. are electrically neutral. This is achieved in a simple manner by selecting the charge of the ligands L and L′ in such a way that they compensate the charge of the complexed metal atom M.


In a preferred embodiment of the present invention, CyC is an aryl or heteroaryl group having 5 to 14 aromatic ring atoms, particularly preferably 6 to 13 aromatic ring atoms, very particularly preferably having 6 to 10 aromatic ring atoms, especially preferably having 6 aromatic ring atoms, which is coordinated to M via a carbon atom and which may be substituted by one or more radicals R and which is bonded to CyD via a covalent bond.


Preferred embodiments of the group CyC are the structures of the following formulae (CyC-1) to (CyC-19), where the group CyC is in each case bonded to CyD at the position denoted by # and is coordinated to the metal M at the position denoted by *,




embedded image


embedded image


embedded image


where R has the meanings given above and the following applies to the other symbols used:


X is on each occurrence, identically or differently, CR or N;


W is on each occurrence, identically or differently, NR, O or S.


If the group of the formula (3) is bonded to CyC, two adjacent groups X in CyC stand for CR and, together with the radicals R which are bonded to these carbon atoms, form a group of the formula (3) mentioned above or described in greater detail below.


Preferably a maximum of three symbols X in CyC stand for N, particularly preferably a maximum of two symbols X in CyC stand for N, very particularly preferably a maximum of one symbol X in CyC stands for N. Especially preferably all symbols X stand for CR.


Particularly preferred groups CyC are the groups of the following formulae (CyC-1a) to (CyC-19a),




embedded image


embedded image


embedded image



where the symbols used have the meanings given above. If the group of the formula (3) is present on CyC, two adjacent radicals R, together with the carbon atoms to which they are bonded, form a ring of the formula (3).


Preferred groups amongst the groups (CyC-1) to (CyC-19) are the groups (CyC-1), (CyC-3), (CyC-8), (CyC-10), (CyC-12), (CyC-13) and (CyC-16), and particular preference is given to the groups (CyC-1a), (CyC-3a), (CyC-8a), (CyC-10a), (CyC-12a), (CyC-13a) and (CyC-16a).


In a further preferred embodiment of the invention, CyD is a heteroaryl group having 5 to 13 aromatic ring atoms, particularly preferably having 5 to 10 aromatic ring atoms, which is coordinated to M via a neutral nitrogen atom or via a carbene carbon atom and which may be substituted by one or more radicals R and which is bonded to CyC via a covalent bond.


Preferred embodiments of the group CyD are the structures of the following formulae (CyD-1) to (CyD-10), where the group CyD is in each case bonded to CyC at the position denoted by # and is coordinated to the metal M at the position denoted by *,




embedded image


where X, W and R have the meanings given above.


If the group of the formula (3) is bonded to CyD, two adjacent groups X in CyD stand for CR and, together with the radicals R which are bonded to these carbon atoms, form a group of the formula (3) mentioned above or described in greater detail below.


Preferably a maximum of three symbols X in CyD stand for N, particularly preferably a maximum of two symbols X in CyD stand for N, very particularly preferably a maximum of one symbol X in CyD stands for N. Especially preferably all symbols X stand for CR.


Particularly preferred groups CyD are the groups of the following formulae (CyD-1a) to (CyD-10a),




embedded image


where the symbols used have the meanings given above. If the group of the formula (3) is present on CyD, two adjacent radicals R, together with the carbon atoms to which they are bonded, form a ring of the formula (3).


Preferred groups amongst the groups (CyD-1) to (CyD-10) are the groups (CyD-1), (CyD-3), (CyD-4), (CyD-5) and (CyD-6), and particular preference is given to the groups (CyD-1a), (CyD-3a), (CyD-4a), (CyD-5a) and (CyD-6a).


In a preferred embodiment of the present invention, CyC is an aryl or heteroaryl group having 5 to 14 aromatic ring atoms and at the same time CyD is a heteroaryl group having 5 to 13 aromatic ring atoms. Particularly preferably, CyC is an aryl or heteroaryl group having 6 to 13 aromatic ring atoms, preferably having 6 to 10 aromatic ring atoms, in particular having 6 aromatic ring atoms, and at the same time CyD is a heteroaryl group having 5 to 10 aromatic ring atoms. CyC and CyD here may be substituted by one or more radicals R.


The above-mentioned preferred groups CyC and CyD can be combined with one another as desired. The following combinations of CyC and CyD are thus suitable in the ligand L:














No.
CyC
CyD

















1
CyC-1
CyD-1


2
CyC-1
CyD-2


3
CyC-1
CyD-3


4
CyC-1
CyD-4


5
CyC-1
CyD-5


6
CyC-1
CyD-6


7
CyC-1
CyD-7


8
CyC-1
CyD-8


9
CyC-1
CyD-9


10
CyC-1
CyD-10


11
CyC-2
CyD-1


12
CyC-2
CyD-2


13
CyC-2
CyD-3


14
CyC-2
CyD-4


15
CyC-2
CyD-5


16
CyC-2
CyD-6


17
CyC-2
CyD-7


18
CyC-2
CyD-8


19
CyC-2
CyD-9


20
CyC-2
CyD-10


21
CyC-3
CyD-1


22
CyC-3
CyD-2


23
CyC-3
CyD-3


24
CyC-3
CyD-4


25
CyC-3
CyD-5


26
CyC-3
CyD-6


27
CyC-3
CyD-7


28
CyC-3
CyD-8


29
CyC-3
CyD-9


30
CyC-3
CyD-10


31
CyC-4
CyD-1


32
CyC-4
CyD-2


33
CyC-4
CyD-3


34
CyC-4
CyD-4


35
CyC-4
CyD-5


36
CyC-4
CyD-6


37
CyC-4
CyD-7


38
CyC-4
CyD-8


39
CyC-4
CyD-9


40
CyC-4
CyD-10


41
CyC-5
CyD-1


42
CyC-5
CyD-2


43
CyC-5
CyD-3


44
CyC-5
CyD-4


45
CyC-5
CyD-5


46
CyC-5
CyD-6


47
CyC-5
CyD-7


48
CyC-5
CyD-8


49
CyC-5
CyD-9


50
CyC-5
CyD-10


51
CyC-6
CyD-1


52
CyC-6
CyD-2


53
CyC-6
CyD-3


54
CyC-6
CyD-4


55
CyC-6
CyD-5


56
CyC-6
CyD-6


57
CyC-6
CyD-7


58
CyC-6
CyD-8


59
CyC-6
CyD-9


60
CyC-6
CyD-10


61
CyC-7
CyD-1


62
CyC-7
CyD-2


63
CyC-7
CyD-3


64
CyC-7
CyD-4


65
CyC-7
CyD-5


66
CyC-7
CyD-6


67
CyC-7
CyD-7


68
CyC-7
CyD-8


69
CyC-7
CyD-9


70
CyC-7
CyD-10


71
CyC-8
CyD-1


72
CyC-8
CyD-2


73
CyC-8
CyD-3


74
CyC-8
CyD-4


75
CyC-8
CyD-5


76
CyC-8
CyD-6


77
CyC-8
CyD-7


78
CyC-8
CyD-8


79
CyC-8
CyD-9


80
CyC-8
CyD-10


81
CyC-9
CyD-1


82
CyC-9
CyD-2


83
CyC-9
CyD-3


84
CyC-9
CyD-4


85
CyC-9
CyD-5


86
CyC-9
CyD-6


87
CyC-9
CyD-7


88
CyC-9
CyD-8


89
CyC-9
CyD-9


90
CyC-9
CyD-10


91
CyC-10
CyD-1


92
CyC-10
CyD-2


93
CyC-10
CyD-3


94
CyC-10
CyD-4


95
CyC-10
CyD-5


96
CyC-10
CyD-6


97
CyC-10
CyD-7


98
CyC-10
CyD-8


99
CyC-10
CyD-9


100
CyC-10
CyD-10


101
CyC-11
CyD-1


102
CyC-11
CyD-2


103
CyC-11
CyD-3


104
CyC-11
CyD-4


105
CyC-11
CyD-5


106
CyC-11
CyD-6


107
CyC-11
CyD-7


108
CyC-11
CyD-8


109
CyC-11
CyD-9


110
CyC-11
CyD-10


111
CyC-12
CyD-1


112
CyC-12
CyD-2


113
CyC-12
CyD-3


114
CyC-12
CyD-4


115
CyC-12
CyD-5


116
CyC-12
CyD-6


117
CyC-12
CyD-7


118
CyC-12
CyD-8


119
CyC-12
CyD-9


120
CyC-12
CyD-10


121
CyC-13
CyD-1


122
CyC-13
CyD-2


123
CyC-13
CyD-3


124
CyC-13
CyD-4


125
CyC-13
CyD-5


126
CyC-13
CyD-6


127
CyC-13
CyD-7


128
CyC-13
CyD-8


129
CyC-13
CyD-9


130
CyC-13
CyD-10


131
CyC-14
CyD-1


132
CyC-14
CyD-2


133
CyC-14
CyD-3


134
CyC-14
CyD-4


135
CyC-14
CyD-5


136
CyC-14
CyD-6


137
CyC-14
CyD-7


138
CyC-14
CyD-8


139
CyC-14
CyD-9


140
CyC-14
CyD-10


141
CyC-15
CyD-1


142
CyC-15
CyD-2


143
CyC-15
CyD-3


144
CyC-15
CyD-4


145
CyC-15
CyD-5


146
CyC-15
CyD-6


147
CyC-15
CyD-7


148
CyC-15
CyD-8


149
CyC-15
CyD-9


150
CyC-15
CyD-10


151
CyC-16
CyD-1


152
CyC-16
CyD-2


153
CyC-16
CyD-3


154
CyC-16
CyD-4


155
CyC-16
CyD-5


156
CyC-16
CyD-6


157
CyC-16
CyD-7


158
CyC-16
CyD-8


159
CyC-16
CyD-9


160
CyC-16
CyD-10


161
CyC-17
CyD-1


162
CyC-17
CyD-2


163
CyC-17
CyD-3


164
CyC-17
CyD-4


165
CyC-17
CyD-5


166
CyC-17
CyD-6


167
CyC-17
CyD-7


168
CyC-17
CyD-8


169
CyC-17
CyD-9


170
CyC-17
CyD-10


171
CyC-18
CyD-1


172
CyC-18
CyD-2


173
CyC-18
CyD-3


174
CyC-18
CyD-4


175
CyC-18
CyD-5


176
CyC-18
CyD-6


177
CyC-18
CyD-7


178
CyC-18
CyD-8


179
CyC-18
CyD-9


180
CyC-18
CyD-10


181
CyC-19
CyD-1


182
CyC-19
CyD-2


183
CyC-19
CyD-3


184
CyC-19
CyD-4


185
CyC-19
CyD-5


186
CyC-19
CyD-6


187
CyC-19
CyD-7


188
CyC-19
CyD-8


189
CyC-19
CyD-9


190
CyC-19
CyD-10









It is particularly preferred for the groups CyC and CyD mentioned above as particularly preferred to be combined with one another. The following combinations of CyC and CyD are thus preferred in the ligand L














No.
C
N

















1
CyC-1a
CyD-1a


2
CyC-1a
CyD-2a


3
CyC-1a
CyD-3a


4
CyC-1a
CyD-4a


5
CyC-1a
CyD-5a


6
CyC-1a
CyD-6a


7
CyC-1a
CyD-7a


8
CyC-1a
CyD-8a


9
CyC-1a
CyD-9a


10
CyC-1a
CyD-10a


11
CyC-2a
CyD-1a


12
CyC-2a
CyD-2a


13
CyC-2a
CyD-3a


14
CyC-2a
CyD-4a


15
CyC-2a
CyD-5a


16
CyC-2a
CyD-6a


17
CyC-2a
CyD-7a


18
CyC-2a
CyD-8a


19
CyC-2a
CyD-9a


20
CyC-2a
CyD-10a


21
CyC-3a
CyD-1a


22
CyC-3a
CyD-2a


23
CyC-3a
CyD-3a


24
CyC-3a
CyD-4a


25
CyC-3a
CyD-5a


26
CyC-3a
CyD-6a


27
CyC-3a
CyD-7a


28
CyC-3a
CyD-8a


29
CyC-3a
CyD-9a


30
CyC-3a
CyD-10a


31
CyC-4a
CyD-1a


32
CyC-4a
CyD-2a


33
CyC-4a
CyD-3a


34
CyC-4a
CyD-4a


35
CyC-4a
CyD-5a


36
CyC-4a
CyD-6a


37
CyC-4a
CyD-7a


38
CyC-4a
CyD-8a


39
CyC-4a
CyD-9a


40
CyC-4a
CyD-10a


41
CyC-5a
CyD-1a


42
CyC-5a
CyD-2a


43
CyC-5a
CyD-3a


44
CyC-5a
CyD-4a


45
CyC-5a
CyD-5a


46
CyC-5a
CyD-6a


47
CyC-5a
CyD-7a


48
CyC-5a
CyD-8a


49
CyC-5a
CyD-9a


50
CyC-5a
CyD-10a


51
CyC-6a
CyD-1a


52
CyC-6a
CyD-2a


53
CyC-6a
CyD-3a


54
CyC-6a
CyD-4a


55
CyC-6a
CyD-5a


56
CyC-6a
CyD-6a


57
CyC-6a
CyD-7a


58
CyC-6a
CyD-8a


59
CyC-6a
CyD-9a


60
CyC-6a
CyD-10a


61
CyC-7a
CyD-1a


62
CyC-7a
CyD-2a


63
CyC-7a
CyD-3a


64
CyC-7a
CyD-4a


65
CyC-7a
CyD-5a


66
CyC-7a
CyD-6a


67
CyC-7a
CyD-7a


68
CyC-7a
CyD-8a


69
CyC-7a
CyD-9a


70
CyC-7a
CyD-10a


71
CyC-8a
CyD-1a


72
CyC-8a
CyD-2a


73
CyC-8a
CyD-3a


74
CyC-8a
CyD-4a


75
CyC-8a
CyD-5a


76
CyC-8a
CyD-6a


77
CyC-8a
CyD-7a


78
CyC-8a
CyD-8a


79
CyC-8a
CyD-9a


80
CyC-8a
CyD-10a


81
CyC-9a
CyD-1a


82
CyC-9a
CyD-2a


83
CyC-9a
CyD-3a


84
CyC-9a
CyD-4a


85
CyC-9a
CyD-5a


86
CyC-9a
CyD-6a


87
CyC-9a
CyD-7a


88
CyC-9a
CyD-8a


89
CyC-9a
CyD-9a


90
CyC-9a
CyD-10a


91
CyC-10a
CyD-1a


92
CyC-10a
CyD-2a


93
CyC-10a
CyD-3a


94
CyC-10a
CyD-4a


95
CyC-10a
CyD-5a


96
CyC-10a
CyD-6a


97
CyC-10a
CyD-7a


98
CyC-10a
CyD-8a


99
CyC-10a
CyD-9a


100
CyC-10a
CyD-10a


101
CyC-11a
CyD-1a


102
CyC-11a
CyD-2a


103
CyC-11a
CyD-3a


104
CyC-11a
CyD-4a


105
CyC-11a
CyD-5a


106
CyC-11a
CyD-6a


107
CyC-11a
CyD-7a


108
CyC-11a
CyD-8a


109
CyC-11a
CyD-9a


110
CyC-11a
CyD-10a


111
CyC-12a
CyD-1a


112
CyC-12a
CyD-2a


113
CyC-12a
CyD-3a


114
CyC-12a
CyD-4a


115
CyC-12a
CyD-5a


116
CyC-12a
CyD-6a


117
CyC-12a
CyD-7a


118
CyC-12a
CyD-8a


119
CyC-12a
CyD-9a


120
CyC-12a
CyD-10a


121
CyC-13a
CyD-1a


122
CyC-13a
CyD-2a


123
CyC-13a
CyD-3a


124
CyC-13a
CyD-4a


125
CyC-13a
CyD-5a


126
CyC-13a
CyD-6a


127
CyC-13a
CyD-7a


128
CyC-13a
CyD-8a


129
CyC-13a
CyD-9a


130
CyC-13a
CyD-10a


131
CyC-14a
CyD-1a


132
CyC-14a
CyD-2a


133
CyC-14a
CyD-3a


134
CyC-14a
CyD-4a


135
CyC-14a
CyD-5a


136
CyC-14a
CyD-6a


137
CyC-14a
CyD-7a


138
CyC-14a
CyD-8a


139
CyC-14a
CyD-9a


140
CyC-14a
CyD-10a


141
CyC-15a
CyD-1a


142
CyC-15a
CyD-2a


143
CyC-15a
CyD-3a


144
CyC-15a
CyD-4a


145
CyC-15a
CyD-5a


146
CyC-15a
CyD-6a


147
CyC-15a
CyD-7a


148
CyC-15a
CyD-8a


149
CyC-15a
CyD-9a


150
CyC-15a
CyD-10a


151
CyC-16a
CyD-1a


152
CyC-16a
CyD-2a


153
CyC-16a
CyD-3a


154
CyC-16a
CyD-4a


155
CyC-16a
CyD-5a


156
CyC-16a
CyD-6a


157
CyC-16a
CyD-7a


158
CyC-16a
CyD-8a


159
CyC-16a
CyD-9a


160
CyC-16a
CyD-10a


161
CyC-17a
CyD-1a


162
CyC-17a
CyD-2a


163
CyC-17a
CyD-3a


164
CyC-17a
CyD-4a


165
CyC-17a
CyD-5a


166
CyC-17a
CyD-6a


167
CyC-17a
CyD-7a


168
CyC-17a
CyD-8a


169
CyC-17a
CyD-9a


170
CyC-17a
CyD-10a


171
CyC-18a
CyD-1a


172
CyC-18a
CyD-2a


173
CyC-18a
CyD-3a


174
CyC-18a
CyD-4a


175
CyC-18a
CyD-5a


176
CyC-18a
CyD-6a


177
CyC-18a
CyD-7a


178
CyC-18a
CyD-8a


179
CyC-18a
CyD-9a


180
CyC-18a
CyD-10a


181
CyC-19a
CyD-1a


182
CyC-19a
CyD-2a


183
CyC-19a
CyD-3a


184
CyC-19a
CyD-4a


185
CyC-19a
CyD-5a


186
CyC-19a
CyD-6a


187
CyC-19a
CyD-7a


188
CyC-19a
CyD-8a


189
CyC-19a
CyD-9a


190
CyC-19a
CyD-10a









As described above, it is essential to the invention that CyD and/or CyC or the preferred embodiments indicated above contain two adjacent carbon atoms, each of which is substituted by radicals R, where the respective radicals R, together with the C atoms, form a ring of the above-mentioned formula (3).


In a preferred embodiment of the invention, the ligand L either contains precisely one group of the formula (3) or it contains two groups of the formula (3), one of which is bonded to CyC and the other is bonded to CyD. In a particularly preferred embodiment, the ligand L contains precisely one group of the formula (3). The group of the formula (3) may be present either on CyC or on CyD here, where the group of the formula (3) can be bonded in any possible position on CyC or CyD.


In the following groups (CyC-1-1) to (CyC-19-1) and (CyD-1-1) to (CyD-10-1), the preferred positions for adjacent groups X which stand for CR are depicted in each case, where the respective radicals R, together with the C atoms to which they are bonded, form a ring of the above-mentioned formula (3),




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


where the symbols and indices used have the meanings given above, and ° in each case denotes the positions which stand for CR, where the respective radicals R, together with the C atoms to which they are bonded, form a ring of the above-mentioned formula (3).


Likewise, the groups (CyC-1-1) to (CyC-19-1) or (CyD-1-1) to (CyD-10-4) in the two tables shown above are preferred instead of the groups (CyC-1) to (CyC-19) or (CyD-1) to (CyD-19) shown in the tables.


Preferred embodiments of the groups of the formula (3) are shown below. It is essential in the case of the group of the formula (3) that it contains no acidic benzylic protons.


If the index p=2, the group of the formula (3) is a six-membered ring structure of the following formula (4), and if the index p=3, the group of the formula (3) is a seven-membered ring structure of the following formula (5):




embedded image


where the symbols used have the meanings given above.


In a preferred embodiment of the invention, p=2, i.e. preference is given to a structure of the formula (4).


In a preferred embodiment of the structure of the formulae (3), (4) and (5), a maximum of one of the groups A stands for a heteroatom, in particular for O or NR3, and the other group A, for p=2, or the other two groups A, for p=3, stand for C(R1)2. In a particularly preferred embodiment of the invention, A stands, identically or differently on each occurrence, for C(R1)2.


Preferred embodiments of the formula (4) are thus the structures of the formulae (4-A) and (4-B), where the structure of the formula (4-A) is particularly preferred,




embedded image


where R1 and R3 have the meanings given above, and A stands for O or NR3.


Preferred embodiments of the formula (5) are the structures of the formulae (5-A), (5-B) and (5-C), where the structure of the formula (5-A) is particularly preferred,




embedded image


where R1 and R3 have the meanings given above, and A stands for O or NR3.


In a preferred embodiment of the formulae (4-A), (4-B), (5-A), (5-B) and (5-C), R1 is, identically or differently on each occurrence, H, D or an alkyl group having 1 to 5 C atoms, particularly preferably methyl, in which, in addition, one or more H atoms may be replaced by F, where two or more adjacent radicals R1 may form an aliphatic ring system with one another. R1 particularly preferably stands for hydrogen.


In a preferred embodiment of the invention, R3 in the group of the formula (3) and in the preferred embodiments stands, identically or differently on each occurrence, for a straight-chain alkyl or alkoxy group having 1 to 10 C atoms or a branched or cyclic alkyl or alkoxy group having 3 to 10 C atoms, where in each case one or more non-adjacent CH2 groups may be replaced by R2C═CR2 and one or more H atoms may be replaced by D or F, or an aromatic or heteroaromatic ring system having 5 to 14 aromatic ring atoms, which may in each case be substituted by one or more radicals R2; two radicals R3 which are bonded to the same carbon atom may form an aliphatic or aromatic ring system here and thus form a spiro system; furthermore, R3 may form an aliphatic ring system with an adjacent radical R or R1.


In a particularly preferred embodiment of the invention, R3 in the group of the formula (3) and in the preferred embodiments stands, identically or differently on each occurrence, for a straight-chain alkyl or alkoxy group having 1 to 3 C atoms, in particular methyl, or a branched or cyclic alkyl or alkoxy group having 3 to 5 C atoms or an aromatic or heteroaromatic ring system having 6 to 12 aromatic ring atoms, which may in each case be substituted by one or more radicals R2, but is preferably unsubstituted; two radicals R3 which are bonded to the same carbon atom may form an aliphatic or aromatic ring system with one another here and thus form a spiro system; furthermore, R3 may form an aliphatic ring system with an adjacent radical R or R1.


Examples of suitable groups of the formula (4) are the groups (4-1) to (4-16) shown below:




embedded image


embedded image


embedded image


Examples of suitable groups of the formula (5) are the groups (5-1) to (5-11) shown below:




embedded image


embedded image


If radicals R are bonded in the moiety of the formula (2), these radicals R are preferably selected on each occurrence, identically or differently, from the group consisting of H, D, F, Br, I, N(R1)2, CN, Si(R1)3, B(OR1)2, C(═O)R1, a straight-chain alkyl group having 1 to 10 C atoms or an alkenyl group having 2 to 10 C atoms or a branched or cyclic alkyl group having 3 to 10 C atoms, each of which may be substituted by one or more radicals R1, where one or more H atoms may be replaced by D or F, or an aromatic or heteroaromatic ring system having 5 to 30 aromatic ring atoms, which may in each case be substituted by one or more radicals R1; two adjacent radical R or R with R1 here may also form a mono- or polycyclic, aliphatic or aromatic ring system with one another. These radicals R are particularly preferably selected on each occurrence, identically or differently, from the group consisting of H, D, F, N(R1)2, a straight-chain alkyl group having 1 to 6 C atoms or a branched or cyclic alkyl group having 3 to 10 C atoms, where one or more H atoms may be replaced by D or F, or an aromatic or heteroaromatic ring system having 5 to 24 aromatic ring atoms, which may in each case be substituted by one or more radicals R1; two adjacent radicals R or R with R1 here may also form a mono- or polycyclic, aliphatic or aromatic ring system with one another.


Radicals R1 which are bonded to R are on each occurrence, identically or differently, preferably H, D, F, N(R2)2, CN, a straight-chain alkyl or alkoxy group having 1 to 10 C atoms or an alkenyl group having 2 to 10 C atoms or a branched or cyclic alkyl or alkoxy group having 3 to 10 C atoms, each of which may be substituted by one or more radicals R2, where one or more non-adjacent CH2 groups may be replaced by R2C═CR2 or O and where one or more H atoms may be replaced by D or F, or an aromatic or heteroaromatic ring system having 5 to 20 aromatic ring atoms, which may in each case be substituted by one or more radicals R2, or a diarylamino group, diheteroarylamino group or arylheteroarylamino group having 10 to 40 aromatic ring atoms, which may be substituted by one or more radicals R2; two or more adjacent radicals R1 here may form a mono- or polycyclic, aliphatic ring system with one another. Particularly preferred radicals R1 which are bonded to R are on each occurrence, identically or differently, H, F, CN, a straight-chain alkyl group having 1 to 5 C atoms or a branched or cyclic alkyl group having 3 to 5 C atoms, each of which may be substituted by one or more radicals R2, or an aromatic or heteroaromatic ring system having 5 to 13 aromatic ring atoms, which may in each case be substituted by one or more radicals R2; two or more adjacent radicals R1 here may form a mono- or polycyclic, aliphatic ring system with one another.


Preferred radicals R2 are on each occurrence, identically or differently, H, F or an aliphatic hydrocarbon radical having 1 to 5 C atoms or an aromatic hydrocarbon radical having 6 to 12 C atoms; two or more substituents R2 here may also form a mono- or polycyclic, aliphatic ring system with one another.


As described above, a bridging unit which links this ligand L to one or more further ligands L or L′ may also be present instead of one of the radicals R. In a preferred embodiment of the invention, a bridging unit is present instead of one of the radicals R, in particular instead of the radicals R which are in the ortho- or meta-position to the coordinating atom, so that the ligands have a tridentate or polydentate or polypodal character. It is also possible for two such bridging units to be present. This results in the formation of macrocyclic ligands or in the formation of cryptates.


Preferred structures containing polydentate ligands are the metal complexes of the following formulae (6) to (11),




embedded image


where the symbols and indices used have the above-mentioned meanings.


In the structures of the formulae (6) to (11), V preferably represents a single bond or a bridging unit containing 1 to 80 atoms from the third, fourth, fifth and/or sixth main group (IUPAC group 13, 14, 15 or 16) or a 3- to 6-membered homo- or heterocycle which covalently bonds the part-ligands L to one another or covalently bonds L to L′. The bridging unit V here may also have an asymmetrical structure, i.e. the linking of V to L and L′ need not be identical. The bridging unit V can be neutral, singly, doubly or triply negatively charged or singly, doubly or triply positively charged. V is preferably neutral or singly negatively charged or singly positively charged, particularly preferably neutral. The charge of V is preferably selected so that overall a neutral complex forms. The preferences mentioned above for the moiety MLn apply to the ligands, and n is preferably at least 2.


The precise structure and chemical composition of the group V does not have a significant effect on the electronic properties of the complex since the job of this group is essentially to increase the chemical and thermal stability of the complexes by bridging L to one another or to L′.


If V is a trivalent group, i.e. bridges three ligands L to one another or two ligands L to L′ or one ligand L to two ligands L′, V is preferably selected, identically or differently on each occurrence, from the group consisting of B, B(R1)—, B(C(R1)2)3, (R1)B(C(R1)2)3—, B(O)3, (R1)B(O)3—, B(C(R1)2C(R1)2)3, (R1)B(C(R1)2C(R1)2)3—, B(C(R1)2O)3, (R1)B(C(R1)2O)3—, B(OC(R1)2)3, (R1)B(OC(R1)2)3—, C(R1), CO—, CN(R1)2, (R1)C(C(R1)2)3, (R1)C(O)3, (R1)C(C(R1)2C(R1)2)3, (R1)C(C(R1)2O)3, (R1)C(OC(R1)2)3, (R1)C(Si(R1)2)3, (R1)C(Si(R1)2C(R1)2)3, (R1)C(C(R1)2Si(R1)2)3, (R1)C(Si(R1)2Si(R1)2)3, Si(R1), (R1)Si(C(R1)2)3, (R1)Si(O)3, (R1)Si(C(R1)2C(R1)2)3, (R1)Si(OC(R1)2)3, (R1)Si(C(R1)2O)3, (R1)Si(Si(R1)2)3, (R1)Si(Si(R1)2C(R1)2)3, (R1)Si(C(R1)2Si(R1)2)3, (R1)Si(Si(R1)2Si(R1)2)3, N, NO, N(R1)+, N(C(R1)2)3, (R1)N(C(R1)2)3+, N(C═O)3, N(C(R1)2C(R1)2)3, (R1)N(C(R1)2C(R1)2)+, P, P(R1)+, PO, PS, P(O)3, PO(O)3, P(OC(R1)2)3, PO(OC(R1)2)3, P(C(R1)2)3, P(R1)(C(R1)2)3+, PO(C(R1)2)3, P(C(R1)2C(R1)2)3, P(R1)(C(R1)2C(R1)2)3+, PO(C(R1)2C(R1)2)3, S+, S(C(R1)2)3+, S(C(R1)2C(R1)2)3+,


or a unit of the formulae (12) to (16),




embedded image


where the dashed bonds in each case indicate the bond to the part-ligands L or L′, and Z is selected, identically or differently on each occurrence, from the group consisting of a single bond, O, S, S(═O), S(═O)2, NR1, PR1, P(═O)R1, C(R1)2, C(═O), C(═NR1), C(═C(R1)2), Si(R1)2 or BR1. The other symbols used have the meanings given above.


If V stands for a group CR2, the two radicals R may also be linked to one another, and consequently structures such as, for example, 9,9-fluorene, are also suitable groups V.


If V is a divalent group, i.e. bridges two ligands L to one another or one ligand L to L′, V is preferably selected, identically or differently on each occurrence, from the group consisting of aus BR1, B(R1)2—, C(R1)2, C(═O), Si(R1)2, NR1, PR1, P(R1)2+, P(═O)(R1), P(═S)(R1), O, S, Se, or a unit of the formulae (17) to (26),




embedded image



where the dashed bonds in each case indicate the bond to the part-ligands L or L′, Y stands on each occurrence, identically or differently, for C(R1)2, N(R1), O or S, and the other symbols used each have the meanings indicated above.


Preferred ligands L′ as occur in formula (1) are described below. The ligand groups L′ can also be selected correspondingly if they are bonded to L via a bridging unit V, as indicated in formulae (6), (8) and (10).


The ligands L′ are preferably monoanionic bidentate ligands which are bonded to M via a neutral nitrogen atom and a negatively charged carbon atom or via a neutral carbon atom and a negatively charged carbon atom. It is preferred here for the ligands L′ to form a cyclometallated five-membered ring or six-membered ring, in particular a cyclometallated five-membered ring, with the metal. As described above, the ligands L′ may also be bonded to L via a bridging group V. The ligands L′ are, in particular, ligands as are generally used in the area of phosphorescent metal complexes for organic electroluminescent devices, i.e. ligands of the type phenylpyridine, naphthylpyridine, phenylquinoline, phenylisoquinoline, etc., each of which may be substituted by one or more radicals R. A multiplicity of ligands of this type is known to the person skilled in the art in the area of phosphorescent electroluminescent devices, and he will be able, without inventive step, to select further ligands of this type as ligand L′ for compounds of the formula (1). The combination of two groups as depicted by the following formulae (27) to (50) is generally particularly suitable for this purpose, where one group is bonded via a neutral nitrogen atom or a carbene carbon atom and the other group is preferably bonded via a negatively charged carbon atom. The ligand L′ can then be formed from the groups of the formulae (27) to (50) through these groups bonding to one another in each case at the position denoted by #. The position at which the groups coordinate to the metal M is denoted by *. These groups may also be bonded to the ligand L via one or two bridging units V.




embedded image


embedded image


embedded image


W here has the meaning given above and X stands on each occurrence, identically or differently, for CR or N, where the above-mentioned limitation, that at least two adjacent groups X stand for CR and the radicals R form a ring of the formula (3), does not apply here. R has the same meaning as described above, where two radicals R which are bonded to two different cyclic groups of the above-mentioned formulae (27) to (50) may also form an aromatic ring system with one another here. Preferably, a maximum of three symbols X in each group stand for N, particularly preferably a maximum of two symbols X in each group stand for N, very particularly preferably a maximum of one symbol X in each group stands for N. Especially preferably, all symbols X stand for CR.


If two radicals R in the ligand L′ which are bonded to two different rings of the above-mentioned formulae (27) to (50) also form an aromatic ring system with one another, ligands may arise, for example, which overall represent a single larger heteroaryl group, such as, for example, benzo[h]quinoline, etc. Preferred ligands which arise through ring formation of two radicals R on the different rings are the structures of the formulae (51) to (55) shown below:




embedded image


where the symbols used have the meanings given above.


Preferred radicals R in the structures of L′ shown above are selected on each occurrence, identically or differently, from the group consisting of H, D, F, Br, N(R1)2, CN, B(OR1)2, C(═O)R1, P(═O)(R1)2, a straight-chain alkyl group having 1 to 10 C atoms or a straight-chain alkenyl or alkynyl group having 2 to 10 C atoms or a branched or cyclic alkyl group having 3 to 10 C atoms, each of which may be substituted by one or more radicals R1, where one or more H atoms may be replaced by D or F, or an aromatic or heteroaromatic ring system having 5 to 14 aromatic ring atoms, which may in each case be substituted by one or more radicals R1; two or more adjacent radicals R here may also form a mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system with one another. Particularly preferred radicals R are selected on each occurrence, identically or differently, from the group consisting of H, D, F, Br, CN, B(OR1)2, a straight-chain alkyl group having 1 to 5 C atoms, in particular methyl, or a branched or cyclic alkyl group having 3 to 5 C atoms, in particular isopropyl or tert-butyl, where one or more H atoms may be replaced by D or F, or an aromatic or heteroaromatic ring system having 5 to 12 aromatic ring atoms, which may in each case be substituted by one or more radicals R1; two or more radicals R here may also form a mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system with one another.


Preferred radicals R1 in the structures of L′ shown above are defined analogously to the preferred radicals R1 shown above.


The complexes according to the invention can be facial or pseudofacial or they can be meridional or pseudomeridional.


The ligands L and/or L′ may also be chiral, depending on the structure. This is the case, in particular, if they contain substituents, for example alkyl, alkoxy, dialkylamino or aralkyl groups, which have one or more stereocentres. Since the basic structure of the complex may also be a chiral structure, the formation of diastereomers and a number of enantiomer pairs is possible. The complexes according to the invention then encompass both the mixtures of the various diastereomers or the corresponding racemates and also the individual isolated diastereomers or enantiomers.


The preferred embodiments indicated above can be combined with one another as desired. In a particularly preferred embodiment of the invention, the preferred embodiments indicated above apply simultaneously.


Examples of suitable compounds of the formula (1) are the structures shown in the following table.

















embedded image


1







embedded image


2







embedded image


3







embedded image


4







embedded image


5







embedded image


6







embedded image


7







embedded image


8







embedded image


9







embedded image


10







embedded image


11







embedded image


12







embedded image


13







embedded image


14







embedded image


15







embedded image


16







embedded image


17







embedded image


18







embedded image


19







embedded image


20







embedded image


21







embedded image


22







embedded image


23







embedded image


24







embedded image


25







embedded image


26







embedded image


27









The metal complexes according to the invention can in principle be prepared by various processes. However, the processes described below have proven particularly suitable.


The present invention therefore furthermore relates to a process for the preparation of the metal complex compounds of the formula (1) by reaction of the corresponding free ligands L and optionally L′ with metal alkoxides of the formula (67), with metal ketoketonates of the formula (68), with metal halides of the formula (69) or with dimeric metal complexes of the formula (70) or with metal complexes of the formula (71),




embedded image


where the symbols M, m, n and R have the meanings indicated above, Hal=F, Cl, Br or I, L″ stands for an alcohol, in particular for an alcohol having 1 to 4 C atoms, or a nitrile, in particular acetonitrile or benzonitrile, and (anion) stands for a non-coordinating anion, such as, for example, triflate


It is likewise possible to use metal compounds, in particular iridium compounds, which carry both alkoxide and/or halide and/or hydroxyl radicals as well as ketoketonate radicals. These compounds may also be charged. Corresponding iridium compounds which are particularly suitable as starting materials are disclosed in WO 2004/085449. [IrCl2(acac)2], for example Na[IrCl2(acac)2], are particularly suitable. Metal complexes with acetylacetonate derivatives as ligand, for example Ir(acac)3 or tris(2,2,6,6-tetra-methylheptane-3,5-dionato)iridium, and IrCl3.xH2O, where x usually stands for a number between 2 and 4.


Suitable platinum starting materials are, for example, PtCl2, K2[PtCl4], PtCl2(DMSO)2, Pt(Me)2(DMSO)2 or PtCl2(benzonitrile)2.


The synthesis can also be carried out by reaction of the ligands L with iridium complexes of the formula [Ir(L′)2(HOMe)2]A or [Ir(L′)2(NCMe)2]A or by reaction of the ligands L′ with iridium complexes of the formula [Ir(L)2(HOMe)2]A or [Ir(L)2(NCMe)2]A, where A in each case represents a non-coordinating anion, such as, for example, triflate, tetrafluoroborate, hexafluorophosphate, etc., in dipolar-protic solvents, such as, for example, ethylene glycol, propylene glycol, glycerol, diethylene glycol, triethylene glycol, etc.


The synthesis of the complexes is preferably carried out as described in WO 2002/060910 and in WO 2004/085449. Heteroleptic complexes can also be synthesised, for example, in accordance with WO 05/042548. The synthesis here can also be activated, for example, thermally, photochemically and/or by microwave radiation. The synthesis can furthermore also be carried out in an autoclave under increased pressure and/or at elevated temperature.


The reactions can be carried out without addition of solvents or melting aids in a melt of the corresponding ligands to be o-metallated. If necessary, solvents or melting aids can be added. Suitable solvents are protic or aprotic solvents, such as aliphatic and/or aromatic alcohols (methanol, ethanol, isopropanol, t-butanol, etc.), oligo- and polyalcohols (ethylene glycol, 1,2-propanediol, glycerol, etc.), alcohol ethers (ethoxyethanol, diethylene glycol, triethylene glycol, polyethylene glycol, etc.), ethers (di- and triethylene glycol dimethyl ether, diphenyl ether, etc.), aromatic, heteroaromatic and/or aliphatic hydrocarbons (toluene, xylene, mesitylene, chlorobenzene, pyridine, lutidine, quinoline, isoquinoline, tridecane, hexadecane, etc.), amides (DMF, DMAC, etc.), lactams (NMP), sulfoxides (DMSO) or sulfones (dimethyl sulfone, sulfolane, etc.). Suitable melting aids are compounds which are in solid form at room temperature, but melt on warming of the reaction mixture and dissolve the reactants, so that a homogeneous melt forms. Particularly suitable are biphenyl, m-terphenyl, triphenylene, 1,2-, 1,3-, 1,4-bisphenoxybenzene, triphenylphosphine oxide, 18-crown-6, phenol, 1-naphthol, hydroquinone, etc.


These processes, optionally followed by purification, such as, for example, recrystallisation or sublimation, enable the compounds of the formula (1) according to the invention to be obtained in high purity, preferably greater than 99% (determined by means of 1H-NMR and/or HPLC).


The compounds according to the invention can also be rendered soluble by suitable substitution, for example by relatively long alkyl groups (about 4 to 20 C atoms), in particular branched alkyl groups, or optionally substituted aryl groups, for example, xylyl, mesityl or branched terphenyl or quater-phenyl groups. Compounds of this type are then soluble in common organic solvents, such as, for example, toluene or xylene, at room temperature in sufficient concentration to be able to process the complexes from solution. These soluble compounds are particularly suitable for processing from solution, for example by printing processes.


The compounds according to the invention can also be mixed with a polymer. It is likewise possible to incorporate these compounds covalently into a polymer. This is possible, in particular, with compounds which are substituted by reactive leaving groups, such as bromine, iodine, chlorine, boronic acid or boronic acid ester, or by reactive, polymerisable groups, such as olefins or oxetanes. These can be used as monomers for the production of corresponding oligomers, dendrimers or polymers. The oligomerisation or polymerisation here preferably takes place via the halogen functionality or the boronic acid functionality or via the polymerisable group. It is furthermore possible to crosslink the polymers via groups of this type. The compounds and polymers according to the invention can be employed as crosslinked or uncrosslinked layer.


The invention therefore furthermore relates to oligomers, polymers or dendrimers containing one or more of the above-mentioned compounds according to the invention, where one or more bonds are present from the compound according to the invention to the polymer, oligomer or dendrimer. Depending on the linking of the compound according to the invention, this therefore forms a side chain of the oligomer or polymer or is linked in the main chain. The polymers, oligomers or dendrimers may be conjugated, partially conjugated or non-conjugated. The oligomers or polymers may be linear, branched or dendritic. The same preferences as described above apply to the recurring units of the compounds according to the invention in oligomers, dendrimers and polymers.


For the preparation of the oligomers or polymers, the monomers according to the invention are homopolymerised or copolymerised with further monomers. Preference is given to copolymers, where the units of the formula (1) or the preferred embodiments described above are present in amounts of 0.01 to 99.9 mol %, preferably 5 to 90 mol %, particularly preferably 20 to 80 mol %. Suitable and preferred comonomers which form the polymer backbone are selected from fluorenes (for example in accordance with EP 842208 or WO 2000/022026), spirobifluorenes (for example in accordance with EP 707020, EP 894107 or WO 2006/061181), para-phenylenes (for example in accordance with WO 92/18552), carbazoles (for example in accordance with WO 2004/070772 or WO 2004/113468), thiophenes (for example in accordance with EP 1028136), dihydrophenanthrenes (for example in accordance with WO 2005/014689), cis- and trans-indeno-fluorenes (for example in accordance with WO 2004/041901 or WO 2004/113412), ketones (for example in accordance with WO 2005/040302), phenanthrenes (for example in accordance with WO 2005/104264 or WO 2007/017066) or also a plurality of these units. The polymers, oligomers and dendrimers may also contain further units, for example hole-transport units, in particular those based on triarylamines, and/or electron-transport units.


Formulations of the compounds according to the invention are necessary for processing of the compounds according to the invention from the liquid phase, for example by spin coating or by printing processes. These formulations can be, for example, solutions, dispersions or emulsions. It may be preferred to use mixtures of two or more solvents for this purpose. Suitable and preferred solvents are, for example, toluene, anisole, o-, m- or p-xylene, methyl benzoate, mesitylene, tetralin, veratrol, THF, methyl-THF, THP, chlorobenzene, dioxane, phenoxytoluene, in particular 3-phenoxytoluene, (−)-fenchone, 1,2,3,5-tetramethylbenzene, 1,2,4,5-tetramethylbenzene, 1-methylnaphthalene, 2-methylbenzothiazole, 2-phenoxyethanol, 2-pyrrolidinone, 3-methylanisole, 4-methylanisole, 3,4-dimethylanisole, 3,5-dimethylanisole, acetophenone, α-terpineol, benzothiazole, butyl benzoate, cumene, cyclohexanol, cyclohexanone, cyclohexylbenzene, decalin, dodecylbenzene, ethyl benzoate, indane, methyl benzoate, NMP, p-cymene, phenetole, 1,4-diisopropylbenzene, dibenzyl ether, diethylene glycol butyl methyl ether, triethylene glycol butyl methyl ether, diethylene glycol dibutyl ether, triethylene glycol dimethyl ether, diethylene glycol mono-butyl ether, tripropylene glycol dimethyl ether, tetraethylene glycol dimethyl ether, 2-isopropylnaphthalene, pentylbenzene, hexylbenzene, heptyl-benzene, octylbenzene, 1,1-bis(3,4-dimethylphenyl)ethane or mixtures of these solvents.


The present invention therefore furthermore relates to a formulation comprising at least one compound according to the invention or at least one oligomer, polymer or dendrimer according to the invention and at least one further compound. The further compound may be, for example, a solvent, in particular one of the above-mentioned solvents or a mixture of these solvents. However, the further compound may also be a further organic or inorganic compound which is likewise employed in the electronic device, for example a matrix material. This further compound may also be polymeric.


The compounds of the formula (1) described above or the preferred embodiments indicated above can be used as active component in the electronic device. The present invention thus furthermore relates to the use of a compound according to the invention in an electronic device. The present invention still furthermore relates to an electronic device comprising at least one compound according to the invention.


An electronic device is taken to mean a device which comprises an anode, a cathode and at least one layer, where this layer comprises at least one organic or organometallic compound. The electronic device according to the invention thus comprises an anode, a cathode and at least one layer which comprises at least one compound of the formula (1) given above. Preferred electronic devices here are selected from the group consisting of organic electroluminescent devices (OLEDs, PLEDs), organic integrated circuits (O-ICs), organic field-effect transistors (O-FETs), organic thin-film transistors (O-TFTs), organic light-emitting transistors (O-LETs), organic solar cells (O-SCs), organic optical detectors, organic photoreceptors, organic field-quench devices (O-FQDs), light-emitting electrochemical cells (LECs) or organic laser diodes (O-lasers), comprising at least one compound of the formula (1) given above in at least one layer. Particular preference is given to organic electroluminescent devices. Active components are generally the organic or inorganic materials which have been introduced between the anode and cathode, for example charge-injection, charge-transport or charge-blocking materials, but in particular emission materials and matrix materials. The compounds according to the invention exhibit particularly good properties as emission material in organic electroluminescent devices. Organic electroluminescent devices are therefore a preferred embodiment of the invention. Furthermore, the compounds according to the invention can be employed for the generation of singlet oxygen or in photocatalysis.


The organic electroluminescent device comprises a cathode, an anode and at least one emitting layer. Apart from these layers, it may also comprise further layers, for example in each case one or more hole-injection layers, hole-transport layers, hole-blocking layers, electron-transport layers, electron-injection layers, exciton-blocking layers, electron-blocking layers, charge-generation layers and/or organic or inorganic p/n junctions. It is possible here for one or more hole-transport layers to be p-doped, for example with metal oxides, such as MoO3 or WO3, or with (per)fluorinated electron-deficient aromatic compounds, and/or for one or more electron-transport layers to be n-doped. Interlayers which have, for example, an exciton-blocking function and/or control the charge balance in the electroluminescent device may likewise be introduced between two emitting layers. However, it should be pointed out that each of these layers does not necessarily have to be present.


The organic electroluminescent device here may comprise one emitting layer or a plurality of emitting layers. If a plurality of emission layers are present, these preferably have in total a plurality of emission maxima between 380 nm and 750 nm, resulting overall in white emission, i.e. various emitting compounds which are able to fluoresce or phosphoresce are used in the emitting layers. Particular preference is given to three-layer systems, where the three layers exhibit blue, green and orange or red emission (for the basic structure see, for example, WO 2005/011013), or systems which have more than three emitting layers. It may also be a hybrid system, where one or more layers fluoresce and one or more other layers phosphoresce.


In a preferred embodiment of the invention, the organic electroluminescent device comprises the compound of the formula (1) or the preferred embodiments indicated above as emitting compound in one or more emitting layers.


If the compound of the formula (1) is employed as emitting compound in an emitting layer, it is preferably employed in combination with one or more matrix materials. The mixture comprising the compound of the formula (1) and the matrix material comprises between 1 and 99% by vol., preferably between 2 and 90% by vol., particularly preferably between 3 and 40% by vol., especially between 5 and 15% by vol., of the compound of the formula (1), based on the mixture as a whole comprising emitter and matrix material. Correspondingly, the mixture comprises between 99.9 and 1% by vol., preferably between 99 and 10% by vol., particularly preferably between 97 and 60% by vol., in particular between 95 and 85% by vol., of the matrix material, based on the mixture as a whole comprising emitter and matrix material.


The matrix material employed can in general be all materials which are known for this purpose in accordance with the prior art. The triplet level of the matrix material is preferably higher than the triplet level of the emitter.


Suitable matrix materials for the compounds according to the invention are ketones, phosphine oxides, sulfoxides and sulfones, for example in accordance with WO 2004/013080, WO 2004/093207, WO 2006/005627 or WO 2010/006680, triarylamines, carbazole derivatives, for example CBP (N,N-biscarbazolylbiphenyl), m-CBP or the carbazole derivatives disclosed in WO 2005/039246, US 2005/0069729, JP 2004/288381, EP 1205527, WO 2008/086851 or US 2009/0134784, indolocarbazole derivatives, for example in accordance with WO 2007/063754 or WO 2008/056746, indenocarbazole derivatives, for example in accordance with WO 2010/136109 or WO 2011/000455, azacarbazoles, for example in accordance with EP 1617710, EP 1617711, EP 1731584, JP 2005/347160, bipolar matrix materials, for example in accordance with WO 2007/137725, silanes, for example in accordance with WO 2005/111172, azaboroles or boronic esters, for example in accordance with WO 2006/117052, diaza-silole derivatives, for example in accordance with WO 2010/054729, diaza-phosphole derivatives, for example in accordance with WO 2010/054730, triazine derivatives, for example in accordance with WO 2010/015306, WO 2007/063754 or WO 2008/056746, zinc complexes, for example in accordance with EP 652273 or WO 2009/062578, dibenzofuran derivatives, for example in accordance with WO 2009/148015, or bridged carbazole derivatives, for example in accordance with US 2009/0136779, WO 2010/050778, WO 2011/042107 or WO 2011/088877.


It may also be preferred to employ a plurality of different matrix materials as a mixture, in particular at least one electron-conducting matrix material and at least one hole-conducting matrix material. A preferred combination is, for example, the use of an aromatic ketone, a triazine derivative or a phosphine oxide derivative with a triarylamine derivative or a carbazole derivative as mixed matrix for the metal complex according to the invention. Preference is likewise given to the use of a mixture of a charge-transporting matrix material and an electrically inert matrix material which is not involved or not essentially involved in charge transport, as described, for example, in WO 2010/108579.


It is furthermore preferred to employ a mixture of two or more triplet emitters together with a matrix. The triplet emitter having the shorter-wave emission spectrum serves as co-matrix for the triplet-emitter having the longer-wave emission spectrum. Thus, for example, the complexes of the formula (1) according to the invention can be employed as co-matrix for triplet emitters emitting at longer wavelength, for example for green- or red-emitting triplet emitters.


The compounds according to the invention can also be employed in other functions in the electronic device, for example as hole-transport material in a hole-injection or -transport layer, as charge-generation material or as electron-blocking material. The complexes according to the invention can likewise be employed as matrix material for other phosphorescent metal complexes in an emitting layer.


The cathode preferably comprises metals having a low work function, metal alloys or multilayered structures comprising various metals, such as, for example, alkaline-earth metals, alkali metals, main-group metals or lanthanoids (for example Ca, Ba, Mg, Al, In, Mg, Yb, Sm, etc.). Also suitable are alloys comprising an alkali metal or alkaline-earth metal and silver, for example an alloy comprising magnesium and silver. In the case of multilayered structures, further metals which have a relatively high work function, such as, for example, Ag, may also be used in addition to the said metals, in which case combinations of the metals, such as, for example, Mg/Ag, Ca/Ag or Ba/Ag, are generally used. It may also be preferred to introduce a thin interlayer of a material having a high dielectric constant between a metallic cathode and the organic semiconductor. Suitable for this purpose are, for example, alkali metal or alkaline-earth metal fluorides, but also the corresponding oxides or carbonates (for example LiF, Li2O, BaF2, MgO, NaF, CsF, Cs2CO3, etc.). Organic alkali-metal complexes, for example Liq (lithium quinolinate), are likewise suitable for this purpose. The layer thickness of this layer is preferably between 0.5 and 5 nm.


The anode preferably comprises materials having a high work function. The anode preferably has a work function of greater than 4.5 eV vs. vacuum. Suitable for this purpose are on the one hand metals having a high redox potential, such as, for example, Ag, Pt or Au. On the other hand, metal/metal oxide electrodes (for example Al/Ni/NiOx, Al/PtOx) may also be preferred. For some applications, at least one of the electrodes must be transparent or partially transparent in order either to facilitate irradiation of the organic material (O-SCs) or the coupling-out of light (OLEDs/PLEDs, O-LASERs). Preferred anode materials here are conductive mixed metal oxides. Particular preference is given to indium tin oxide (ITO) or indium zinc oxide (IZO). Preference is furthermore given to conductive, doped organic materials, in particular conductive doped polymers, for example PEDOT, PANI or derivatives of these polymers. It is furthermore preferred for a p-doped hole-transport material to be applied to the anode as hole-injection layer, where suitable p-dopants are metal oxides, for example MoO3 or WO3, or (per)fluorinated electron-deficient aromatic compounds. Further suitable p-dopants are HAT-CN (hexacyanohexaazatriphenylene) or the compound NPD9 from Novaled. A layer of this type simplifies hole injection in materials having a low HOMO, i.e. a large value of the HOMO.


All materials as are used in accordance with the prior art for the layers can generally be used in the further layers, and the person skilled in the art will be able to combine each of these materials with the materials according to the invention in an electronic device without inventive step.


The device is correspondingly structured (depending on the application), provided with contacts and finally hermetically sealed, since the lifetime of such devices is drastically shortened in the presence of water and/or air.


Preference is furthermore given to an organic electroluminescent device, characterised in that one or more layers are applied by means of a sublimation process, in which the materials are vapour-deposited in vacuum sublimation units at an initial pressure of usually less than 10−5 mbar, preferably less than 10−6 mbar. It is also possible for the initial pressure to be even lower or even higher, for example less than 10−7 mbar.


Preference is likewise given to an organic electroluminescent device, characterised in that one or more layers are applied by means of the OVPD (organic vapour phase deposition) process or with the aid of carrier-gas sublimation, in which the materials are applied at a pressure of between 10−5 mbar and 1 bar. A special case of this process is the OVJP (organic vapour jet printing) process, in which the materials are applied directly through a nozzle and thus structured (for example M. S. Arnold et al., Appl. Phys. Left. 2008, 92, 053301).


Preference is furthermore given to an organic electroluminescent device, characterised in that one or more layers are produced from solution, such as, for example, by spin coating, or by means of any desired printing process, such as, for example, screen printing, flexographic printing, offset printing or nozzle printing, but particularly preferably LIT (light induced thermal imaging, thermal transfer printing) or ink-jet printing. Soluble compounds are necessary for this purpose, which are obtained, for example, through suitable substitution.


The organic electroluminescent device may also be produced as a hybrid system by applying one or more layers from solution and applying one or more other layers by vapour deposition. Thus, for example, it is possible to apply an emitting layer comprising a compound of the formula (1) and a matrix material from solution and to apply a hole-blocking layer and/or an electron-transport layer on top by vacuum vapour deposition.


These processes are generally known to the person skilled in the art and can be applied by him without problems to organic electroluminescent devices comprising compounds of the formula (1) or the preferred embodiments indicated above.


The electronic devices according to the invention, in particular organic electroluminescent devices, are distinguished over the prior art by one or more of the following surprising advantages:

  • 1. The metal complexes according to the invention have a reduced sublimation temperature compared with analogous compounds which contain no structural unit of the formula (3). This results in significant advantages during purification of the complexes and during production of vacuum-processed electroluminescent devices, since the thermal stress to which the materials are subjected during sublimation is significantly reduced. Alternatively, higher sublimation rates are possible on use of a higher sublimation temperature, which represents an advantage in the industrial preparation of the complexes. For some tris-ortho-metallated metal complexes, decomposition-free or substantially decomposition-free sublimation is only made possible at all by this, and is otherwise impossible due to the high sublimation temperature.
  • 2. The metal complexes according to the invention have higher solubility compared with analogous compounds which contain no structural unit of the formula (3). Thus, many compounds which are otherwise identical to the compounds according to the invention, but contain no structural unit of the formula (3), have only poor solubility or are only soluble in low concentration in a multiplicity of common organic solvents. By contrast, the compounds according to the invention are soluble in significantly higher concentration in a multiplicity of common organic solvents, which also enables the processing and production of the electroluminescent devices from solution. Higher solubility furthermore represents an advantage in the purification of the complexes in the synthesis.
  • 3. The metal complexes according to the invention in some cases have a very narrow emission spectrum, which results in high colour purity of the emission, as is desirable, in particular, for display applications.
  • 4. Organic electroluminescent devices comprising compounds of the formula (1) as emitting materials have a very good lifetime.
  • 5. Organic electroluminescent devices comprising compounds of the formula (1) as emitting materials have excellent efficiency. In particular, the efficiency is significantly higher compared with analogous compounds which contain no structural unit of the formula (3).
  • 6. The compounds according to the invention have higher oxidation stability, in particular in solution, compared with analogous compounds which contain no structural unit of the formula (3) in which one or more groups R3 stand for hydrogen.


These advantages mentioned above are not accompanied by an impairment of the other electronic properties.


The invention is explained in greater detail by the following examples, without wishing to restrict it thereby. The person skilled in the art will be able to produce further electronic devices on the basis of the descriptions without inventive step and will thus be able to carry out the invention throughout the range claimed.







EXAMPLES

The following syntheses are carried out, unless indicated otherwise, in dried solvents under a protective-gas atmosphere. The metal complexes are additionally handled with exclusion of light or under yellow light. The solvents and reagents can be purchased, for example, from Sigma-ALDRICH or ABCR. The respective numbers in square brackets or the numbers indicated for individual compounds relate to the CAS numbers of the compounds known from the literature.


A: Synthesis of the Synthones S, SP, SH, SB
Example SP1: Pinacolyl 1,1,3,3-Tetramethylindane-5-boronate

Variant 1:




embedded image


A) 5-Bromo-1,1,3,3-tetramethylindane[169695-24-3], SP1-Br



embedded image


0.6 g of anhydrous iron(III) chloride and then, dropwise with exclusion of light, a mixture of 25.6 ml (500 mol) of bromine and 300 ml of dichloromethane are added to a solution, cooled to 0° C., of 87.2 g (500 mmol) of 1,1,3,3-tetramethylindane [4834-33-7] in 1000 ml of dichloromethane at such a rate that the temperature does not exceed +5° C. The reaction mixture is stirred at room temperature for a further 16 h, 300 ml of saturated sodium sulfite solution are then slowly added, the aqueous phase is separated off, the organic phase is washed three times with 1000 ml of water each time, dried over sodium sulfate, filtered through a short silica-gel column, and the solvent is then stripped off. Finally, the solid is recrystallised once from a little (about 100-150 ml) ethanol. Yield: 121.5 g (480 mmol), 96%; purity: about 95% according to 1H-NMR.


B) Pinacolyl 1,1,3,3-tetramethylindane-5-boronate, SP1

A mixture of 25.3 g (100 mmol) of S4-Br, 25.4 g (120 mmol) of bis(pinacolato)diborane [73183-34-3], 29.5 g (300 mmol) of potassium acetate, anhydrous, 561 mg (2 mmol) of tricyclohexylphosphine and 249 mg (1 mmol) of palladium(II) acetate and 400 ml of dioxane is stirred at 80° C. for 16 h. After removal of the solvent in vacuo, the residue is taken up in 500 ml of dichloromethane, filtered through a Celite bed, the filtrate is evaporated in vacuo until crystallisation commences, and finally about 100 ml of methanol are also added dropwise in order to complete the crystallisation. Yield: 27.9 g (93 mmol), 93%; purity: about 95% according to 1H-NMR. Boronic acid esters formed as oil can also be reacted further without purification.


Variant 2:




embedded image


3.3 g (5 mmol) of bis[(1,2,5,6-η)-1,5-cyclooctadiene]di-μ-methoxydiiridium-(I) [12148-71-9], then 2.7 g (10 mmol) of 4,4′-di-tert-butyl-[2,2′]bipyridinyl [72914-19-3] and then 5.1 g (10 mmol) of bis(pinacolato)diborane are added to 800 ml of n-heptane, and the mixture is stirred at room temperature for 15 min. 127.0 g (500 mmol) of bis(pinacolato)diborane and then 87.2 g (500 mmol) of 1,1,3,3-tetramethylindane [4834-33-7] are subsequently added, and the mixture is warmed at 80° C. for 12 h (TLC check, heptane:ethyl acetate 5:1). After cooling of the reaction mixture, 300 ml of ethyl acetate are added, the mixture is filtered through a silica-gel bed, and the filtrate is evaporated to dryness in vacuo. The crude product is recrystallised twice from acetone (about 800 ml). Yield: 136.6 g (455 mmol), 91%; purity: about 99% according to 1H-NMR.


The following compounds can be prepared analogously:



















Product




Starting

Boronic acid ester



Ex.
material
Bromide
Variant
Yield







SP2


embedded image

  91324-94-6



embedded image

  SP2-Br



embedded image

  SP2 1

80%





SP2


embedded image

  91324-94-6




embedded image

  SP2 1

95%





SP3


embedded image

  142076-41-3



embedded image

  SP3-Br



embedded image

  SP3 1

81%





SP4


embedded image

  59508-28-0



embedded image

  SP4-Br



embedded image

  SP4 1

78%





SP5


embedded image

  4486-29-7



embedded image

  16499-72-2 SP5-Br



embedded image

  SP5 1

80%





SP6


embedded image

  35185-96-7



embedded image

  SP6-Br



embedded image

  SP6 1

82%





SP7


embedded image

  113710-83-1



embedded image

  SP7-Br



embedded image

  SP7 1

79%





SP7


embedded image

  113710-83-1




embedded image

  SP7 2

89%





SH1


embedded image

  6683-46-1



embedded image

  SH1-Br 27452-17-1



embedded image

  SH1 1

74%





SH1


embedded image

  6683-46-1




embedded image

  2 SH1

92%





SB1


embedded image

  4175-52-4



embedded image

  SB1-Br



embedded image

  SB1 1

80%





SB1


embedded image

  4175-52-4




embedded image

  SB1 2

93%





SB2


embedded image

  2716-23-6



embedded image

  SB2-Br



embedded image

  SB2 1

81%





SB2


embedded image

  2716-23-6




embedded image

  SB2 2

90%





SB3


embedded image

  60749-53-3



embedded image

  SB3-Br



embedded image

  SB3 1

74%





SB3


embedded image

  60749-53-3




embedded image

  SB3 2

94%





SH17


embedded image

  853763-39-0




embedded image

  SH17 2

84%





SH18


embedded image

  872286-95-8




embedded image

  SH18 2

90%









Example SP8: 5,6-Dibromo-1,1,2,2,3,3-hexamethylindane



embedded image


1.3 g of anhydrous iron(III) chloride and then, dropwise with exclusion of light, a mixture of 64.0 ml (1.25 mol) of bromine and 300 ml of dichloromethane are added to a solution of 101.2 g (500 mmol) of 1,1,2,2,3,3-hexamethylindane [91324-94-6] in 2000 ml of dichloromethane at such a rate that the temperature does not exceed 25° C. If necessary, the mixture is counter-cooled using a cold-water bath. The reaction mixture is stirred at room temperature for a further 16 h, 500 ml of saturated sodium sulfite solution are then slowly added, the aqueous phase is separated off, the organic phase is washed three times with 1000 ml of water each time, dried over sodium sulfate, filtered through a short silica-gel column, and the solvent is then stripped off. Finally, the solid is recrystallised once from a little (about 100 ml) ethanol. Yield: 135.8 g (377 mmol), 75%; purity: about 95% according to 1H-NMR.


The following compounds are prepared analogously:

















Ex.
Starting materials
Product
Yield








SP9


embedded image

  113710-83-1



embedded image

  SP9

80%






SH2


embedded image

  6683-46-1



embedded image

  184885-74-3 SH2

76%






SB4


embedded image

  4175-52-4



embedded image

  SB4

69%






SB5


embedded image

  2716-23-6



embedded image

  SB5

72%






SB6


embedded image

  60749-53-3



embedded image

  SB6

78%









Example SP10: 5,6-Diamino-1,1,2,2,3,3-hexamethylindane



embedded image


A: 6,6-Dinitro-1,1,2,2,3,3-tetramethylindane, SP10a



embedded image


350 ml of 100% by weight nitric acid are slowly added dropwise to a vigorously stirred mixture, cooled to 0° C., of 101.2 g (500 mmol) of 1,1,2,2,3,3-hexamethylindane [91324-94-6] and 350 ml of 95% by weight sulfuric acid at such a rate that the temperature does not exceed +5° C. The reaction mixture is subsequently allowed to warm slowly to room temperature over 2-3 h and is then poured into a vigorously stirred mixture of 6 kg of ice and 2 kg of water. The pH is adjusted to 8-9 by addition of 40% by weight NaOH, the mixture is extracted three times with 1000 ml of ethyl acetate each time, the combined organic phases are washed twice with 1000 ml of water each time, dried over magnesium sulfate, the ethyl acetate is then removed virtually completely in vacuo until crystallisation commences, and the crystallisation is completed by addition of 500 ml of heptane. The beige crystals obtained in this way are filtered off with suction and dried in vacuo. Yield: 136.2 g (466 mmol), 93%; purity: about 94% according to 1H-NMR, remainder about 4% of 4,6-dinitro-1,1,3,3-tetramethylindane. About 3% of 4,5-dinitro-1,1,3,3-tetramethylindane, S35b, can be isolated from the mother liquor.


B: 5,6-Diamino-1,1,2,2,3,3-hexamethylindane, S35

136.2 g (466 mmol) of 5,6-dinitro-1,1,2,2,3,3-hexamethylindane, S35a, are hydrogenated at room temperature in 1200 ml of ethanol on 10 g of palladium/carbon at a hydrogen pressure of 3 bar for 24 h. The reaction mixture is filtered twice through a Celite bed, the brown solid obtained after removal of the ethanol is subjected to a bulb-tube distillation (T about 160° C., p about 10−4 mbar). Yield: 98.5 g (424 mmol), 91%; purity: about 95% according to 1H-NMR.


The following compounds are prepared analogously:















Ex.
Starting materials
Product
Yield







SP11


embedded image

  4834-33-7



embedded image

  SP11

84%





SP12


embedded image

  142076-41-3



embedded image

  SP11

76%





SH3


embedded image

  6683-46-1



embedded image

  SH3

75%





SB7


embedded image

  4175-52-4



embedded image

  SB7

72%





SB8


embedded image

  2716-23-6



embedded image

  SB8

70%





SB9


embedded image

  60749-53-3



embedded image

  SB9

74%









Example SP13: N-[2-(1,1,2,2,3,3-Hexamethylindan-5-yl)ethyl]benzamide



embedded image


A: 1,1,2,2,3,3-Hexamethylindane-5-carboxaldehyde, SP13a



embedded image


200 ml (500 mmol) of n-BuLi, 2.5 M in n-hexane, are added dropwise to a vigorously stirred solution, cooled to −78° C., of 140.6 g (500 mmol) of 5-bromo-1,1,2,2,3,3-hexamethylindane, SP2-Br, in 1000 ml of THF at such a rate that the temperature does not exceed −55° C. When the addition is complete, the mixture is stirred for a further 30 min., and a mixture of 42.3 ml (550 mmol) of DMF and 50 ml of THF is then allowed to run in with vigorous stirring. The mixture is stirred at −78° C. for a further 1 h, then allowed to warm to room temperature and quenched by addition of 300 ml of saturated ammonium chloride solution. The organic phase is separated off, the THF is removed in vacuo, the residue is taken up in 500 ml of ethyl acetate, washed once with 300 ml of 5% hydrochloric acid, twice with 300 ml of water each time, once with 300 ml of saturated sodium chloride solution, the organic phase is dried over magnesium sulfate, and the solvent is then removed in vacuo. The residue is employed in step B without further purification. Yield: 107.1 g (465 mmol), 93%; purity: about 95% according to 1H-NMR.


The following compounds can be prepared analogously:
















Starting




Ex.
material
Product
Yield







SP14a


embedded image

  SP3-Br



embedded image

  SP14a

91%





SH4a


embedded image

  SH1-Br



embedded image

  SH4a

89%





SB10a


embedded image

  SB3-Br



embedded image

  SB10a

88%









B: 2-(1,1,2,2,3,3-Hexamethyl-5-Indanyl)ethylamine, SP13b



embedded image


A mixture of 80.6 g (350 mmol) of 1,1,2,2,3,3-hexamethylindane-5-carboxaldehyde, SP13a, 400 ml of nitromethane and 4.6 g (70 mmol) of ammonium acetate, anhydrous, is heated under reflux for 2 h until the starting material has been consumed (TLC check). After cooling, the reaction mixture is poured into 1000 ml of water, extracted three times with 300 ml of dichloromethane each time, the combined organic phases are washed three times with saturated sodium hydrogencarbonate solution, three times with 300 ml of water each time and once with 300 ml of saturated sodium chloride solution, dried over magnesium sulfate, and the solvent is removed in vacuo. The dark oily residue is dissolved in 100 ml of THF and slowly added dropwise with ice-cooling to a solution of 38.0 g (1.0 mol) of lithium aluminium hydride in 1000 ml of THF (care: exothermic reaction?). When the addition is complete, the reaction mixture is allowed to warm to room temperature and is stirred at room temperature for a further 20 h. The reaction mixture is hydrolysed with ice-cooling by slow addition of 500 ml of saturated sodium sulfate solution. The salts are filtered off with suction, rinsed with 500 ml of THF, the THF is removed in vacuo, the residue is taken up in 1000 ml of dichloromethane, the solution is washed three times with 300 ml of water each time, once with 300 ml of saturated sodium chloride solution, dried over magnesium sulfate, and the solvent is then removed in vacuo. The purification is carried out by bulb-tube distillation (p about 10−4 mbar, T=200° C.). Yield: 67.0 g (273 mmol), 78%; purity: about 95% according to 1H-NMR.


The following compounds can be prepared analogously:
















Starting




Ex.
material
Product
Yield







SP14b


embedded image

  S14a



embedded image

  S14b

74%





SH4b


embedded image

  SH4a



embedded image

  SH4b

70%





SB10b


embedded image

  SB10a



embedded image

  SB10b

72%









C: N-[2-(1,1,2,2,3,3-Hexamethylindan-5-yl)ethyl]benzamide, SP13

A solution of 14.1 ml (100 mmol) of benzoyl chloride [98-88-4] in 100 ml of dichloromethane is added dropwise with vigorous stirring at 0° C. to a mixture of 24.5 g (100 mmol) of 2-(1,1,2,2,3,3-hexamethyl-5-indanyl)ethylamine, SP13b, 14.1 ml (100 mmol) of triethylamine and 150 ml of dichloromethane at such a rate that the temperature does not exceed 30° C. The mixture is subsequently stirred at room temperature for a further 1 h. The dichloromethane is removed in vacuo, 100 ml of methanol are added to the colourless solid, which is filtered off with suction, washed three times with 50 ml of methanol and dried in vacuo. Yield: 31.1 g (89 mmol), 89%; purity: about 98% according to 1H-NMR.


The following compounds can be prepared analogously:

















Starting
Carboxylic




Ex.
material
acid chloride
Product
Yield







SP14


embedded image

  SP14b



embedded image

  6613-441



embedded image

  SP14

74%





SP15


embedded image

  SP13b



embedded image

  6613-441



embedded image

  SP15

86%





SP16


embedded image

  SP13b



embedded image

  765314- 57-6



embedded image

  SP16

88%





SP17


embedded image

  SP13b



embedded image

  1710-98-1



embedded image

  SP17

83%





SP18


embedded image

  SP13b



embedded image

  14002-51-8



embedded image

  SP18

80%





SH4


embedded image

  SH4b



embedded image

  98-88-4



embedded image

  SH4

70%





SH5


embedded image

  SH4b



embedded image

  1710-98-1



embedded image

  SH5

76%





SH6


embedded image

  SH4b



embedded image

  14002-51-8



embedded image

  SH6

73%





SH7


embedded image

  SH4b



embedded image

  1005786-37- 7



embedded image

  SH7

74%





SH8


embedded image

  SH4b



embedded image

  104224-50-2



embedded image

  SH8

72%





SH9


embedded image

  SH4b



embedded image

  104224-50-2



embedded image

  SH9

72%





SH10


embedded image

  SH4b



embedded image

  100793-48-4



embedded image

  SH10

76%





SB10


embedded image

  SB10b



embedded image

  98-88-4



embedded image

  SB10

82%









Example SP19: 7-Bromo-1,2,3,4-tetrahydro-1,4-methanonaphthalene-6-carbaldehyde



embedded image


Procedure analogous to L. S. Chen et al., J. Organomet. Chem. 1980, 193, 283-292. 40 mil (100 mmol) of n-BuLi, 2.5 M in hexane, pre-cooled to −110° C., are added to a solution, cooled to −110° C., of 30.2 g (100 mmol) of 6,7-dibromo-1,2,3,4-tetrahydro-1,4-methanonaphthalene [42810-32-2] in a mixture of 1000 ml of THF and 1000 ml of diethyl ether at such a rate that the temperature does not exceed −105° C. The mixture is stirred for a further 30 min., a mixture, pre-cooled to −110° C., of 9.2 ml (120 mmol) of DMF and 100 ml of diethyl ether is then added dropwise, the mixture is then stirred for a further 2 h, allowed to warm to −10° C., 1000 ml of 2 N HCl are added, and the mixture is stirred at room temperature for a further 2 h. The organic phase is separated off, washed once with 500 ml of water, once with 500 ml of saturated sodium chloride solution, dried over magnesium sulfate, the solvent is removed in vacuo, and the residue is subjected to a bulb-tube distillation (T about 90° C., p about 10−4 mbar). Yield: 15.8 g (63 mmol), 63%; purity: about 95% according to 1H-NMR.















Ex.
Starting materials
Product
Yield







SP20


embedded image

  SP8



embedded image

  SP20

68%





SP21


embedded image

  SP9



embedded image

  SP21

60%





SH11


embedded image

  SH2



embedded image

  SH11

60%





SB11


embedded image

  SB4



embedded image

  SB11

55%





SB12


embedded image

  SB5



embedded image

  SB12

50%





SB13


embedded image

  SB6



embedded image

  SB13

53%









Example SP22: 7-Phenylethynyl-1,2,3,4-tetrahydro-1,4-methanonaphthalene-6-carbaldehyde



embedded image


1.6 g (6 mmol) of triphenylphosphine, 674 mg (3 mmol) of palladium(II) acetate, 571 mg (30 mmol) of copper(I) iodide and 15.3 g (150 mmol) of phenylacetylene [536-74-3] are added consecutively to a solution of 25.1 g (100 mmol) of 7-bromo-1,2,3,4-tetrahydro-1,4-methanonaphthalene-6-carbaldehyde, SP19, in a mixture of 200 ml of DMF and 100 ml of triethylamine, and the mixture is stirred at 65° C. for 4 h. After cooling, the precipitated triethylammonium hydrochloride is filtered off with suction, rinsed with 30 ml of DMF. The filtrate is freed from the solvents in vacuo. The oily residue is taken up in 300 ml of ethyl acetate, the solution is washed five times with 100 ml of water each time and once with 100 ml of saturated sodium chloride solution, and the organic phase is dried over magnesium sulfate. After removal of the ethyl acetate in vacuo, the oily residue is chromatographed on silica gel (n-heptane:ethyl acetate 99:1). Yield: 19.6 g (72 mmol), 72%; purity: about 97% according to 1H-NMR.


The following derivatives can be prepared analogously:

















Bromo-





Ex.
arylaldeyde
Alkyne
Product
Yield







SP23


embedded image

  SP20



embedded image

  536-74-3



embedded image

  SP23

69%





SP24


embedded image

  SP20



embedded image

  25837-46-1



embedded image

  S24

69%





SP25


embedded image

  SP21



embedded image

  2949-26-0



embedded image

  SP25

70%





SH12


embedded image

  SH11



embedded image

  536-74-3



embedded image

  SH12

66%





SH13


embedded image

  SH11



embedded image

  188889-51-2



embedded image

  SH13

67%





SB14


embedded image

  SB11



embedded image

  536-74-3



embedded image

  SB14

61%





SB15


embedded image

  SB12



embedded image

  876726-86-2



embedded image

  SB15

63%





SB16


embedded image

  SB13



embedded image

  188889-51-2



embedded image

  SB16

73%









Example SB17



embedded image


Procedure analogous to G. Zhang et al., Ad. Synth. & Catal., 2011, 353(2+3), 291. A mixture of 28.4 g (100 mmol) of SB1, 9.4 g (105 mmol) of copper(I) cyanide, 41.5 g (300 mmol) of potassium carbonate, 100 g of glass beads (diameter 3 mm) and 400 ml of DMF and 3.6 ml of water is stirred at 70° C. for 10 h. After cooling, the DMF is substantially removed in vacuo, the residue is diluted with 500 ml of dichloromethane, the salts are filtered off through a Celite bed, the filtrate is washed three times with 200 ml of water and once with 100 ml of saturated sodium chloride solution and then dried over magnesium sulfate. The oily residue which remains after removal of the dichloromethane is distilled in a bulb tube. Yield: 11.5 g (63 mmol), 63%; purity: about 97% according to 1H NMR.


The following compounds can be prepared analogously:















Ex.
Starting material
Product
Yield







SP26


embedded image

  SP1



embedded image

  SP26

58%





SP27


embedded image

  SP2



embedded image

  SP27

60%





SP28


embedded image

  SP7



embedded image

  S28

61%





SH14


embedded image

  SH1



embedded image

  SH14

62%





SB18


embedded image

  SB2



embedded image

  SB18

65%





SB19


embedded image

  SB3



embedded image

  SB19

66%









Example SH15: Bis-(1,1,4,4-tetramethyltetrahydronaphth-6-yl) ether



embedded image


Procedure analogous to G. Chen et al., Tetrahedron Letters 2007, 48, 3, 47. A vigorously stirred mixture of 53.5 g (200 mmol) of 6-bromo-1,1,4,4-tetramethyltetrahydronaphthalene, SH1-Br, 212.2 g (800 mmol) of tripotassium phosphate trihydrate, 300 g of glass beads (diameter 3 mm), 449 mg (2 mmol) of palladium(II) acetate, 809 mg (4 mmol) of tri-tert-butylphosphine and 1000 ml of dioxane is heated under reflux for 20 h. After cooling, the salts are filtered off with suction and rinsed with 300 ml of dioxane, the filtrate is evaporated in vacuo, the residue is taken up in 500 ml of ethyl acetate, the solution is washed three times with 300 ml of water each time, once with 300 ml of saturated sodium chloride solution and dried over magnesium sulfate, and the ethyl acetate is then removed in vacuo. The residue is purified by bulb-tube distillation (p about 10−4 mbar, T about 180° C.). Yield: 28.1 g (72 mmol), 72%; purity: about 96% according to 1H-NMR.


Example S1: 27-Di-tert-butyl-9,9′-(6-bromopyridin-2-yl)xanthene, S1



embedded image


120 ml (300 mmol) of n-BuLi, 2.5 M in n-hexane, are added at room temperature to a solution of 84.7 g (300 mmol) of di(4-tert-butylphenyl) ether [24085-65-2] in 1500 ml of diethyl ether, and the mixture is then stirred under reflux for 60 h. After the reaction mixture has been cooled to −10° C., 82.1 g (240 mmol) of bis(6-bromopyridin-2-yl)methanone are added in portions, and the mixture is then stirred at −10° C. for a further 1.5 h. The reaction mixture is quenched by addition of 30 ml of ethanol, the solvent is removed completely in vacuo in a rotary evaporator, the residue is taken up in 1000 ml of glacial acetic acid, 150 ml of acetic anhydride and then, dropwise, 30 ml of conc. sulfuric acid are added with stirring, and the mixture is stirred at 60° C. for a further 3 h. The solvent is then removed in vacuo, the residue is taken up in 1000 ml of dichloromethane, and the mixture is rendered alkaline by addition of 10% by weight aqueous NaOH with ice-cooling. The organic phase is separated off, washed three times with 500 ml of water each time, dried over magnesium sulfate, the organic phase is evaporated to dryness, and the residue is taken up in 500 ml of methanol, homogenised at elevated temperature and then stirred for a further 12 h, during which the product crystallises. The solid obtained after filtration with suction is dissolved in 1000 ml of dichloromethane, the solution is filtered through a Celite bed, the filtrate is evaporated to dryness, the residue is recrystallised twice from toluene:methanol (1:1) and then dried in vacuo. Yield: 56.3 g (87 mmol), 36%; purity: about 95% according to 1H-NMR.


The following compound can be prepared analogously:















Ex.
Starting material
Product
Yield







SH16


embedded image

  SH15



embedded image

  SH16

30%









B: Synthesis of Ligands LP, LH and LB
Example LP1: 2-(1,1,3,3-Tetramethylindan-5-yl)pyridine, LP1



embedded image


821 mg (2 mmol) of S-Phos and then 249 mg (1 mmol) of palladium(II) acetate are added to a mixture of 30.0 g (100 mmol) of pinacolyl 1,1,3,3-tetramethylindane-5-boronate, SP-1, 17.4 g (110 mmol) of 2-bromo-pyridine [109-04-6], 46.1 g (200 mmol) of tripotassium phosphate monohydrate, 300 ml of dioxane and 100 ml of water, and the mixture is heated under reflux for 16 h. After cooling, the aqueous phase is separated off, the organic phase is evaporated to dryness, the residue is taken up in 500 ml of ethyl acetate, the organic phase is washed three times with 200 ml of water each time, once with 200 ml of saturated sodium chloride solution, dried over magnesium sulfate, the desiccant is filtered off via a Celite bed, and the filtrate is re-evaporated to dryness. The oil obtained in this way is freed from low-boiling components and non-volatile secondary components by fractional bulb-tube distillation twice. Yield: 15.3 g (61 mmol), 61%; purity: about 99.5% according to 1H-NMR.


The following compounds are prepared analogously. Solids are freed from low-boiling components and non-volatile secondary components by recrystallisation and fractional sublimation (p about 10−4-10−5 mbar, T about 160-240° C.). Oils are purified by chromatography, subjected to fractional bulb-tube distillation or dried in vacuo in order to remove low-boiling components.

















Product





Ex.
Boronic acid ester
Bromide
Ligand
Yield







LP2


embedded image

  SP2



embedded image

  54151-74-5



embedded image


66%





LP3


embedded image

  SP2



embedded image

  1532-71-4



embedded image


67%





LP4


embedded image

  SP3



embedded image

  23952-31-0



embedded image


61%





LP5


embedded image

  SP4



embedded image

  3430-17-9



embedded image


63%





LP6


embedded image

  SP5



embedded image

  23952-31-0



embedded image


58%





LP7


embedded image

  SP7



embedded image

  132118-28-6



embedded image


59%





LH1


embedded image

  SH1



embedded image

  109-04-6



embedded image


60%





LH2


embedded image

  SH1



embedded image

  107351-82-6



embedded image


63%





LH3


embedded image

  SH1



embedded image

  1142197-19-0



embedded image


63%





LH4


embedded image

  SH1



embedded image

  23952-31-0



embedded image


64%





LH5


embedded image

  SH1



embedded image

  106203-65-0



embedded image


61%





LH6


embedded image

  SH1



embedded image

  54151-74-5



embedded image


59%





LH7


embedded image

  SH1



embedded image

  3430-17-9



embedded image


60%





LH8


embedded image

  SH1



embedded image

  959238-69-8



embedded image


69%





LH9


embedded image

  SH1



embedded image

  19493-45-9



embedded image


63%





LH10


embedded image

  SH1



embedded image

  132118-28-6



embedded image


64%





LH11


embedded image

  SH1



embedded image

  19136-36-8



embedded image


67%





LH12


embedded image

  SH1



embedded image

  1438809-78-9



embedded image


60%





LH13


embedded image

  SH1



embedded image

  1251041-55-0



embedded image


62%





LH14


embedded image

  SH1 2.2 eq. of boronic acid



embedded image

  26452-80-2



embedded image


65%





LH15


embedded image

  SH1 2.2 eq. of boronic acid



embedded image

  3430-26-0



embedded image


63%





LB1


embedded image

  SB1



embedded image

  109-04-6



embedded image


60%





LB2


embedded image

  SB1



embedded image

  107351-82-6



embedded image


55%





LB3


embedded image

  SB1



embedded image

  54151-74-5



embedded image


58%





LB4


embedded image

  SB1



embedded image

  1532-71-4



embedded image


54%





LB5


embedded image

  SB1



embedded image

  19493-45-9



embedded image


50%





LB6


embedded image

  SB1



embedded image

  132118-28-6



embedded image


48%





LB7


embedded image

  SB1



embedded image

  959238-69-8



embedded image


57%





LB8


embedded image

  SB1



embedded image

  106203-65-0



embedded image


55%





LB9


embedded image

  SB1 2.2 eq. of boronic acid



embedded image

  26452-80-2



embedded image


48%





LB10


embedded image

  SB2



embedded image

  109-04-6



embedded image


61%





LB11


embedded image

  SB2



embedded image

  1438809-789-9



embedded image


60%





LB12


embedded image

  SB2



embedded image

  139585-70-9



embedded image


57%





LB13


embedded image

  SB2



embedded image

  19493-45-9



embedded image


56%





LB14


embedded image

  SB2



embedded image

  132118-28-6



embedded image


59%





LB15


embedded image

  SB2



embedded image

  106203-65-0



embedded image


53%





LB16


embedded image

  SB3



embedded image

  107351-82-6



embedded image


62%





LB17


embedded image

  SB3



embedded image

  106203-65-0



embedded image


59%





LB18


embedded image

  SB3



embedded image

  1532-71-4



embedded image


57%





LB19


embedded image

  SB4



embedded image

  19493-45-9



embedded image


60%





LB20


embedded image

  SB3



embedded image

  132118-28-6



embedded image


62%





LB21


embedded image

  SB4 2.2 eq. of boronic acid



embedded image

  3430-26-0



embedded image


47%





LH53


embedded image

  SH17



embedded image

  54151-74-5



embedded image


45%





LH54


embedded image

  SH17



embedded image

  1438809-78-9



embedded image


48%





LH55


embedded image

  SH18



embedded image

  54151-74-5



embedded image


40%





LH56


embedded image

  SH18



embedded image

  1438809-78-9



embedded image


42%









Example LP8: 5,5,7,7-Tetramethyl-3-phenyl-6,7-dihydro-5H-[2]pyridino



embedded image


Procedure analogous to A. Mazzanti et al., Eur. J. Org. Chem., 2011, 6725.


40 ml (100 mmol) of n-butyllithium, 2.5 M in n-hexane, are added dropwise to a mixture, cooled to −78° C., of 10.5 ml (100 mmol) of bromobenzene and 500 ml of diethyl ether, and the mixture is stirred for a further 30 min. 17.5 g (100 mmol) of 5,5,7,7-tetramethyl-6,7-dihydro-5H-[2]pyridine [1562418-53-4], are then added dropwise, the mixture is allowed to warm to room temperature, stirred for a further 12 h, quenched by addition of 100 ml of water, the organic phase is separated off, dried over magnesium sulfate. After removal of the solvent, the oily residue is chromatographed on silica gel with diethyl ether:n-heptane (3:7, v:v) and subsequently subjected to fractional bulb-tube distillation twice. Yield: 12.1 g (48 mmol), 48%; purity: about 99.5% according to 1H-NMR.


The following compounds can be prepared analogously. Solids are freed from low-boiling components and non-volatile secondary components by recrystallisation and fractional sublimation (p about 10−4-10−5 mbar, T about 160-240° C.). Oils are purified by chromatography, subjected to fractional bulb-tube distillation or dried in vacuo in order to remove low-boiling components.
















Ex.
Pyridine
Bromide
Ligand
Yield







LH16


embedded image




embedded image




embedded image


38%









Example LP9: 6,6,7,7,8,8-Hexamethyl-2-phenyl-7,8-dihydro-6H-cyclopenta[g]quinoxaline



embedded image


Procedure analogous to S. V. More et al., Tetrahedron Lett. 2005, 46, 6345.


A mixture of 23.2 g (100 mmol) of 1,1,2,2,3,3-hexamethylindane-5,6-diamine, SP10, 13.4 g (100 mmol) of oxophenylacetaldehyde [1074-12-0], 767 mg (3 mmol) of iodine and 75 ml of acetonitrile is stirred at room temperature for 16 h. The precipitated solid is filtered off with suction, washed once with 20 ml of acetonitrile, twice with 75 ml of n-heptane each time and then recrystallised twice from ethanolethyl acetate. Finally, the solid is freed from low-boiling components and non-volatile secondary components by fractional sublimation (p about 10−4-10−5 mbar, T about 220° C.). Yield: 22.1 g (67 mmol), 67%; purity: about 99.5% according to 1H-NMR.


The following compounds are prepared analogously. Solids are freed from low-boiling components and non-volatile secondary components by recrystallisation and fractional sublimation (p about 10−4-10−5 mbar, T about 160-240° C.). Oils are purified by chromatography, subjected to fractional bulb-tube distillation or dried in vacuo in order to remove low-boiling components.
















Ex.
Diamine
Diketone
Ligand
Yield







LP10


embedded image




embedded image




embedded image


58%





LH17


embedded image




embedded image




embedded image


46%





LH18


embedded image




embedded image




embedded image


49%





LH19


embedded image




embedded image




embedded image


64%





LB22


embedded image




embedded image




embedded image


44%





LB23


embedded image




embedded image




embedded image


67%





LB24


embedded image




embedded image




embedded image


43%





LB25


embedded image




embedded image




embedded image


59%









Example LP11: 5,5,6,6,7,7-Hexamethyl-1,2-diphenyl-1,5,6,7-tetrahydroindeno[5,6-d]imidazole



embedded image


Procedure analogous to D. Zhao et al., Org. Lett., 2011, 13, 24, 6516. A mixture of 36.0 g (100 mmol) of 5,6-dibromo-1,1,2,2,3,3-hexamethylindane SP8, 21.6 g (110 mmol) of N-phenylbenzamidine [1527-91-9], 97.8 g (300 mmol) of caesium carbonate, 100 g of 4 A molecular sieve, 1.2 g (2 mmol) of xantphos, 449 mg (2 mmol) of palladium(II) acetate and 600 ml of o-xylene is heated under reflux with vigorous stirring for 24 h. After cooling, the salts are filtered off with suction via a Celite bed, rinsed with 500 ml of o-xylene, the solvent is removed in vacuo, and the residue is recrystallised three times from cyclohexane/ethyl acetate. Finally, the solid is freed from low-boiling components and non-volatile secondary components by fractional sublimation (p about 10−4-10−5 mbar, T about 230° C.). Yield: 28.0 g (71 mmol), 71%; purity: about 99.5% according to 1H-NMR.


The following compounds are prepared analogously. Solids are freed from low-boiling components and non-volatile secondary components by recrystallisation and fractional sublimation (p about 10−4-10−5 mbar, T about 160-240° C.). Oils can be purified by chromatography, subjected to fractional bulb-tube distillation or dried in vacuo in order to remove low-boiling components.

















1,2-Dihalogen





Ex.
compound
Benzamidine
Ligand
Yield







LH20


embedded image




embedded image




embedded image


41%





LH21


embedded image




embedded image




embedded image


36%





LH22


embedded image




embedded image




embedded image


40%





LB26


embedded image




embedded image




embedded image


44%









Example LP12: 1,1,5,6,6,7,7-Heptamethyl-3-phenyl-1,5,6,7-tetrahydroindeno[5,6-d]imidazolium iodide, LP12



embedded image


A) 5,6,6,6,7,7-Hexamethyl-1,5,6,7-tetrahydroindeno[5,6-d]imidazole



embedded image


Procedure analogous to Z.-H. Zhang et al., J. Heterocycl. Chem. 2007, 44, 6, 1509. 1.3 g (5 mmol) of iodine are added to a vigorously stirred mixture of 116.2 g (500 mmol) of 1,1,2,2,3,3-hexamethylindane-5,6-diamine, S35, 90.9 ml (550 mmol) of triethoxymethane [122-51-0] and 400 ml of acetonitrile, and the mixture is stirred at room temperature for 5 h. The precipitated solid is filtered off with suction, washed once with a little acetonitrile, three times with 100 ml of n-heptane each time and dried in vacuo. Yield: 108.8 g (449 mmol), 90%; purity: about 97% according to 1H-NMR.


B) 5,5,6,6,7,7-Hexamethyl-1-phenyl-1,5,6,7-tetrahydroindeno[5,6-d]-imidazole



embedded image


Procedure analogous to S. Zhang et al., Chem. Commun. 2008, 46, 6170. A mixture of 24.2 g (100 mmol) of 5,5,6,6,7,7-hexamethyl-1,5,6,7-tetrahydroindeno[5,6-d]imidazole, A), 12.6 ml (120 mmol) of bromobenzene [108-86-1], 27.6 g (200 mmol) of potassium carbonate, 952 mg (5 mmol) of copper(I) iodide, 1.0 g (10 mmol) of N,N-dimethylglycine, 200 g of glass beads (diameter 3 mm) and 300 ml of DMSO is heated at 120° C. with vigorous stirring for 36 h. After cooling, the salts are filtered off with suction, rinsed with 1000 ml of ethyl acetate, the combined organic phases are washed five times with 500 ml of water each time, once with 500 ml of saturated sodium chloride solution, dried over magnesium sulfate, the solvent is removed in vacuo, and the residue is recrystallised twice from cyclohexane. Yield: 28.3 g (89 mmol), 89%; purity: about 97% according to 1H-NMR.


C) 1,5,5,6,6,7,7-Heptamethyl-3-phenyl-1,5,6,7-tetrahydroindeno-[5,6-d]imidazolium Iodide

12.6 ml (200 mmol) of methyl iodide [74-88-4] are added with stirring to a suspension of 28.3 g (89 mmol) of 5,5,6,6,7,7-hexamethyl-1-phenyl-1,5,6,7-tetrahydroindeno[5,6-d]imidazole, B), in 100 ml of THF, and the mixture is stirred at 45° C. for 24 h. After cooling, the precipitated solid is filtered off with suction, washed three times with 50 ml of ethanol each time and dried in vacuo. Yield: 23.5 g (51 mmol), 57%; purity: about 99% according to 1H-NMR.


The following compounds are prepared analogously:


















Brominated






aromatic

Yield




compound

over 3


Ex.
1,2-Diamine
Alkyl halide
Ligand
steps







LP13


embedded image




embedded image




embedded image


46%





LH23


embedded image




embedded image




embedded image


40%





LH24


embedded image




embedded image




embedded image


38%





LB27


embedded image




embedded image




embedded image


37%





LB28


embedded image




embedded image




embedded image


39%









Example LP14: 1,4,4,6,6-Pentamethyl-3-phenyl-1,4,5,6-tetrahydro-cyclopentaimidazolium iodide



embedded image


A) 4,4,6,6-Tetramethyl-1,4,5,6-tetrahydrocyclopentaimidazole



embedded image


Preparation analogous to G. Bratulescu, Synthesis, 2009, 14, 2319. An intimate mixture of 1.54 g (10.0 mmol) of 3,3,5,5-tetramethylcyclopentane-1,2-dione [20633-06-1], 4.21 g (3.0 mmol) of urotropin, 7.7 g (10 mmol) of ammonium acetate and 0.3 ml of glacial acetic acid is heated in a temperature-controlled microwave until an internal temperature of about 120° C. has been reached, and is then held at this temperature for about 15 min. After cooling, the mass is added to 150 ml of water, the pH is adjusted to 8 using aqueous ammonia solution (10% by weight) with stirring, the precipitated solid is then filtered off with suction and washed with water. After drying, the product is recrystallised from ethanol/ethyl acetate. Yield: 1.17 g (7.1 mmol), 71%; purity: about 98% according to 1H-NMR.


B) 4,4,6,6-Tetramethyl-1-phenyl-,4,5,6-tetrahydrocyclopentaimidazole



embedded image


Preparation analogous to LP12, B). Use of 1.64 g (10.0 mmol) of 4,4,6,6-tetramethyl-1,4,5,6-tetrahydrocyclopentaimidazole, A), the remaining starting materials and solvents are correspondingly adapted stoichiometrically. Yield: 1.53 g (6.3 mmol), 63%; purity: about 98% according to 1H-NMR.


C) 1,4,4,6,6-Pentamethyl-3-phenyl-1,4,5,6-tetrahydrocyclopenta-imidazolium Iodide

Preparation analogous to LP12, C). Use of 2.4 g (10.0 mmol) of 4,4,6,6-tetramethyl-1-phenyl-1,4,5,6-tetrahydrocyclopentaimidazole, B), the remaining starting materials and solvents are correspondingly adapted stoichiometrically. Yield: 2.26 g (5.9 mmol), 59%; purity: about 99% according to 1H-NMR.


The following compounds are prepared analogously:


















Brominated






aromatic






compound

Yield


Ex.
1,2-Dione
Alkyl halide
Ligand
3 steps







LH25


embedded image




embedded image




embedded image


28%





LB29


embedded image




embedded image




embedded image


33%









Example LP15: 1,1,2,2,3,3-Hexamethyl-5-phenyl-2,3-dihydro-1H-6-azacyclopenta[b]naphthalene



embedded image


17.0 g (120 mmol) of phosphorus pentoxide are added in portions with vigorous stirring at 90° C. to a solution of 34.8 g (100 mmol) of N-[2-(1,1,2,2,3,3-hexamethylindan-5-yl)ethyl]benzamide, SP13, in 150 ml of o-xylene. 28.0 ml (300 mmol) of phosphoryl chloride are added dropwise to this reaction mixture, which is then stirred under reflux for a further 4 h. The reaction mixture cooled to 80° C. is poured onto 1000 g of ice with vigorous stirring and then rendered alkaline (pH about 12) by addition of solid NaOH. The mixture is extracted three times with 300 ml of toluene each time, the organic phase is washed three times with water, dried over magnesium sulfate, and the solvent is removed in vacuo. The oily residue is dissolved in 200 ml of o-dichlorobenzene, 86.9 g (1 mol) of manganese dioxide are added to the solution, and the mixture is subsequently boiled under reflux on a water separator for 16 h. After cooling, the manganese dioxide is filtered off via a Celite bed, the solid is washed with 500 ml of a mixture of dichloromethane and ethanol (10:1), and the combined filtrates are freed from the solvents in vacuo. The residue is recrystallised from cyclohexane/ethyl acetate and finally freed from low-boiling components and non-volatile secondary components by fractional sublimation (p about 10−4-10−5 mbar, T about 230° C.). Yield: 20.1 g (61 mmol), 61%; purity: about 99.5% according to 1H-NMR.


The following compounds can be prepared analogously:















Ex.
Starting material
Product
Yield







LP16


embedded image




embedded image


66%





LP17


embedded image




embedded image


67%





LP18


embedded image




embedded image


65%





LH26


embedded image




embedded image


63%





LH27


embedded image




embedded image


60%





LH28


embedded image




embedded image


63%





LH29


embedded image




embedded image


48%





LH30


embedded image




embedded image


65%





LH31


embedded image




embedded image


61%





LH32


embedded image




embedded image


66%





LB30


embedded image




embedded image


63%









Example LP19: 7,8,9,10-Tetrahydro-7,10-methano-6-phenylphenanthridine



embedded image


14.2 g (100 mmol) of boron trifluoride etherate are added dropwise to a vigorously stirred mixture of 46.6 g (500 mmol) of aniline, 58.4 g (550 mmol) of benzaldehyde, 94.2 g (1 mol) of norbornene and 1300 ml of dichloromethane, and the mixture is then heated under reflux for 40 h. After cooling, the reaction mixture is washed twice with 400 ml of water each time, the organic phase is dried over magnesium sulfate, and the dichloromethane is then removed in vacuo. The residue is taken up in 1000 ml of o-dichlorobenzene, 435 g (5 mol) of manganese dioxide are added, and the mixture is heated under reflux on a water separator for 16 h. After cooling, 1000 ml of ethyl acetate are added, the manganese dioxide is filtered off with suction via a Celite bed, the manganese dioxide is rinsed with 1000 ml of ethyl acetate, and the combined filtrates are freed from the solvents in vacuo. The residue is recrystallised twice from cyclohexane and finally freed from low-boiling components and non-volatile secondary components by fractional sublimation (p about 10−4-10−5 mbar, T about 230° C.). Yield: 76.0 g (280 mmol), 56%; purity: about 99.5% according to 1H-NMR.


The following compounds can be prepared analogously:















Ex.
Starting material
Product
Yield







LP20


embedded image




embedded image


66%





LB31


embedded image




embedded image


27%





LB32


embedded image




embedded image


27%









Example LP21: 5,8-Methano-5,6,7,8-tetrahydro-3-phenyl-2-aza-anthracene



embedded image


A mixture of 13.6 g (50 mmol) of 7-(3,3-dimethylbut-1-ynyl)-1,2,3,4-tetrahydro-1,4-methanonaphthalene-6-carbaldehyde, SP22, and 500 ml of methanolic ammonia solution (2 M) is stirred at 140° C. for 5 h in an autoclave. After cooling, the methanol is removed in vacuo, the oily residue is chromatographed on silica gel (n-heptane:ethyl acetate 95:5) and finally freed from low-boiling components and non-volatile secondary components by fractional sublimation (p about 10−4-10−5 mbar, T about 230° C.). Yield: 5.1 g (17 mmol), 34%; purity: about 99.5% according to 1H-NMR.


The following derivatives can be prepared analogously:















Ex.
Starting material
Product
Yield







LP22


embedded image




embedded image


37%





LP23


embedded image




embedded image


29%





LP24


embedded image




embedded image


30%





LH33


embedded image




embedded image


27%





LH34


embedded image




embedded image


29%





LB33


embedded image




embedded image


28%





LB34


embedded image




embedded image


26%





LB35


embedded image




embedded image


29%









Example LP25: 1R,4S-Methano-1,2,3,4-tetrahydro-9-phenyl-10-aza-phenanthrene



embedded image


One drop of conc. sulfuric acid is added to a mixture of 26.1 g (100 mmol) of 2-bromophenylphenylmethanone [13047-06-8], 11.1 g (100 mmol) of (1R,2R,4S)-bicyclo[2.2.1]heptan-2-amine [7242-92-4] and 23.3 ml (105 mmol) of tetraethoxysilane [78-10-4], and the mixture is then heated at 160° C. in a water separator for 16 h, during which the ethanol distils off. After cooling, 500 ml of diethyl ether are added to the residue, the mixture is washed twice with 100 ml of saturated sodium hydrogencarbonate solution each time and twice with 300 ml of water each time and then dried over magnesium sulfate. After removal of the diethyl ether, 27.6 g (200 mmol) of potassium carbonate, 5 g of palladium/carbon (5% by weight), 2.6 g (10 mmol) of triphenylphosphine, 100 g of glass beads (diameter 3 mm) and 300 ml of mesitylene are added to the oily residue, and the mixture is again heated under reflux for 16 h. After cooling, the salts are filtered off with suction via a Celite bed, rinsed with 500 ml of toluene, and the combined filtrates are evaporated to dryness in vacuo. The residue is recrystallised three times from DMF/ethanol and finally freed from low-boiling components and non-volatile secondary components by fractional sublimation (p about 10−4-10−5 mbar, T about 230° C.). Yield: 14.9 g (55 mmol), 55%; purity: about 99.5% according to 1H-NMR.


The following derivatives can be prepared analogously:















Ex.
Starting material
Product
Yield







LB36


embedded image




embedded image


35%









Example LB37



embedded image


Preparation analogous to M. Ohashi et al., J. Am. Chem. Soc, 2011, 133, 18018.


A mixture of 13.4 g (100 mmol) of 2,3-dimethylenebicyclo[2.2.2]octane [36439-79-9], 5.2 g (50 mmol) of benzonitrile [100-47-0], 1.4 g (5 mmol) of biscyclooctadienenickel(0) [1295-35-8], 5.6 g (20 mmol) of tricyclohexylphosphine [2622-14-2] and 200 ml of o-xylene is heated under gentle reflux for 30 h while a gentle stream of argon is passed in. After cooling, the mixture is filtered through a Celite bed, and the solvent is removed in vacuo. The residue is distilled twice in a bulb tube. Yield: 6.4 g (27 mmol), 54%; purity: about 98% according to 1H NMR.


The following compounds can be prepared analogously:
















Ex.
Olefin
Nitrile
Product
Yield







LH35


embedded image




embedded image




embedded image


22%





LH36


embedded image




embedded image




embedded image


18%





LH37


embedded image




embedded image




embedded image


24%





LH38


embedded image




embedded image




embedded image


20%





LH39


embedded image




embedded image




embedded image


19%





LH40


embedded image




embedded image




embedded image


17%





LH41


embedded image




embedded image




embedded image


20%





LH42


embedded image




embedded image




embedded image


22%





LB38


embedded image




embedded image




embedded image


24%









Example LH43: Tetradentate Ligands



embedded image


A mixture of 71.5 g (100 mmol) of SH16, 61.2 g (230 mmol) of phenyl-boronic acid [24388-23-6], 42.4 g (400 mmol) of sodium carbonate, 1.2 g (1 mmol) of tetrakistriphenylphosphinopalladium(0), 300 ml of toluene, 200 ml of dioxane and 300 ml of water is heated under reflux for 30 h. After cooling, the organic phase is separated off, filtered through a Celite bed, with the Celite being rinsed with 300 ml of toluene, the combined filtrates are washed three times with 300 ml of water each time, dried over magnesium sulfate and then freed from toluene in vacuo. The residue is recrystallised three times from ethanol with addition of a little ethyl acetate and finally freed from low-boiling components and non-volatile secondary components by fractional sublimation (p about 10−5 mbar, T about 310° C.). Yield: 33.3 g (47 mmol), 47%; purity: about 99.5% according to 1H-NMR.


The following compounds can be prepared analogously:


















Starting




Ex.
Starting material
material
Product
Yield







LH44


embedded image




embedded image




embedded image


46%





LH45


embedded image




embedded image




embedded image


42%









Example LH46: Tetradentate Ligands



embedded image


Procedure analogous to C. Cao et al., Synth. Commun. 2012, 42, 380. A mixture of 15.2 g (50 mmol) of LH23 B), and 4.7 g (25 mmol) of 1,2-dibromoethane [106-93-4] is heated at 120° C. for 6 h in an autoclave. After cooling, the solid mass is taken up in 100 ml of tert-butyl methyl ether, homogenised with stirring, the white solid is filtered off, washed twice with 50 ml of tert-butyl methyl ether each time and dried in vacuo. Yield: 15.1 g (19 mmol), 76%; purity: about 98.0% according to 1H-NMR.


The following compounds can be prepared analogously:















Ex.
Imidazole
Ligand
Yield







LH47


embedded image




embedded image


73%









Example LH48: Hexadentate Ligands



embedded image


A mixture of 51.4 g (100 mmol) of tris(6-bromopyridin-2-yl)methoxy-methane [336158-91-9], 103.7 g (330 mmol) of SH1, 42.4 g (400 mmol) of sodium carbonate, 1.2 g (1 mmol) of tetrakistriphenylphosphinopalladium(0), 500 ml of toluene, 300 ml of dioxane and 500 ml of water is heated under reflux for 36 h. After cooling, the organic phase is separated off, filtered through a Celite bed, with the Celite being rinsed with 400 ml of toluene, the combined filtrates are washed three times with 300 ml of water each time, dried over magnesium sulfate and then freed from toluene in vacuo. The residue is recrystallised three times from isopropanol with addition of a little ethyl acetate and finally freed from low-boiling components and non-volatile secondary components by fractional sublimation (p about 10−5 mbar, T about 310° C.). Yield: 38.7 g (44 mmol), 44%; purity: about 99.5% according to 1H-NMR.


The following compounds can be prepared analogously:

















Starting
Starting




Ex.
material
material
Product
Yield







LH49


embedded image




embedded image




embedded image


47%





LH50


embedded image




embedded image




embedded image


40%









Example LH51: Hexadentate Ligands



embedded image


Procedure analogous to LH46, where the 1,2-dibromoethane is replaced by 5.2 g (16.7 mmol) of 1,1,1-tris(bromomethyl)ethane [60111-68-4]. Yield: 14.8 g (12 mmol), 72%; purity: about 99.0% according to 1H-NMR.


Compound LH52 can be prepared analogously:




embedded image


1,1,1-Tris(bromomethyl)ethane is replaced by 6.1 g (16.7 mmol) of cis,cis-1,2,3-cyclopropanetrimethanol trimethanesulfonate [945230-85-3]. Yield: 14.8 g (11.5 mmol), 69%; purity: about 99.0% according to 1H-NMR.


Example LH1: 2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)pyridine, LP1



embedded image


A mixture of 16.4 g (100 mmol) of 1,1,4,4-tetramethyl-2,3-dimethylene-cyclohexane [153495-32-0], 12.4 g (120 mmol) of 2-ethynylpyridine [1945-84-2] and 50 ml of chlorobenzene is stirred at 120° C. for 16 h. 26.1 g (300 mmol) of activated manganese(II) oxide are then added, and the mixture is stirred at 120° C. for a further 3 h. After cooling, the mixture is diluted with 200 ml of ethyl acetate and filtered through a Celite bed, and the solvent and excess 2-ethynylpyridine are removed in vacuo. The oily residue is distilled twice in a bulb tube (p about 10−4 mbar, T about 190° C.). Yield: 18.8 g (71 mmol), 71%; purity: about 99.0% according to 1H NMR.


The following compounds can be prepared analogously:

















Starting
Starting




Ex.
material
material
Product
Yield







LH57


embedded image




embedded image




embedded image


68%





LH7


embedded image




embedded image




embedded image


65%





LH58


embedded image




embedded image




embedded image


73%





LH59


embedded image




embedded image




embedded image


70%





LH60


embedded image




embedded image




embedded image


63%





LH61


embedded image




embedded image




embedded image


78%









C: Synthesis of the Metal Complexes

1) Homoleptic tris-facial Iridium complexes of the phenylpyridine, phenylimidazole or phenylbenzimidazole type:


Variant A: Trisacetylacetonatoiridium(III) as Iridium Starting Material

A mixture of 10 mmol of trisacetylacetonatoiridium(III) [15635-87-7] and 40-60 mmol (preferably 40 mmol) of the ligand L, optionally 1-10 g—typically in of an inert high-boiling additive as melting aid or solvent, e.g. hexadecane, m-terphenyl, triphenylene, diphenyl ether, 3-phenoxytoluene, 1,2-, 1,3-, 1,4-bisphenoxybenzene, triphenylphosphine oxide, sulfolane, 18-crown-6, triethylene glckol, glycerol, polyethylene glycols, phenol, 1-naphthol, hydroquinone, etc., and a glass-clad magnetic stirrer bar are melted into a thick-walled 50 ml glass ampoule in vacuo (10−5 mbar). The ampoule is heated at the temperature indicated for the time indicated, during which the molten mixture is stirred with the aid of a magnetic stirrer. In order to prevent sublimation of the ligands onto relatively cold parts of the ampoule, the entire ampoule must have the temperature indicated. Alternatively, the synthesis can be carried out in a stirred autoclave with glass insert. After cooling (NOTE: the ampoules are usually under pressure!), the ampoule is opened, the sinter cake is stirred for 3 h with 100 g of glass beads (diameter 3 mm) in 100 ml of a suspension medium (the suspension medium is selected so that the ligand is readily soluble, but the metal complex has low solubility therein, typical suspension media are methanol, ethanol, dichloromethane, acetone, THF, ethyl acetate, toluene, etc.) and mechanically digested in the process. The fine suspension is decanted off from the glass beads, the solid is filtered off with suction, rinsed with 50 ml of the suspension medium and dried in vacuo. The dry solid is placed on a 3-5 cm deep aluminium oxide bed (aluminium oxide, basic, activity grade 1) in a continuous hot extractor and then extracted with an extractant (initially introduced amount about 500 ml, the extractant is selected so that the complex is readily soluble therein at elevated temperature and has low solubility therein when cold, particularly suitable extractants are hydrocarbons, such as toluene, xylenes, mesitylene, naphthalene, o-dichlorobenzene, halogenated aliphatic hydrocarbons are generally unsuitable since they may halogenate or decompose the complexes). When the extraction is complete, the extractant is evaporated to about 100 ml in vacuo. Metal complexes which have excessively good solubility in the extractant are brought to crystallisation by dropwise addition of 200 ml of methanol. The solid of the suspensions obtained in this way is filtered off with suction, washed once with about 50 ml of methanol and dried. After drying, the purity of the metal complex is determined by means of NMR and/or HPLC. If the purity is below 99.5%, the hot extraction step is repeated, omitting the aluminium oxide bed from the 2nd extraction. When a purity of 99.5-99.9% has been reached, the metal complex is heated or sublimed. The heating is carried out in a high vacuum (p about 10−6 mbar) in the temperature range from about 200-300° C., preferably for complexes having molecular weights greater than about 1300 g/mol. The sublimation is carried out in a high vacuum (p about 10−6 mbar) in the temperature range from about 230-400° C., with the sublimation preferably being carried out in the form of a fractional sublimation. Complexes which are readily soluble in organic solvents may alternatively also be chromatographed on silica gel.


If chiral ligands are employed, the derived fac-metal complexes are produced in the form of a diastereomer mixture. The enantiomers Λ,Δ in point group C3 generally have significantly lower solubility in the extractant than the enantiomers in point group C1, which are consequently enriched in the mother liquor. Separation of the C3 diastereomers from the C1 diastereomers is frequently possible by this method. In addition, the diastereomers can also be separated by chromatography. If ligands in point group C1 are employed in enantiomerically pure form, a diastereomer pair Λ,Δ in point group C3 is formed. The diastereomers can be separated by crystallisation or chromatography and thus obtained as enantiomerically pure compounds.


Variant B: Tris-(2,2,6,6-tetramethyl-3,5-heptanedionato)iridium(III) as Iridium Starting Material

Procedure analogous to variant A, using 10 mmol of tris(2,2,6,6-tetramethyl-3,5-heptanedionato)iridium [99581-86-9] instead of 10 mmol of tris-acetylacetonatoiridium(III) [15635-87-7]. The use of this starting material is advantageous since the purity of the crude products obtained is frequently better than in the case of variant A. In addition, the build-up of pressure in the ampoule is frequently not so pronounced.


Variant C: Sodium [cis,trans-dichloro(bisacetylacetonato)]iridate(III) as Iridium Starting Material

A mixture of 10 mmol of sodium [cis,trans-dichloro(bisacetylacetonato)]-iridate(III) [876296-21-8] and 60 mmol of the ligand in 50 ml of ethylene glycol, propylene glycol or diethylene glycol is heated under gentle reflux under a gentle stream of argon for the time indicated. After cooling to 60° C., the reaction mixture is diluted with a mixture of 50 ml of ethanol and 50 ml of 2 N hydrochloric acid with stirring and stirred for a further 1 h, the precipitated solid is filtered off with suction, washed three times with 30 ml of ethanol each time and then dried in vacuo. Purification by hot extraction or chromatography and fractional sublimation, as described under A.



















Variant






Reaction medium






Melting aid






Reaction temp.






Reaction time




Ligand
Ir complex
Suspension medium



Ex.
L
Diastereomer
Extractant
Yield







Ir(LH1)3
LH1


embedded image


A — — 270° C. 24 h EtOH Ethyl acetate
46%





Ir(LH1)3
LH1


embedded image


C Propylene glycol — RF 100 h — o-Xylene
37%





Ir(LH2)3
LH2


embedded image


A — — 270° C. 24 h EtOH Ethyl acetate
52%





Ir(LH3)3
LH3


embedded image


as for Ir(LH2)3
50%





Ir(LH4)3
LH4


embedded image


A — Hydroquinone 280° C. 40 h EtOH Ethyl acetate
 9%





Ir(LH5)3
LH5


embedded image


as for Ir(LH2)3
18%





Ir(LH6)3
LH6


embedded image


as for Ir(LH2)3
43%





Ir(LH7)3
LH7


embedded image


as for Ir(LH2)3
37%





Ir(LH8)3
LH8


embedded image


A — Hydroquinone 280° C. 40 h EtOH Ethyl acetate
24%





Ir(LH9)3
LH9


embedded image


as for Ir(LH2)3
37%





Ir(LH10)3
LH10


embedded image


as for Ir(LH4)3
10%





Ir(LH11)3
LH11


embedded image


as for Ir(LH8)3
31%





Ir(LH12)3
LH12


embedded image


as for Ir(LH2)3
35%





Ir(LH13)3
LH13


embedded image


as for Ir(LH2)3
32%





Ir(LH14)3
LH14


embedded image


as for Ir(LH2)3 Chromatography Silica gel n-Heptane:DCM 8:1
40%





Ir(LH15)3
LH15


embedded image


as for Ir(LH2)3 Chromatography Silica gel n-Heptane:DCM 8:1
37%





Ir(LH16)3
LH16


embedded image


as for Ir(LH2)3
39%





Ir(LH20)3
LH20


embedded image


A — — 280° C. 30 h EtOH Toluene
40%





Ir(LH21)3
LH21


embedded image


as for Ir(LH20)3
34%





Ir(LH22)3
LH22


embedded image


as for Ir(LH20)3
30%





Ir(LH26)3
LH26


embedded image


as for Ir(LH2)3
41%





Ir(LH27)3
LH27


embedded image


as for Ir(LH2)3
43%





Ir(LH28)3
LH28


embedded image


as for Ir(LH2)3
42%





Ir(LH29)3
LH29


embedded image


A — — 280° C. 30 h Acetone Toluene
28%





Ir(LH30)3
LH30


embedded image


as for Ir(LH2)3 Chromatography Silica gel n-Heptane:DCM 8:1
30%





Ir(LH31)3
LH31


embedded image


as for Ir(LH2)3
36%





Ir(LH32)3
LH32


embedded image


as for Ir(LH2)3 Chromatography Silica gel n-Heptane:DCM 8:1
35%





Ir(LH33)3
LH33


embedded image


as for Ir(LH2)3
41%





Ir(LH34)3
LH34


embedded image


as for Ir(LH2)3
40%





Ir(LH35)3
LH35


embedded image


as for Ir(LH2)3
40%





Ir(LH36)3
LH36


embedded image


as for Ir(LH2)3
28%





Ir(LH37)3
LH37


embedded image


as for Ir(LH2)3
40%





Ir(LH38)3
LH38


embedded image


as for Ir(LH2)3
44%





Ir(LH39)3
LH39


embedded image


as for Ir(LH2)3
38%





Ir(LH40)3
LH40


embedded image


A — Hydroquinone 280° C. 35 h Toluene Ethyl acetate
30%





Ir(LH41)3
LH41


embedded image


as for Ir(LH2)3 Chromatography Silica gel Toluene
42%





Ir(LH42)3
LH42


embedded image


as for Ir(LH2)3 Chromatography Silica gel Toluene
39%





Ir(LH53)3
LH53


embedded image


A — — 270° C. 24 h EtOH Acetonitrile
38%





Ir(LH54)3
LH54


embedded image


as for Ir(L53)3
44%





Ir(LH55)3
LH55


embedded image


as for Ir(LH2)3 Chromatography Silica gel Toluene
33%





Ir(LH56)3
LH56


embedded image


as for Ir(LH2)3 Chromatography Silica gel Toluene
37%





Ir(LH57)3
LH57


embedded image


as for Ir(L53)3
46%





Ir(LH58)3
LH58


embedded image


as for Ir(L53)3
43%





Ir(LH59)3
LH59


embedded image


as for Ir(L53)3
37%





Ir(LH60)3
LH60


embedded image


as for Ir(L53)3
41%





Ir(LH61)3
LH61


embedded image


as for Ir(L2)3
47%










2) Homoleptic Iridium Complexes of the Arduengo Carbene Type:


Preparation analogous to K. Tsuchiya, et al., Eur. J. Inorg. Chem., 2010, 926.


A mixture of 10 mmol of the ligand, 3 mmol of iridium(III) chloride hydrate, 10 mmol of silver carbonate, 10 mmol of sodium carbonate in 75 ml of 2-ethoxyethanol is warmed under reflux for 24 h. After cooling, 300 ml of water are added, the precipitated solid is filtered off with suction, washed once with 30 ml of water and three times with 15 ml of ethanol each time and dried in vacuo. The fac/mer isomer mixture obtained in this way is chromatographed on silica gel. The isomers are subsequently subjected to fractional sublimation or freed from the solvent in a high vacuum.
















Ligand
Ir complex



Ex.
L
Diastereomer
Yield







fac-Ir(LH23)3 mer-Ir(LH23)3
LH23


embedded image


35% 10%





fac-Ir(LH24)3 mer-Ir(LH24)3
LH24


embedded image


37% 12%





fac-Ir(LH25)3
LH25


embedded image


33%





fac-Ir(LB29)3
LB29


embedded image


29%










3) Iridium Complexes of the [Ir(L)2Cl]2 Type


Variant A:


A mixture of 22 mmol of the ligand, 10 mmol of iridium(III) chloride hydrate, 75 ml of 2-ethoxyethanol and 25 ml of water is heated under reflux for 16-24 h with vigorous stirring. If the ligand does not dissolve or does not dissolve completely in the solvent mixture under reflux, 1,4-dioxane is added until a solution has formed. After cooling, the precipitated solid is filtered off with suction, washed twice with ethanol/water (1:1, vv) and then dried in vacuo. The chloro dimer of the formula [Ir(L)2Cl]2 obtained in this way is reacted further without purification.


Variant B:


A mixture of 10 mmol of sodium bisacetylacetonatodichloroiridate(III) [770720-50-8], 24 mmol of ligand L and a glass-clad magnetic stirrer bar are melted into a thick-walled 50 ml glass ampoule in vacuo (10−5 mbar). The ampoule is heated at the temperature indicated for the time indicated, during which the molten mixture is stirred with the aid of a magnetic stirrer. After cooling—NOTE: the ampoules are usually under pressure!—the ampoule is opened, the sinter cake is stirred for 3 h with 100 g of glass beads (diameter 3 mm) in 100 ml of the suspension medium indicated (the suspension medium is selected so that the ligand is readily soluble, but the chloro dimer of the formula [Ir(L)2Cl]2 has low solubility therein, typical suspension media are dichloromethane, acetone, ethyl acetate, toluene, etc.) and mechanically digested at the same time. The fine suspension is decanted off from the glass beads, the solid [Ir(L)2Cl]2 which still contains about 2 eq. of NaCl, referred to below as the crude chloro dimer) is filtered off with suction and dried in vacuo. The crude chloro dimer of the formula [Ir(L)2Cl]2 obtained in this way is reacted further without purification.

















Ir complex





Variant




Ligand
Temp./time



Ex.
L
Diastereomer
Yield







[Ir(LP1)2Cl]2
L1


embedded image


76%





[Ir(LP2)2Cl]2
L2
Ir[(LP2)Cl]2
81%




A






[Ir(LH1)2Cl]2
LH1


embedded image


76%





[Ir(LH2)2Cl]2
LH2
[Ir(LH2)2Cl]2
80%




as for [Ir(LH1)2Cl]2



[Ir(LH3)2Cl]2
LH3
[Ir(LH3)2Cl]2
78%




as for [Ir(LH1)2Cl]2



[Ir(LH4)2Cl]2
LH4
[Ir(LH4)2Cl]2
81%




as for [Ir(LH1)2Cl]2



[Ir(LH5)2Cl]2
LH5
[Ir(LH5)2Cl]2
80%




as for [Ir(LH1)2Cl]2



[Ir(LH6)2Cl]2
LH6
[Ir(LH6)2Cl]2
75%




as for [Ir(LH1)2Cl]2



[Ir(LH7)2Cl]2
LH7
[Ir(LH7)2Cl]2
77%




as for [Ir(LH1)2Cl]2



[Ir(LH9)2Cl]2
LH9
[Ir(LH9)2Cl]2
81%




as for [Ir(LH1)2Cl]2



[Ir(LH10)2Cl]2
LH10
[Ir(LH10)2Cl]2
80%




as for [Ir(LH1)2Cl]2



[Ir(LH12)2Cl]2
LH12
[Ir(LH12)2Cl]2
76%




as for [Ir(LH1)2Cl]2



[Ir(LH14)2Cl]2
LH14
[Ir(LH14)2Cl]2
78%




as for [Ir(LH1)2Cl]2



[Ir(LH15)2Cl]2
LH15
[Ir(LH15)2Cl]2
78%




as for [Ir(LH1)2Cl]2



[Ir(LH16)2Cl]2
LH16
[Ir(LH16)2Cl]2
79%




as for [Ir(LH1)2Cl]2



[Ir(LH17)2Cl]2
LH17
[Ir(LH17)2Cl]2
46%




as for [Ir(LH1)2Cl]2



[Ir(LH18)2Cl]2
LH18
[Ir(LH18)2Cl]2
38%




as for [Ir(LH1)2Cl]2



[Ir(LH19)2Cl]2
LH19
[Ir(LH19)2Cl]2
40%




as for [Ir(LH1)2Cl]2






[Ir(LH20)2Cl]2
LH20


embedded image


84%





[Ir(LH21)2Cl]2
LH21
[Ir(LH21)2Cl]2
86%




as for [Ir(LH20)2Cl]2



[Ir(LH22)2Cl]2
LH22
[Ir(LH22)2Cl]2
83%




as for [Ir(LH20)2Cl]2






[Ir(LH26)2Cl]2
LH26


embedded image


85%





[Ir(LH27)2Cl]2
LH27
[Ir(LH27)2Cl]2
85%




as for [Ir(LH26)2Cl]2



[Ir(LH28)2Cl]2
LH28
[Ir(LH28)2Cl]2
83%




as for [Ir(LH26)2Cl]2



[Ir(LH29)2Cl]2
LH29
[Ir(LH29)2Cl]2
67%




as for [Ir(LH26)2Cl]2



[Ir(LH30)2Cl]2
LH30
[Ir(LH30)2Cl]2
83%




as for [Ir(LH26)2Cl]2



[Ir(LH31)2Cl]2
LH31
[Ir(LH31)2Cl]2
85%




as for [Ir(LH26)2Cl]2



[Ir(LH32)2Cl]2
LH32
[Ir(LH32)2Cl]2
86%




as for [Ir(LH26)2Cl]2



[Ir(LH33)2Cl]2
LH33
[Ir(LH32)2Cl]2
86%




B





260°C./30 h



[Ir(LH34)2Cl]2
LH34
[Ir(LH34)2Cl]2
88%




as for [Ir(LH33)2Cl]2






[Ir(LH35)2Cl]2
LH35


embedded image


86%





[Ir(LH36)2Cl]2
LH36
[Ir(LH36)2Cl]2
90%




as for [Ir(LH35)2Cl]2



[Ir(LH37)2Cl]2
LH37
[Ir(LH37)2Cl]2
88%




as for [Ir(LH35)2Cl]2



[Ir(LH38)2Cl]2
LH38
[Ir(LH38)2Cl]2
89%




as for [Ir(LH35)2Cl]2



[Ir(LH39)2Cl]2
LH39
[Ir(LH39)2Cl]2
87%




as for [Ir(LH35)2Cl]2



[Ir(LH40)2Cl]2
LH40
[Ir(LH40)2Cl]2
63%




B





265° C./35 h



[Ir(LH41)2Cl]2
LH41
[Ir(LH41)2Cl]2
89%




as for [Ir(LH35)2Cl]2



[Ir(LH42)2Cl]2
LH42
[Ir(LH42)2Cl]2
89%




as for [Ir(LH35)2Cl]2






[Ir(LB1)2Cl]2
LB1


embedded image


76%





[Ir(LB2)2Cl]2
LB2


embedded image


76%





[Ir(LB5)2Cl]2
LB5
[Ir(L85)2Cl]2
79%




as for [Ir(LB1)2Cl]2



[Ir(LB9)2Cl]2
LB9
[Ir(LB9)2Cl]2
81%




as for [Ir(LB2)2Cl]2



[Ir(LB10)2Cl]2
LB10
[Ir(LB10)2Cl]2
76%




as for [Ir(LB1)2Cl]2



[Ir(LB16)2Cl]2
LB16
[Ir(LB16)2Cl]2
82%




as for [Ir(LB2)2Cl]2






[Ir(LB26)2Cl]2
LB26


embedded image


75%





[Ir(LB30)2Cl]2
LB30


embedded image


83%





[Ir(LB31)2Cl]2
LB31


embedded image


81%





[Ir(LB33)2Cl]2
LB33


embedded image


88%





[Ir(LB36)2Cl]2
LB36


embedded image


53%





[Ir(LB37)2Cl]2
LB37


embedded image


88%





[Ir(LB38)2Cl]2
LH42
[Ir(LB38)2Cl]2
87%




as for [Ir(LH35)2Cl]2










4) Iridium Complexes of the [Ir(L)2(HOMe)2]OTf Type


5 ml of methanol and then 10 mmol of silver(I) trifluoromethanesulfonate [2923-28-6] are added to a suspension of 5 mmol of the chloro dimer [Ir(L)2Cl]2 in 150 ml of dichloromethane, and the mixture is stirred at room temperature for 18 h. The precipitated silver(I) chloride is filtered off with suction via a Celite bed, the filtrate is evaporated to dryness, the yellow residue is taken up in 30 ml of toluene or cyclohexane, the solid is filtered off, washed with n-heptane and dried in vacuo. The product of the formula [Ir(L)2(HOMe)2]OTf obtained in this way is reacted further without purification.















Ex.
[Ir(L)2Cl]2
[Ir(L)2(HOMe)2]OTf
Yield







[Ir(LP1)2(HOMe)2]OTf
Ir[(LP1)Cl]2


embedded image


81%





[Ir(LP2)2(HOMe)2]OTf
[Ir(LP2)2Cl]2
[Ir(LP2)2(HOMe)2]OTf
79%





[Ir(LH1)2(HOMe)2]OTf
[Ir(LH1)2Cl]2


embedded image








[Ir(LH2)2(HOMe)2]OTf
[Ir(LH2)2Cl]2
[Ir(LH2)2(HOMe)2]OTf
80%


[Ir(LH3)2(HOMe)2]OTf
[Ir(LH3)2Cl]2
[Ir(LH3)2(HOMe)2]OTf
78%


[Ir(LH4)2(HOMe)2]OTf
[Ir(LH4)2Cl]2
[Ir(LH4)2(HOMe)2]OTf
81%


[Ir(LH5)2(HOMe)2]OTf
[Ir(LH5)2Cl]2
[Ir(LH5)2(HOMe)2]OTf
83%


[Ir(LH6)2(HOMe)2]OTf
[Ir(LH6)2Cl]2
[Ir(LH6)2(HOMe)2]OTf
80%


[Ir(LH7)2(HOMe)2]OTf
[Ir(LH7)2Cl]2
[Ir(LH7)2(HOMe)2]OTf
81%


[Ir(LH9)2(HOMe)2]OTf
[Ir(LH9)2Cl]2
[Ir(LH9)2(HOMe)2]OTf
81%


[Ir(LH10)2(HOMe)2]OTf
[Ir(LH10)2Cl]2
[Ir(LH10)2(HOMe)2]OTf
86%


[Ir(LH12)2(HOMe)2]OTf
[Ir(LH12)2Cl]2
[Ir(LH12)2(HOMe)2]OTf
79%


[Ir(LH14)2(HOMe)2]OTf
[Ir(LH14)2Cl]2
[Ir(LH14)2(HOMe)2]OTf
80%


[Ir(LH15)2(HOMe)2]OTf
[Ir(LH15)2Cl]2
[Ir(LH15)2(HOMe)2]OTf
83%


[Ir(LH16)2(HOMe)2]OTf
[Ir(LH16)2Cl]2
[Ir(LH16)2(HOMe)2]OTf
78%


[Ir(LH17)2(HOMe)2]OTf
[Ir(LH17)2Cl]2
[Ir(LH17)2(HOMe)2]OTf
80%


[Ir(LH18)2(HOMe)2]OTf
[Ir(LH18)2Cl]2
[Ir(LH18)2(HOMe)2]OTf
82%


[Ir(LH19)2(HOMe)2]OTf
[Ir(LH19)2Cl]2
[Ir(LH19)2(HOMe)2]OTf
80%


[Ir(LH20)2(HOMe)2]OTf
[Ir(LH20)2Cl]2
[Ir(LH20)2(HOMe)2]OTf
85%


[Ir(LH21)2(HOMe)2]OTf
[Ir(LH21)2Cl]2
[Ir(LH21)2(HOMe)2]OTf
86%


[Ir(LH22)2(HOMe)2]OTf
[Ir(LH22)2Cl]2
[Ir(LH22)2(HOMe)2]OTf
80%


[Ir(LH26)2(HOMe)2]OTf
[Ir(LH26)2Cl]2
[Ir(LH26)2(HOMe)2]OTf
85%


[Ir(LH27)2(HOMe)2]OTf
[Ir(LH27)2Cl]2
[Ir(LH27)2(HOMe)2]OTf
84%


[Ir(LH28)2(HOMe)2]OTf
[Ir(LH28)2Cl]2
[Ir(LH28)2(HOMe)2]OTf
82%


[Ir(LH29)2(HOMe)2]OTf
[Ir(LH29)2Cl]2
[Ir(LH29)2(HOMe)2]OTf
85%


[Ir(LH30)2(HOMe)2]OTf
[Ir(LH30)2Cl]2
[Ir(LH30)2(HOMe)2]OTf
84%


[Ir(LH31)2(HOMe)2]OTf
[Ir(LH31)2Cl]2
[Ir(LH31)2(HOMe)2]OTf
79%


[Ir(LH32)2(HOMe)2]OTf
[Ir(LH32)2Cl]2
[Ir(LH32)2(HOMe)2]OTf
80%


[Ir(LH33)2(HOMe)2]OTf
[Ir(LH33)2Cl]2
[Ir(LH33)2(HOMe)2]OTf
82%


[Ir(LH34)2(HOMe)2]OTf
[Ir(LH34)2Cl]2
[Ir(LH34)2(HOMe)2]OTf
83%


[Ir(LH35)2(HOMe)2]OTf
[Ir(LH35)2Cl]2
[Ir(LH35)2(HOMe)2]OTf
85%


[Ir(LH36)2(HOMe)2]OTf
[Ir(LH36)2Cl]2
[Ir(LH36)2(HOMe)2]OTf
81%


[Ir(LH37)2(HOMe)2]OTf
[Ir(LH37)2Cl]2
[Ir(LH37)2(HOMe)2]OTf
80%


[Ir(LH38)2(HOMe)2]OTf
[Ir(LH38)2Cl]2
[Ir(LH38)2(HOMe)2]OTf
85%


[Ir(LH39)2(HOMe)2]OTf
[Ir(LH39)2Cl]2
[Ir(LH39)2(HOMe)2]OTf
80%


[Ir(LH40)2(HOMe)2]OTf
[Ir(LH40)2Cl]2
[Ir(LH40)2(HOMe)2]OTf
84%


[Ir(LH41)2(HOMe)2]OTf
[Ir(LH41)2Cl]2
[Ir(LH41)2(HOMe)2]OTf
84%


[Ir(LH42)2(HOMe)2]OTf
[Ir(LH42)2Cl]2
[Ir(LH42)2(HOMe)2]OTf
86%





[Ir(LB1)2(HOMe)2]OTf
[Ir(LB1)2Cl]2


embedded image


82%





[Ir(LB2)2(HOMe)2]OTf
[Ir(LB2)2Cl]2
[Ir(LB2)2(HOMe)2]OTf
75%


[Ir(LB5)2(HOMe)2]OTf
[Ir(LB5)2Cl]2
[Ir(LB5)2(HOMe)2]OTf
78%


[Ir(LB9)2(HOMe)2]OTf
[Ir(LB9)2Cl]2
[Ir(LB9)2(HOMe)2]OTf
79%


[Ir(LB10)2(HOMe)2]OTf
[Ir(LB10)2Cl]2
[Ir(LB10)2(HOMe)2]OTf
80%


[Ir(LB16)2(HOMe)2]OTf
[Ir(LB16)2Cl]2
[Ir(LB16)2(HOMe)2]OTf
78%


[Ir(LB26)2(HOMe)2]OTf
[Ir(LB26)2Cl]2
[Ir(LB26)2(HOMe)2]OTf
78%


[Ir(LB30)2(HOMe)2]OTf
[Ir(LB30)2Cl]2
[Ir(LB30)2(HOMe)2]OTf
82%


[Ir(LB31)2(HOMe)2]OTf
[Ir(LB31)2Cl]2
[Ir(LB31)2(HOMe)2]OTf
82%


[Ir(LB33)2(HOMe)2]OTf
[Ir(LB33)2Cl]2
[Ir(LB33)2(HOMe)2]OTf
76%


[Ir(LB36)2(HOMe)2]OTf
[Ir(LB36)2Cl]2
[Ir(LB36)2(HOMe)2]OTf
75%


[Ir(LB37)2(HOMe)2]OTf
[Ir(LB37)2Cl]2
[Ir(LB37)2(HOMe)2]OTf
77%


[Ir(LB38)2(HOMe)2]OTf
[Ir(LB38)2Cl]2
[Ir(LB38)2(HOMe)2]OTf
74%










5) Heteroleptic Iridium Complexes of the Phenylpyridine, Phenylimidazole or Phenylbenzimidazole Type:


A mixture of 10 mmol of the ligand L, 10 mmol of bis(methanol)bis[2-(2-pyridinyl-κN)phenyl-κC]iridium(III) trifluoromethanesulfonate [1215692-14-0] or bis(methanol)bis[2-(6-methyl-2-pyridinyl-κN)phenyl-κC]iridium(II) trifluoromethanesulfonate [1215692-29-7] or iridium complexes of the [Ir(L)2(HOMe)2]OTf type according to the invention, 11 mmol of 2,6-dimethylpyridine and 150 ml of ethanol is heated under reflux for 40 h. After cooling, the precipitated solid is filtered off with suction, washed three times with 30 ml of ethanol each time and dried in vacuo. The crude product obtained in this way is chromatographed on silica gel (solvent or mixtures thereof, for example DCM, THF, toluene, n-heptane, cyclohexane) and subjected to fractional sublimation as described under 1) variant A.
















[Ir(L)2(HOMe)2]OTf





Ligand
Ir complex



Ex.
L
Diastereomer
Yield







Ir500
1215692-14-0 LH1


embedded image


44%





Ir501
1215692-14-0 LH2


embedded image


43%





Ir502
1215692-14-0 LH3


embedded image


45%





Ir503
1215692-29-7 LH4


embedded image


27%





Ir504
1215692-14-0 LH5


embedded image


38%





Ir505
1215692-14-0 LH6


embedded image


50%





Ir506
1215692-14-0 LH7


embedded image


48%





Ir507
1215692-14-0 LH8


embedded image


24%





IR508
1215692-14-0 LH9


embedded image


42%





Ir509
1215692-14-0 LH10


embedded image


23%





Ir510
1215692-14-0 LH11


embedded image


26%





Ir511
1215692-29-7 LH12


embedded image


44%





Ir512
1215692-29-7 LH13


embedded image


46%





Ir513
1215692-14-0 LH14


embedded image


43%





Ir514
1215692-14-0 LH15


embedded image


52%





Ir515
1215692-14-0 LH16


embedded image


40%





Ir516
1215692-14-0 LH17


embedded image


23%





Ir517
1215692-14-0 LH18


embedded image


21%





Ir518
1215692-14-0 LH19


embedded image


25%





Ir519
1215692-14-0 LH20


embedded image


25%





Ir520
1215692-14-0 LH26


embedded image


45%





Ir521
1215692-14-0 LH27


embedded image


41%





Ir522
1215692-14-0 LH30


embedded image


38%





Ir523
1215692-14-0 LH31


embedded image


43%





Ir524
1215692-14-0 LH33


embedded image


43%





Ir525
1215692-14-0 LH34


embedded image


43%





Ir526
1215692-14-0 LH35


embedded image


43%





Ir527
1215692-14-0 LH36


embedded image


43%





Ir528
1215692-14-0 LH37


embedded image


43%





Ir529
1215692-14-0 LH41


embedded image


43%





Ir530
1215692-14-0 LH42


embedded image


43%





Ir531
1215692-14-0 LB38


embedded image


43%





Ir532
[Ir(LP1)2(HOMe)2]OTf LH1


embedded image


46%





Ir533
[Ir(LP2)2(HOMe)2]OTf LH2


embedded image


44%





Ir534
[Ir(LH1)2(HOMe)2]OTf 1008-89-56


embedded image


46%





Ir535
[Ir(LH2)2(HOMe)2]OTf 1008-89-56


embedded image


50%





Ir536
[Ir(LH3)2(HOMe)2]OTf 1008-89-56


embedded image


43%





Ir537
[Ir(LH6)2(HOMe)2]OTf 10273-90-2


embedded image


45%





Ir538
[Ir(LH7)2(HOMe)2]OTf 10273-90-2


embedded image


38%





Ir539
[Ir(LH9)2(HOMe)2]OTf 458541-39-4


embedded image


46%





Ir540
[Ir(LH12)2(HOMe)2]OTf 1008-89-56


embedded image


45%





Ir541
[Ir(LH14)2(HOMe)2]OTf 1008-89-56


embedded image


40%





Ir542
[Ir(LH15)2(HOMe)2]OTf 1008-89-56


embedded image


40%





Ir543
[Ir(LH16)2(HOMe)2]OTf LH1


embedded image


42%





Ir544
[Ir(LH20)2(HOMe)2]OTf 340026-65-5


embedded image


20%





Ir545
[Ir(LH21)2(HOMe)2]OTf 1008-89-56


embedded image


26%





Ir546
[Ir(LH22)2(HOMe)2]OTf 4350-51-0


embedded image


29%





Ir547
[Ir(LH26)2(HOMe)2]OTf 1008-89-56


embedded image


45%





Ir548
[Ir(LH27)2(HOMe)2]OTf 37993-76-3


embedded image


43%





Ir549
[Ir(LH28)2(HOMe)2]OTf 37993-76-3


embedded image


43%





Ir550
[Ir(LH29)2(HOMe)2]OTf 230-27-3


embedded image


21%





Ir551
[Ir(LH30)2(HOMe)2]OTf LP2


embedded image


38%





Ir552
[Ir(LH31)2(HOMe)2]OTf LB18


embedded image


36%





Ir553
[Ir(LH32)2(HOMe)2]OTf LB19


embedded image


39%





Ir554
[Ir(LH33)2(HOMe)2]OTf 1008-89-56


embedded image


48%





Ir555
[Ir(LH34)2(HOMe)2]OTf LH33


embedded image


45%





Ir556
[Ir(LH35)2(HOMe)2]OTf 1008-89-56


embedded image


47%





Ir557
[Ir(LH36)2(HOMe)2]OTf LH1


embedded image


36%





Ir558
[Ir(LH37)2(HOMe)2]OTf 26274-35-1


embedded image


41%





Ir559
[Ir(LH)382(HOMe)2]OTf LB37


embedded image


45%





Ir560
[Ir(LH39)2(HOMe)2]OTf LH6


embedded image


42%





Ir561
[Ir(LH40)2(HOMe)2]OTf 4350-51-0


embedded image


31%





Ir562
[Ir(LH41)2(HOMe)2]OTf 1008-89-56


embedded image


46%





Ir563
[Ir(LH42)2(HOMe)2]OTf 1008-89-56


embedded image


45%





Ir564
[Ir(LB1)2(HOMe)2]OTf LH1


embedded image


44%





Ir565
[Ir(LB2)2(HOMe)2]OTf LH38


embedded image


39%





Ir566
[Ir(LB3)2(HOMe)2]OTf LH35


embedded image


40%





Ir567
[Ir(LB10)2(HOMe)2]OTf LH35


embedded image


41%





Ir568
[Ir(LB16)2(HOMe)2]OTf LH38


embedded image


39%





Ir569
[Ir(LB33)2(HOMe)2]OTf LH1


embedded image


40%





Ir570
[Ir(LB37)2(HOMe)2]OTf LH35


embedded image


45%





Ir571
[Ir(LB38)2(HOMe)2]OTf 1008-89-56


embedded image


47%










6) Heteroleptic Tris-Facial Iridium Complexes Containing Ligands of the Arduengo Carbene Type:


Preparation analogous to A. G. Tennyson et al., Inorg. Chem., 2009, 48, 6924.


A mixture of 22 mmol of the ligand, 10 mmol of iridium chloro dimer [Ir(L)2Cl]2, 10 mmol of silver(I) oxide and 300 ml of 1,2-dichloroethane is stirred at 90° C. for 30 h. After cooling, the precipitated solid is filtered off with suction via a Celite bed, washed once with 30 ml of 1,2-dichloroethane, and the filtrate is evaporated to dryness in vacuo. The crude product obtained in this way is chromatographed on silica gel (solvent or mixtures thereof, for example dichloromethane, THF, toluene, n-heptane, cyclohexane) and subjected to fractional sublimation as described under 1) variant A.
















[Ir(L)2Cl]2
Ir complex



Ex.
Ligand L
Diastereomer
Yield







Ir572
[Ir(PPy)2Cl]2 603109-48-4 LH23


embedded image


43%





Ir573
[Ir(LH20)2Cl]2 LH24


embedded image


45%










7) Platinum Complexes of Tetradentate Ligands:


A mixture of 10 mmol of the ligand L, 10 mmol of K2PtCl4, 400 mmol of lithium acetate, anhydrous, and 200 ml of glacial acetic acid is heated under reflux for 60 h. After cooling and addition of 200 ml of water, the mixture is extracted twice with 250 ml of toluene each time, dried over magnesium sulfate, filtered through a Celite bed, the Celite is rinsed with 200 ml of toluene, and the toluene is then removed in vacuo. The solid obtained in this way is purified as described under 1) variant A by hot extraction and then subjected to fractional sublimation.

















Ligand





Ex.
L
Pt complex
Extractant
Yield







Pt(LH43)
LH43


embedded image


Toluene
40%





Pt(LH44)
LH44
Pt(LH44)
Toluene
19%


Pt(LH45)
LH45
Pt(LH45)
Cyclohexane
37%










10) Platinum Complexes of Tetradentate Ligands of the Arduengo Carbene Type:


A mixture of 10 mmol of the ligand, 10 mmol of silver(I) oxide and 200 ml of dioxane is stirred at room temperature for 16 h, 100 ml of butanone, 20 mmol of sodium carbonate and 10 mmol of cyclooctadienylplatinum dichloride are then added, and the mixture is heated under reflux for 16 h. After removal of the solvent, the solid is extracted by stirring with 500 ml of hot toluene, the suspension is filtered through a Celite bed, and the filtrate is evaporated to dryness. The solid obtained in this way is chromatographed on silica gel with DCM and then subjected to fractional sublimation as described under 1) variant A.















Ex.
Ligand
Pt complex
Yield







Pt(LH46)
LH46


embedded image


25%





Pt(LH47)
LH47
Pt(LH47)
28%










11) Iridium Complexes of Hexadentate Ligands:


A mixture of 10 mmol of the ligand L, 10 mmol of sodium bisacetylacetonatodichloroiridate(III) [770720-50-8] and 200 ml of triethylene glycol dimethyl ether is heated at 210° C. on a water separator for 48 h (the acetyl-acetone and thermal cleavage products of the solvent distil off). After cooling and addition of 200 ml of water, the precipitated solid is filtered off with suction and dried in vacuo. The solid is extracted by stirring with 500 ml of hot THF, the suspension is filtered through a Celite bed while still hot, the Celite is rinsed with 200 ml of THF, and the combined filtrates are evaporated to dryness. The solid obtained in this way is purified as described under 1) variant A by hot extraction with toluene and then subjected to fractional sublimation.















Ex.
Ligand
Ir complex
Yield







Ir(LH48)
LH48


embedded image


21%





Ir(LH49)
LH49
Ir(LH49)
22%


Ir(LH50)
LH50
Ir(LH50)
19%










12) Iridium Complexes of Hexadentate Ligands of the Arduengo Carbene Type:


Preparation analogous to K. Tsuchiya et al., Eur. J. Inorg. Chem. 2010, 926.


A mixture of 3 mmol of the ligand, 3 mmol of iridium(III) chloride hydrate, 10 mmol of silver carbonate and 10 mmol of sodium carbonate in 75 ml of 2-ethoxyethanol is warmed under reflux for 48 h. After cooling, 300 ml of water are added, the precipitated solid is filtered off with suction, washed once with 30 ml of water and three times with 15 ml of ethanol each time and dried in vacuo. The crude product obtained in this way is chromatographed on silica gel (DCM) and then subjected to fractional sublimation as described under 1) variant A.















Ex.
Ligand
Ir complex
Yield







Ir(LH51)
LH51


embedded image


23%





Ir(LH52)
LH52
Ir(LH52)
17%










Derivatisation of the Metal Complexes


1) Halogenation of the Fac-Iridium Complexes:


A×10.5 mmol of N-halosuccinimide (halogen: Cl, Br, I) are added to a solution or suspension of 10 mmol of a complex carrying A×C—H groups (where A=1, 2 or 3) in the para-position to the iridium in 500 ml of dichloromethane at 30° C. with exclusion of light and air, and the mixture is stirred for 20 h. Complexes which have low solubility in DCM can also be reacted in other solvents (TCE, THF, DMF, etc.) and at elevated temperature. The solvent is subsequently substantially removed in vacuo. The residue is boiled with 100 ml of methanol, the solid is filtered off with suction, washed three times with 30 ml of methanol and then dried in vacuo, giving the fac-iridium complexes which are brominated in the para-position to the iridium


Synthesis of Ir(LH35-Br)3:




embedded image


5.6 g (31.5 mmol) of N-bromosuccinimide are added in one portion to a suspension, stirred at 30° C., of 9.8 g (10 mmol) of Ir(LH35)3 in 500 ml of DCM, and the mixture is then stirred for a further 20 h. After removal of about 450 ml of the DCM in vacuo, 100 ml of methanol are added to the yellow suspension, the solid is filtered off with suction, washed three times with about 30 ml of methanol and then dried in vacuo. Yield: 11.4 g (9.3 mmol), 953%; purity: >99.0% according to NMR.


The following compounds can be prepared analogously:















Ex.
Complex
Brominated complex
Yield







Ir(LH20-Br)3


embedded image




embedded image


90%





Ir(LH23-Br)3


embedded image




embedded image


88%





Ir(LH26-Br)3


embedded image




embedded image


85%





Ir(LH33-Br)3


embedded image




embedded image


87%





Ir(LH38-Br)3


embedded image




embedded image


90%





Ir500-Br2


embedded image




embedded image


85%





Ir501-Br2


embedded image




embedded image


91%





Ir505-Br2


embedded image




embedded image


90%





Ir529-Br2


embedded image




embedded image


88%





Ir534-Br


embedded image




embedded image


89%





Ir535-Br


embedded image




embedded image


91%





Ir541-Br


embedded image




embedded image


85%





Ir563-Br


embedded image




embedded image


87%










2) Suzuki Coupling to the Brominated Fac-Iridium Complexes:


Variant a, Two-Phase Reaction Mixture:


0.6 mmol of tri-o-tolylphosphine and then 0.1 mmol of palladium(II) acetate are added to a suspension of 10 mmol of a brominated complex, 12-20 mmol of the boronic acid or boronic acid ester per Br function and 40-80 mmol of tripotassium phosphate in a mixture of 300 ml of toluene, 100 ml of dioxane and 300 ml of water, and the mixture is heated under reflux for 16 h. After cooling, 500 ml of water and 200 ml of toluene are added, the aqueous phase is separated off, the organic phase is washed three times with 200 ml of water, once with 200 ml of saturated sodium chloride solution and dried over magnesium sulfate. The solid material is filtered off through a Celite bed and rinsed with toluene, the toluene is removed virtually completely in vacuo, 300 ml of methanol are added, the precipitated crude product is filtered off with suction, washed three times with 50 ml of methanol each time and dried in vacuo. The crude product is passed through a silica-gel column twice. The metal complex is finally heated or sublimed. The heating is carried out in a high vacuum (p about 10−6 mbar) in the temperature range from about 200-300° C. The sublimation is carried out in a high vacuum (p about 10−6 mbar) in the temperature range from about 300-400° C., with the sublimation preferably being carried out in the form of a fractional sublimation.


Variant B, One-Phase Reaction Mixture:


0.6 mmol of tri-o-tolylphosphine and then 0.1 mmol of palladium(II) acetate are added to a suspension of 10 mmol of a brominated complex, 12-20 mmol of the boronic acid or boronic acid ester per Br function and 60-100 mmol of the base (potassium fluoride, tripotassium phosphate (anhydrous or monohydrate or trihydrate), potassium carbonate, caesium carbonate, etc.) and 100 g of glass beads (diameter 3 mm) in 100 ml-500 ml of an aprotic solvent (THF, dioxane, xylene, mesitylene, dimethylacetamide, NMP, DMSO, etc.), and the mixture is heated under reflux for 1-24 h. Alternatively, other phosphines, such as tri-tert-butylphosphine, SPhos, XPhos, RuPhos, XanthPhos, etc., can be employed, where the preferred phosphine:palladium ratio in the case of these phosphines is 2:1 to 1.2:1. The solvent is removed in vacuo, the product is taken up in a suitable solvent (toluene, dichloromethane, ethyl acetate, etc.) and purified as described under Variant A.


Synthesis of Ir600:




embedded image



Variant A:


Use of 12.2 g (10.0 mmol) of Ir(LH35-Br)3 and 4.9 g (40.0 mmol) of phenyl-boronic acid [98-80-6], 17.7 (60 mmol) of tripotassium phosphate (anhydrous), 183 mg (0.6 mmol) of tri-o-tolylphosphine [6163-58-2], 23 mg (0.1 mmol) of palladium(II) acetate, 300 ml of toluene, 100 ml of dioxane and 300 ml of water, 100° C., 12 h. Chromatographic separation on silica gel with toluene/ethyl acetate (90:10, w) twice. Yield: 6.3 g (5.2 mmol), 52%; purity: about 99.9% according to HPLC.


The following compounds can be prepared analogously:
















Complex





Boronic acid




Ex.
Variant
Product
Yield







Ir601
Ir(LH38-Br)3 1233200-59-3 A Chromatographic separation using toluene


embedded image


57%





Ir602
Ir(LH33-Br)3 84110-40-7 B SPhos:Pd(ac)2/2:1 K3PO4 * 3H2O Toluene Chromatographic separation using toluene


embedded image


53%





Ir603
Ir(LH26-Br)3 5122-95-2 A Chromatographic separation using toluene


embedded image


64%





Ir604
Ir(LH20-Br)3 84110-40-7 B SPhos:Pd(ac)2/2:1 K3PO4 * 3H2O Toluene Chromatographic separation using toluene


embedded image


61%





Ir605
Ir500-Br2 100379-00-8 B SPhos:Pd(ac)2/2:1 Cs2CO3/dioxane Chromatographic separation using tol/DCM (95:5 vv)


embedded image


33%





Ir606
Ir529-Br2 1251825-65-6 A Chromatographic separation using n-heptane/EA (90:10)


embedded image


58%





Ir607
Ir535-Br 654664-63-8 A Chromatographic separation using n-heptane/DCM (90:10)


embedded image


51%










3) Buchwald Coupling to the Iridium Complexes:


0.4 mmol of tri-tert-butylphosphine and then 0.3 mmol of palladium(II) acetate are added to a mixture of 10 mmol of the brominated complex, 12-20 mmol of the diarylamine or carbazole p[er bromine function, 1.1 molar amount of sodium tert-butoxide per amine employed or 80 mmol of tripotassium phosphate (anhydrous) in the case of carbazoles, 100 g of glass beads (diameter 3 mm) and 300-500 ml of toluene or o-xylene in the case of carbazoles, and the mixture is heated under reflux for 16-30 h with vigorous stirring. After cooling, 500 ml of water are added, the aqueous phase is separated off, and the organic phase is washed twice with 200 ml of water and once with 200 ml of saturated sodium chloride solution and dried over magnesium sulfate. The solid material is filtered off through a Celite bed and rinsed with toluene or o-xylene, the solvent is removed virtually completely in vacuo, 300 ml of ethanol are added, the precipitated crude product is filtered off with suction, washed three times with 50 ml of EtOH each time and dried in vacuo. The crude product is purified by chromatography on silica gel twice. The metal complex is finally heated or sublimed. The heating is carried out in a high vacuum (p about 10−6 mbar) in the temperature range from about 200-300° C. The sublimation is carried out in a high vacuum (p about 10−6 mbar) in the temperature range from about 300-400° C., with the sublimation preferably being carried out in the form of a fractional sublimation.


Synthesis of Ir700:




embedded image


Use of 12.2 g (10 mmol) of Ir(LH35-Br)3 and 14.5 g (40 mmol) of N-[1,1′-biphenyl]-4-yl-9,9-dimethyl-9H-fluoren-2-amine [897671-69-1]. Heating. Yield: 8.5 g (4.1 mmol), 41%; purity: about 99.8% according to HPLC.


The following compounds can be prepared analogously:















Product




Starting material



Ex.
Amine or carbazole
Yield







Ir701


embedded image


40%





Ir702


embedded image


45%





Ir703


embedded image


47%





Ir704


embedded image


37%










4) Cyanation of the Iridium Complexes:


A mixture of 10 mmol of the brominated complex, 13 mmol of copper(I) cyanide per bromine function and 300 ml of NMP is stirred at 200° C. for 20 h. After cooling, the solvent is removed in vacuo, the residue is taken up in 500 ml of dichloromethane, the copper salts are filtered off via Celite, the dichloromethane is evaporated virtually to dryness in vacuo, 100 ml of ethanol are added, the precipitated solid is filtered off with suction, washed twice with 50 ml of ethanol each time and dried in vacuo. Chromatography or hot extraction and fractional sublimation of the crude product as described in C: Synthesis of the metal complexes, 1) Homoleptic tris-facial iridium complexes of the phenylpyridine, phenylimidazole or phenylbenzimidazole type: variant A.


Synthesis of Ir800:




embedded image


Use of 12.2 g (10 mmol) of Ir(LH35-Br)3 and 3.5 g (39 mmol) of copper(I) cyanide. Sublimation. Yield: 4.6 g (4.3 mmol), 43%; purity: about 99.8% according to HPLC.


The Following Compounds can be Prepared Analogously:















Product



Ex.
Starting material
Yield







Ir801


embedded image


35%





Ir802


embedded image


37%





Ir803


embedded image


44%










5) Borylation of the Iridium Complexes:


A mixture of 10 mmol of the brominated complex, 12 mmol of bis(pinacolato)diborane [73183-34-3] per bromine function, 30 mmol of potassium acetate, anhydrous, per bromine function, 0.2 mmol of tricyclohexylphosphine, 0.1 mmol of palladium(II) acetate and 300 ml of solvent (dioxane, DMSO, NMP, etc.) is stirred at 80-160° C. for 4-16 h. After removal of the solvent in vacuo, the residue is taken up in 300 ml of dichloromethane, THF or ethyl acetate, filtered through a Celite bed, the filtrate is evaporated in vacuo until crystallisation commences, and finally about 100 ml of methanol are added dropwise in order to complete the crystallisation. The compounds can be recrystallised from dichloromethane, ethyl acetate or THF with addition of methanol or alternatively from cyclohexane.


Synthesis of Ir900:




embedded image


Use of 12.2 g (10 mmol) of Ir(LH35-Br)3 and 9.1 g (36 mmol) of bis(pinacolato)diborane [73183-34-3], DMSO, 120° C., 6 h, taking-up and Celite filtration in THF, recrystallisation from THF:methanol. Yield: 6.8 g (5.0 mmol), 50%; purity: about 99.8% according to HPLC.


The following compounds can be prepared analogously:















Ex.
Starting material
Product
Yield







Ir901


embedded image




embedded image


60%





Ir902


embedded image




embedded image


64%










6) Suzuki Coupling to the Borylated Fac-Iridium Complexes:


Variant A, Two-Phase Reaction Mixture:


0.6 mmol of tri-o-tolylphosphine and then 0.1 mmol of palladium(II) acetate are added to a suspension of 10 mmol of a borylated complex, 12-20 mmol of aryl bromide per (RO)2B function and 80 mmol of tripotassium phosphate in a mixture of 300 ml of toluene, 100 ml of dioxane and 300 ml of water, and the mixture is heated under reflux for 16 h. After cooling, 500 ml of water and 200 ml of toluene are added, the aqueous phase is separated off, and the organic phase is washed three times with 200 ml of water, once with 200 ml of saturated sodium chloride solution and dried over magnesium sulfate. The mixture is filtered through a Celite bed, the latter is rinsed with toluene, the toluene is removed virtually completely in vacuo, 300 ml of methanol are added, and the crude product which has precipitated out is filtered off with suction, washed three times with 50 ml of methanol each time and dried in vacuo. The crude product is passed through a silica-gel column twice. The metal complex is finally heated or sublimed. The heating is carried out in a high vacuum (p about 10−6 mbar) in the temperature range from about 200-300° C. The sublimation is carried out in a high vacuum (p about 10−6 mbar) in the temperature range from about 300-400° C., where the sublimation is preferably carried out in the form of a fractional sublimation.


Variant B, Single-Phase Reaction Mixture:


0.6 mmol of tri-o-tolylphosphine and then 0.1 mmol of palladium(II) acetate are added to a suspension of 10 mmol of a borylated complex, 12-20 mmol of aryl bromide per (RO)2B function and 60-100 mmol of the base (potassium fluoride, tripotassium phosphate (anhydrous, monohydrate or trihydrate), potassium carbonate, caesium carbonate, etc.) and 100 g of glass beads (diameter 3 mm) in 100 ml-500 ml of an aprotic solvent (THF, dioxane, xylene, mesitylene, dimethylacetamide, NMP, DMSO, etc.), and the mixture is heated under reflux for 1-24 h. Alternatively, other phosphines, such as tri-tert-butylphosphine, SPhos, XPhos, RuPhos, XanthPhos, etc., can be employed, where in the case of these phosphines the preferred phosphine:palladium ratio is 2:1 to 1.2:1. The solvent is removed in vacuo, and the product is taken up in a suitable solvent (toluene, dichloromethane, ethyl acetate, etc.) and purified as described under variant A.


Synthesis of Ir600:




embedded image



Variant A:


Use of 13.6 g (10.0 mmol) of Ir900 and 4.2 ml (40.0 mmol) of bromobenzene [108-86-1], 17.7 g (60 mmol) of tripotassium phosphate (anhydrous), 183 mg (0.6 mmol) of tri-o-tolylphosphine [6163-58-2], 23 mg (0.1 mmol) of palladium(II) acetate, 300 ml of toluene, 100 ml of dioxane and 300 ml of water, 100° C., 12 h. Chromatographic separation on silica gel using toluene/ethyl acetate (90:10, vv) twice. Yield: 6.3 g (5.2 mmol), 52%; purity: about 99.9% according to HPLC.


The following compounds can be prepared analogously:
















Complex





Boronic acid




Ex.
Variant
Product
Yield







Ir608
Ir901 1153-85-1 A Chromatographic separation using toluene


embedded image


63%





Ir609
Ir902 1369587-63-2 A Chromatographic separation using toluene


embedded image


55%










Polymers Containing the Metal Complexes:


General Polymerisation Procedure for the Bromides or Boronic Acid Derivatives as Polymerisable Group, Suzuki Polymerisation


Variant A—Two-Phase Reaction Mixture:


The monomers (bromides and boronic acids or boronic acid esters, purity according to HPLC>99.8%) in the composition indicated in the table are dissolved or suspended in a mixture of 2 parts by volume of toluene:6 parts by volume of dioxane:1 part by volume of water in a total concentration of about 100 mmol/l. 2 mol equivalents of tripotassium phosphate per Br functionality employed are then added, the mixture is stirred for a further 5 min., 0.03 to 0.003 mol equivalent of tri-ortho-tolylphosphine and then 0.005 to 0.0005 mol equivalent of palladium(II) acetate (phosphine to Pd ratio preferably 6:1) per Br functionality employed are then added, and the mixture is heated under reflux for 2-3 h with very vigorous stirring. If the viscosity of the mixture increases excessively, it can be diluted with a mixture of 2 parts by volume of toluene:3 parts by volume of dioxane. After a total reaction time of 4-6 h, 0.05 mol equivalent per boronic acid functionality employed of a monobromoaromatic compound are added for end capping, and then, 30 min. later, 0.05 mol equivalent per Br functionality employed of a monoboronic acid or a monoboronic acid ester is added, and the mixture is boiled for a further 1 h. After cooling, the mixture is diluted with 300 ml of toluene. The aqueous phase is separated off, the organic phase is washed twice with 300 ml of water each time, dried over magnesium sulfate, filtered through a Celite bed in order to remove palladium and then evaporated to dryness. The crude polymer is dissolved in THF (concentration about 10-30 g/l), and the solution is allowed to run slowly, with very vigorous stirring, into twice the volume of methanol. The polymer is filtered off with suction and washed three times with methanol. The reprecipitation process is repeated five times, the polymer is then dried to constant weight at 30-50° C. in vacuo.


Variant B—One-Phase Reaction Mixture:


The monomers (bromides and boronic acids or boronic acid esters, purity according to HPLC>99.8%) in the composition indicated in the table are dissolved or suspended in a solvent (THF, dioxane, xylene, mesitylene, dimethylacetamide, NMP, DMSO, etc.) in a total concentration of about 100 mmol/l. 3 mol equivalents of base (potassium fluoride, tripotassium phosphate (anhydrous, monohydrate or trihydrate), potassium carbonate, caesium carbonate, etc., in each case anhydrous) per Br functionality are then added, and the weight equivalent of glass beads (diameter 3 mm) is added, the mixture is stirred for a further 5 min., 0.03 to 0.003 mol equivalent of tri-ortho-tolylphosphine and then 0.005 to 0.0005 mol equivalent of palladium(II) acetate (phosphine to Pd ratio preferably 6:1) per Br functionality are then added, and the mixture is then heated under reflux for 2-3 h with very vigorous stirring. Alternatively, other phosphines, such as tri-tert-butylphosphine, SPhos, XPhos, RuPhos, XanthPhos, etc., can be employed, where the preferred phosphine:palladium ratio in the case of these phosphines is 2:1 to 1.3:1. After a total reaction time of 4-12 h, 0.05 mol equivalent of a monobromoaromatic compound and then, 30 min. later, 0.05 mol equivalent of a monoboronic acid or a monoboronic acid ester is added for end capping, and the mixture is boiled for a further 1 h. The solvent is substantially removed in vacuo, the residue is taken up in toluene, and the polymer is purified as described under variant A.


Monomers M/End Cappers E:



















embedded image


M1








embedded image


M2








embedded image


M3








embedded image


M4








embedded image


E1








embedded image


E2










Polymers:


Composition of the Polymers, Mol %:


















M1
M2
M3
M4



Polymer
[%]
[%]
[%]
[%]
Ir complex/[%]







P1

30

45
Ir(LH35—Br)3/10


P2

30

40
Ir500—Br2/10


P3
20
30
25
20
Ir902/5










Molecular Weights and Yield of the Polymers According to the Invention:

















Polymer
Mn [gmol−1]
Polydispersity
Yield








P1
180,000
4.8
56%



P2
250,000
2.3
61%



P3
310,000
2.4
66%









Comparison of the Solubility of the Complexes in Organic Solvents:


The complexes according to the invention have the solubility shown in the table, in the solvents indicated at 25° C. Comparison with the complexes without the cyclic group according to the invention shows that the solubility of the complexes according to the invention is significantly greater (factor about 5-50).

















Comparative complex
Complex


Ex.
Solvent
Solubility
Solubility [g/ml]







Sol1
Toluene


embedded image




embedded image







Sol2
o-Xylene


embedded image




embedded image







Sol3
3-Phenoxy- toluene


embedded image




embedded image







Sol4
Toluene


embedded image




embedded image







Sol5
Toluene


embedded image




embedded image







Sol6
Toluene


embedded image




embedded image







Sol7
Toluene


embedded image




embedded image







Sol8
Toluene


embedded image




embedded image







Sol9
Toluene


embedded image




embedded image







Sol10
Toluene


embedded image




embedded image







Sol11
Cyclohexane


embedded image




embedded image







Sol12
Toluene


embedded image




embedded image







Sol13
Toluene


embedded image




embedded image







Sol14
Toluene


embedded image




embedded image







Sol15
Toluene


embedded image




embedded image







Sol16
Toluene


embedded image




embedded image







Sol17
Toluene


embedded image




embedded image












Sublimation of the Complexes:


The complexes according to the invention have the sublimation temperature and rate shown in the table at a base pressure of about 10−5 mbar. Comparison with complexes without the bicyclic group according to the invention shows that the sublimation temperature of the complexes according to the invention is lower and the sublimation rate is significantly greater. In addition, the complexes according to the invention are stable under the sublimation conditions.














Ex.
Comparative complex
Complex







Sub1


embedded image




embedded image







Sub2


embedded image




embedded image







Sub3


embedded image




embedded image







Sub4


embedded image




embedded image







Sub5


embedded image




embedded image







Sub6


embedded image




embedded image







Sub7


embedded image




embedded image







Sub8


embedded image




embedded image







Sub9


embedded image




embedded image











Example: Production of OLEDs

1) Vacuum-Processed Devices:


OLEDs according to the invention and OLEDs in accordance with the prior art are produced by a general process in accordance with WO 2004/058911, which is adapted to the circumstances described here (layer-thickness variation, materials used).


The results of various OLEDs are presented in the following examples. Glass plates with structured ITO (50 nm, indium tin oxide) form the substrates to which the OLEDs are applied. The OLEDs have in principle the following layer structure: substrate/hole-transport layer 1 (HTL1) consisting of HTM doped with 3% of NDP-9 (commercially available from Novaled), 20 nm/hole-transport layer 2 (HTL2)/optional electron-blocking layer (EBL)/emission layer (EML)/optional hole-blocking layer (HBL)/electron-transport layer (ETL)/optional electron-injection layer (EIL) and finally a cathode. The cathode is formed by an aluminium layer with a thickness of 100 nm


Firstly, vacuum-processed OLEDs are described. For this purpose, all materials are applied by thermal vapour deposition in a vacuum chamber. The emission layer here always consists of at least one matrix material (host material) and an emitting dopant (emitter), which is admixed with the matrix material or matrix materials in a certain proportion by volume by co-evaporation. An expression such as M3:M2:Ir(LH1)3 (55%:35%:10%) here means that material M3 is present in the layer in a proportion by volume of 55%, M2 is present in the layer in a proportion of 35% and Ir(LH1)3 is present in the layer in a proportion of 10%. Analogously, the electron-transport layer may also consist of a mixture of two materials. The precise structure of the OLEDs is shown in Table 1. The materials used for the production of the OLEDs are shown in Table 7.


The OLEDs are characterised by standard methods. For this purpose, the electroluminescence spectra, the current efficiency (measured in cd/A) and the voltage (measured at 1000 cd/m2 in V) are determined from current/voltage/luminance characteristic lines (IUL characteristic lines). For selected experiments, the lifetime is determined. The lifetime is defined as the time after which the luminous density has dropped to a certain proportion from a certain initial luminous density. The expression LT50 means that the lifetime given is the time at which the luminous density has dropped to 50% of the initial luminous density, i.e. from, for example, 1000 cd/m2 to 500 cd/m2. Depending on the emission colour, different initial luminances were selected. The values for the lifetime can be converted to a FIGURE for other initial luminous densities with the aid of conversion formulae known to the person skilled in the art. The lifetime for an initial luminous density of 1000 cd/m2 is a usual FIGURE here.


Use of Compounds According to the Invention as Emitter Materials in Phosphorescent OLEDs


The compounds according to the invention can be employed, inter alia, as phosphorescent emitter materials in the emission layer in OLEDs. The iridium compounds shown in Table 3 are used as comparison in accordance with the prior art. The results for the OLEDs are summarised in Table 2.









TABLE 1







Structure of the OLEDs













HTL2
EBL
EML
HBL
ETL


Ex.
Thickness
Thickness
Thickness
Thickness
Thickness










Orange - red OLEDs












D-IrR1
HTM

M7:M8:Ir-R1

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-IrR2
HTM

M7:M8:Ir-R2

ETM1:ETM2



270 nm

(60%:30%:10%)

(50%:50%)





35 nm

35 nm


D-IrR3
HTM

M7:M8:Ir-R3

ETM1:ETM2



270 nm

(60%:30%:10%)

(50%:50%)





35 nm

35 nm


D-Ir(LH4)3
HTM

M7:M8:Ir(LH4)3

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir(LH9)3
HTM

M7:M8:Ir(LH9)3

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir(LH10)3
HTM

M7:M8:Ir(LH10)3

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir(LH26)3
HTM

M7:M8:Ir(LH26)3

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir(LH27)3
HTM

M7:M8:Ir(LH27)3

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir(LH32)3
HTM

M7:M8:Ir(LH32)3

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir(LH33)3
HTM

M7:M8:Ir(LH33)3

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir(LH61)3
HTM

M7:M8:Ir(LH61)3

ETM1:ETM2



270 nm

(60%:30%:10%)

(50%:50%)





35 nm

35 nm


D-Ir503
HTM

M7:M8:Ir503

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir509
HTM

M7:M8:Ir509

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir516
HTM

M7:M8:Ir516

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir517
HTM

M7:M8:Ir517

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir520
HTM

M7:M8:Ir520

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir521
HTM

M7:M8:Ir521

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir522
HTM

M7:M8:Ir522

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir523
HTM

M7:M8:Ir523

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir524
HTM

M7:M8:Ir524

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir539
HTM

M7:M8:Ir539

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir547
HTM

M7:M8:Ir547

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir548
HTM

M7:M8:Ir548

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm


D-Ir554
HTM

M7:M8:Ir554

ETM1:ETM2



270 nm

(65%:30%:5%)

(50%:50%)





35 nm

35 nm







Yellow OLEDs












D-Ir-Y1
HTM

M7:M8:Ir-Y1

ETM1:ETM2



240 nm

(58%:30%:12%)

(50%:50%)





25 nm

40 nm


D-Ir-Y2
HTM

M7:M8:Ir-Y2

ETM1:ETM2



240 nm

(62%:30%:8%)

(50%:50%)





25 nm

40 nm


D-Ir(LH6)3
HTM

M7:M8:Ir(LH6)3

ETM1:ETM2



240 nm

(62%:30%:8%)

(50%:50%)





25 nm

40 nm


D-Ir(LH8)3
HTM

M7:M8:Ir(LH8)3

ETM1:ETM2



240 nm

(60%:30%:10%)

(50%:50%)





25 nm

40 nm


D-Ir505
HTM

M7:M8:Ir505

ETM1:ETM2



240 nm

(62%:30%:8%)

(50%:50%)





25 nm

40 nm


D-Ir508
HTM

M7:M8:Ir508

ETM1:ETM2



240 nm

(62%:30%:8%)

(50%: 50%)





25 nm

40 nm


D-Ir512
HTM

M7:M8:Ir512

ETM1:ETM2



240 nm

(62%:30%:8%)

(50%:50%)





25 nm

40 nm


D-Ir537
HTM

M7:M8:Ir537

ETM1:ETM2



240 nm

(62%:30%:8%)

(50%:50%)





25 nm

40 nm







Green OLEDs












D-Ir-G1
HTM

M7:M8:Ir-G1
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir-G2
HTM

M7:M8:Ir-G2
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir-G4
HTM

M7:M8:Ir-G4
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir-G4b
NPB

CBP:Ir-G4
BCP
AlQ (20 nm)



40 nm

(80%:20%)
10 nm
LiQ (2 nm)





30 nm




D-Ir(LH1)3
HTM

M7:M8:Ir(LH1)3
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir(LH1)3
HTM

M7:M8:Ir(LH1)3
HBM2
ETM1:ETM2



220 nm

(55%:30%:15%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir(LH3)3
HTM

M7:M8:Ir(LH3)3
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir(LH7)3
HTM

M7:M8:Ir(LH7)3
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir(LH16)3
HTM

M7:M8:Ir(LH16)3
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir(LH35)3
HTM

M7:M8:Ir(LH35)3
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir(LH36)3
HTM

M7:M8:Ir(LH36)3
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir(LH41)3
HTM

M7:M8:Ir(LH41)3
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir(LH42)3
HTM

M7:M8:Ir(LH42)3
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir(LH49)3
HTM

M7:M8:Ir(LH49)3
HBM2
ETM1:ETM2



220 nm

(62%:30%:8%)
10 nm
(50%:50%)





30 nm

30 nm


D-Ir(LH57)3
HTM

M7:M8:Ir(LH57)3
HBM2
ETM1:ETM2



220 nm

(62%:30%:8%)
10 nm
(50%:50%)





30 nm

30 nm


D-Ir(LH58)3
HTM

M7:M8:Ir(LH58)3
HBM2
ETM1:ETM2



220 nm

(62%:30%:8%)
10 nm
(50%:50%)





30 nm

30 nm


D-Ir(LH59)3
HTM

M7:M8:Ir(LH59)3
HBM2
ETM1:ETM2



220 nm

(62%:30%:8%)
10 nm
(50%:50%)





30 nm

30 nm


D-Ir(LH60)3
HTM

M7:M8:Ir(LH60)3
HBM2
ETM1:ETM2



220 nm

(62%:30%:8%)
10 nm
(50%:50%)





30 nm

30 nm


D-Ir500
HTM

M7:M8:Ir500
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir501
HTM

M7:M8:Ir501
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir502
HTM

M7:M8:Ir502
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir506
HTM

M7:M8:Ir506
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir507
HTM

M7:M8:Ir507
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir510
HTM

M7:M8:Ir510
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir511
HTM

M7:M8:Ir511
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir519
HTM

M7:M8:Ir519
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir526
HTM

M7:M8:Ir526
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir527
HTM

M7:M8:Ir527
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir529
HTM

M7:M8:Ir529
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir530
HTM

M7:M8:Ir530
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir531
HTM

M7:M8:Ir531
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir532
HTM

M7:M8:Ir532
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir533
HTM

M7:M8:Ir533
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir534
HTM

M7:M8:Ir534
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir536
HTM

M7:M8:Ir536
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir538
HTM

M7:M8:Ir538
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir543
HTM

M7:M8:Ir543
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir556
HTM

M7:M8:Ir556
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir557
HTM

M7:M8:Ir557
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir562
HTM

M7:M8:Ir562
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir563
HTM

M7:M8:Ir563
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir570
HTM

M7:M8:Ir570
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir571
HTM

M7:M8:Ir571
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Ir572
HTM

M7:M8:Ir572
HBM2
ETM1:ETM2



220 nm

(65%:30%:5%)
10 nm
(50%:50%)





25 nm

30 nm


D-Pt(LH43)
HTM

M7:M8:Pt(LH43)
HBM2
ETM1:ETM2



220 nm

(60%:30%:10%)
10 nm
(50%:50%)





30 nm

30 nm


D-Pt(LH45)
HTM

M7:M8:Pt(LH45)
HBM2
ETM1:ETM2



220 nm

(60%:30%:10%)
10 nm
(50%:50%)





30 nm

30 nm







Blue OLEDs












D-Ir-B1
HTM
EBM
M1:M4:Ir-B1
HBM1
ETM1:ETM2



180 nm
10 nm
(60%:35%:5%)
10 nm
(50%:50%)





25 nm

20 nm


D-Ir-B2
HTM
EBM
M10:M4:Ir-B2
HBM1
ETM1:ETM2



180 nm
10 nm
(45%:45%:10%)
10 nm
(50%:50%)





25 nm

20 nm


D-Ir(LH23)3
HTM
EBM
M10:M4:fac-Ir(LH23)3
HBM1
ETM1:ETM2



180 nm
10 nm
(45%:45%:10%)
10 nm
(50%:50%)





25 nm

20 nm


D-Ir(LH25)3
HTM
EBM
M10:M4:fac-Ir(LH25)3
HBM1
ETM1:ETM2



180 nm
10 nm
(45%:45%:10%)
10 nm
(50%:50%)





25 nm

20 nm


D-Ir(LH40)3
HTM
EBM
M1:M4:Ir(LH40)3
HBM1
ETM1:ETM2



180 nm
10 nm
(60%:35%:5%)
10 nm
(50%:50%)





25 nm

20 nm


D-Ir561
HTM
EBM
M1:M4:Ir561
HBM1
ETM1:ETM2



180 nm
10 nm
(60%:35%:5%)
10 nm
(50%:50%)





25 nm

20 nm


D-Pt(LH44)
HTM
EBM
M10:M4:Pt(LH44)
HBM1
ETM1:ETM2



180 nm
10 nm
(45%:45%:10%)
10 nm
(50%:50%)





25 nm

20 nm


D-Pt(LH46)
HTM
EBM
M10:M4:Pt(LH46)
HBM1
ETM1:ETM2



180 nm
10 nm
(45%:45%:10%)
10 nm
(50%:50%)





25 nm

20 nm


D-Pt(LH47)
HTM
EBM
M10:M4 Pt(LH47)
HBM1
ETM1:ETM2



180 nm
10 nm
(45%:45%:10%)
10 nm
(50%:50%)





25 nm

20 nm


D-Ir(LH51)
HTM
EBM
M10:M4:Ir(LH51)
HBM1
ETM1:ETM2



180 nm
10 nm
(45%:45%:10%)
10 nm
(50%:50%)





25 nm

20 nm


D-Ir(LH52)
HTM
EBM
M10:M4:Ir(LH52)
HBM1
ETM1:ETM2



180 nm
10 nm
(45%:45%:10%)
10 nm
(50%:50%)





25 nm

20 nm
















TABLE 2







Results of the vacuum-processed OLEDs












EQE (%)
Voltage (V)
CIE x/y



Ex.
1000 cd/m2
1000 cd/m2
1000 cd/m2










Orange - red OLEDs















LT80 (h)






1000 cd/m2


D-IrR1
13.2
2.9
0.67/0.33
13000


D-IrR2
19.1
3.2
0.66/0.35
23000


D-IrR3
15.1
3.3
0.68/0.31
 8000


D-Ir(LH4)3
18.5
3.1
0.69/0.30



D-Ir(LH9)3
19.6
3.0
0.65/0.34
17000


D-Ir(LH10)3
18.9
3.1
0.69/0.30



D-Ir(LH26)3
18.5
3.0
0.69/0.30
19000


D-Ir(LH27)3
18.4
3.0
0.69/0.30
18000


D-Ir(LH32)3
18.9
3.2
0.70/0.30
18000


D-Ir(LH33)3
19.2
3.1
0.64/0.35
14000


D-Ir(LH61)3
18.0
3.0
0.70/0.30
21000


D-Ir503
19.3
3.0
0.64/0.35
22000


D-Ir509
19.5
3.1
0.64/0.35
23000


D-Ir516
17.1
3.1
0.63/0.36



D-Ir517
17.4
3.2
0.65/0.34
11000


D-Ir520
17.2
3.1
0.63/0.36
18000


D-Ir521
17.8
3.1
0.63/0.36
18000


D-Ir522
18.2
3.1
0.63/0.36
20000


D-Ir523
18.0
3.0
0.66/0.33
22000


D-Ir524
19.3
3.0
0.65/0.34
21000


D-Ir539
19.5
3.1
0.66/0.34



D-Ir547
18.9
3.0
0.67/0.31
20000


D-Ir548
19.5
3.0
0.68/0.32
22000


D-Ir554
 19.688
3.0
0.64/0.35
19000







Yellow OLEDs











D-Ir-Y1
19.6
2.8
0.39/0.62
35000


D-Ir-Y2
22.1
2.9
0.44/0.56
34000


D-Ir(LH6)3
23.7
3.0
0.47/0.52
38000


D-Ir(LH8)3
21.3
3.0
0.45/0.55



D-Ir505
23.9
2.9
0.44/0.55
41000


D-Ir508
22.6
3.0
0.59/0.38



D-Ir537
22.1
2.9
0.46/0.52
40000







Green OLEDs











D-Ir-G1
18.1
3.3
0.32/0.64
 7000


D-Ir-G2
19.2
3.2
0.35/0.62
16000


D-Ir-G4
16.3
3.7
0.34/0.63
 600


D-Ir-G4b
14.6
5.8
0.34/0.63
 160


D-Ir(LH1)3
23.3
3.2
0.33/0.64
18000


D-Ir(LH1)3
22.9
3.3
0.36/0.61
16000


D-Ir(LH3)3
24.1
3.3
0.35/0.62
20000


D-Ir(LH7)3
23.7
3.3
0.34/0.64
21000


D-Ir(LH16)3
24.3
3.3
0.35/0.63
24000


D-Ir(LH35)3
22.8
3.2
0.33/0.64
22000


D-Ir(LH36)3
23.4
3.2
0.33/0.65
25000


D-Ir(LH41)3
24.5
3.3
0.35/0.62
25000


D-Ir(LH42)3
24.3
3.3
0.35/0.61
24000


D-Ir(LH49)3
20.7
3.4
0.41/0.56



D-Ir(LH57)3
22.3
3.3
0.34/0.64
21000


D-Ir(LH58)3
23.0
3.2
0.32/0.65
23000


D-Ir(LH59)3
22.9
3.3
0.34/0.63



D-Ir(LH60)3
21.4
3.3
0.39/0.58



D-Ir500
23.3
3.2
0.33/0.63
22000


D-lr501
24.0
3.1
0.35/0.62
27000


D-Ir502
23.9
3.2
0.33/0.63
20000


D-Ir506
24.0
3.1
0.33/0.63
20000


D-Ir507
22.8
3.2
0.38/0.59
20000


D-Ir510
23.3
3.3
0.39/0.58
18000


D-Ir511
24.1
3.2
0.34/0.63
23000


D-Ir519
23.1
3.4
0.18/0.53



D-Ir526
24.4
3.2
0.34/0.63
23000


D-Ir527
24.5
3.2
0.34/0.62
24000


D-Ir529
24.3
3.2
0.33/0.63
25000


D-Ir530
24.2
3.2
0.33/0.63
24000


D-Ir531
24.4
3.2
0.33/0.63
25000


D-Ir532
24.6
3.2
0.33/0.63
23000


D-Ir533
24.5
3.1
0.35/0.62
26000


D-Ir534
24.1
3.2
0.33/0.63



D-Ir536
24.4
3.2
0.33/0.62
25000


D-Ir538
24.0
3.2
0.35/0.61
24000


D-Ir543
24.3
3.3
0.33/0.63
25000


D-Ir556
22.8
3.2
0.33/0.62
22000


D-Ir557
23.9
3.2
0.33/0.62
22000


D-Ir562
24.0
3.3
0.33/0.63
25000


D-Ir563
24.3
3.3
0.33/0.63



D-Ir570
23.9
3.2
0.33/0.62
20000


D-Ir571
24.1
3.2
0.34/0.62
22000


D-Ir572
20.4
3.3
0.26/0.51



D-Pt(LH43)
19.9
3.2
0.35/0.61
16000


D-Pt(LH45)
20.9
3.2
0.35/0.61
18000







Blue OLEDs















LT50 (h)






1000 cd/m2


D-Ir-B1
16.1
4.9
0.18/0.37
 1100


D-Ir-B2
 3.0
5.2
0.16/0.07
  60


D-Ir(LH23)3
 9.4
5.4
0.15/0.17
 100


D-Ir(LH25)3
 6.5
5.9
0.15/0.11



D-Ir(LH40)3
21.9
4.1
0.15/0.26
 500


D-Ir561
21.0
4.3
0.16/0.29
 700


D-Pt(LH44)
19.5
3.5
0.18/0.38
16000


D-Pt(LH46)
12.5
5.3
0.16/0.25



D-Pt(LH47)
12.1
5.1
0.16/0.26



D-Ir(LH51)
13.9
5.1
0.15/0.23



D-Ir(LH52)
14.4
5.0
0.15/0.22











2) Solution-Processed Devices:


A: From Soluble Functional Materials


The iridium complexes according to the invention can also be processed from solution, where they result in OLEDs which are significantly simpler as far as the process is concerned, compared with the vacuum-processed OLEDs, with nevertheless good properties. The production of components of this type is based on the production of polymeric light-emitting diodes (PLEDs), which has already been described many times in the literature (for example in WO 2004/037887). The structure is composed of substrate/ITO/PEDOT (80 nm)/interlayer (80 nm)/emission layer (80 nm)/cathode. To this end, use is made of substrates from Technoprint (soda-lime glass), to which the ITO structure (indium tin oxide, a transparent, conductive anode) is applied. The substrates are cleaned with DI water and a detergent (Deconex 15 PF) in a clean room and then activated by a UV/ozone plasma treatment. An 80 nm layer of PEDOT (PEDOT is a polythiophene derivative (Baytron P VAI 4083sp.) from H. C. Starck, Goslar, which is supplied as an aqueous dispersion) is then applied as buffer layer by spin coating, likewise in the clean room. The spin rate required depends on the degree of dilution and the specific spin coater geometry (typically for 80 nm: 4500 rpm). In order to remove residual water from the layer, the substrates are dried by heating on a hotplate at 180° C. for 10 minutes. The interlayer used serves for hole injection, in this case HIL-012 from Merck is used. The interlayer may alternatively also be replaced by one or more layers, which merely have to satisfy the condition of not being detached again by the subsequent processing step of EML deposition from solution. In order to produce the emission layer, the emitters according to the invention are dissolved in toluene together with the matrix materials. The typical solids content of such solutions is between 16 and 25 g/l if, as here, the typical layer thickness of 80 nm for a device is to be achieved by means of spin coating. The solution-processed devices of type 1 comprise an emission layer comprising (polystyrene):M5:M6:Ir(LH)3 (20%:35%:35%:10%) and those of type 2 comprise an emission layer comprising (polystyrene):M5:M6:Ir(LH6)3:Ir(LH)3 (20%:25%:40%:10%:5%). The emission layer is applied by spin coating in an inert-gas atmosphere, in the present case argon, and dried by heating at 130° C. for 30 min. Finally, a cathode is applied by vapour deposition from barium (5 nm) and then aluminium (100 nm) (high-purity metals from Aldrich, particularly barium 99.99% (Order No. 474711); vapour-deposition equipment from Lesker, inter alia, typical vapour-deposition pressure 5×10−6 mbar). Optionally, firstly a hole-blocking layer and then an electron-transport layer and only then the cathode (for example Al or LiF/Al) can be applied by vacuum vapour deposition. In order to protect the device against air and atmospheric moisture, the device is finally encapsulated and then characterised. The OLED examples given have not yet been optimised, Table 4 summarises the data obtained.









TABLE 3







Results with solution-processed materials













Emitter
EQE (%)
Voltage (V)

LT50 (h)


Ex.
Device
1000 cd/m2
1000 cd/m2
CIE x/y
1000 cd/m2










Orange and red OLEDs












Sol-D-Ir-R2
Ir-R2
18.8
3.6
0.67/0.33
 20000



Type 2






Sol-D-Ir(LH28)3
Ir(LH28)3
18.8
3.9
0.65/0.35
150000



Type 1






Sol-D-Ir(LH29)3
Ir(LH29)3
19.5
3.7
0.61/0.38




Type 1






Sol-D-Ir(LH30)3
Ir(LH30)3
19.1
3.7
0.69/0.30
180000



Type 2






Sol-D-Ir(LH31)3
Ir(LH31)3
19.5
3.6
0.68/0.31




Type 1






Sol-D-Ir(LH34)3
Ir(LH34)3
19.9
3.7
0.65/0.35




Type 1






Sol-D-Ir518
Ir518
17.1
3.7
0.70/0.30




Type 1






Sol-D-Ir523
Ir523
19.1
3.8
0.64/0.35
160000



Type 2






Sol-D-Ir525
Ir525
19.8
3.8
0.63/0.36




Type 2






Sol-D-Ir549
Ir549
19.5
3.8
0.65/0.35




Type 2






Sol-D-Ir550
Ir550
19.0
3.9
0.62/0.35
170000



Type 2






Sol-D-Ir551
Ir551
20.0
3.8
0.67/0.33
200000



Type 2






Sol-D-Ir552
Ir552
19.7
3.9
0.68/0.32




Type 2






Sol-D-Ir553
Ir553
20.0
3.9
0.68/0.32




Type 2






Sol-D-Ir555
Ir555
20.5
3.8
0.65/0.34




Type 2






Sol-D-Ir569
Ir569
20.2
3.8
0.65/0.33




Type 2






Sol-D-Ir602
Ir602
19.0
4.0
0.63/0.36




Type 2






Sol-D-Ir603
Ir603
18.1
3.9
0.66/0.33




Type 2






Sol-D-Ir700
Ir700
17.0
3.7
0.62/0.37




Type 2











Yellow OLEDs of type 1












Sol-D-Ir-Y3
Ir-Y3
19.7
3.9
0.48/0.49
120000


Sol-D-Ir(LH6)3
Ir(LH6)3
21.5
4.1
0.45/0.54
200000


Sol-D-Ir(LH11)3
Ir(L11)3
22.1
4.3
0.53/0.46



Sol-D-Ir(LH53)3
Ir(L53)3
21.0
4.3
0.44/0.54
140000


Sol-D-Ir(LH55)3
Ir(L55)3
21.2
4.4
0.43/0.55



Sol-D-Ir513
Ir513
22.4
4.2
0.44/0.55
250000


Sol-D-Ir541
Ir541
22.1
4.1
0.45/0.54



Sol-D-Ir558
Ir558
21.4
4.1
0.46/0.53



Sol-D-Ir560
Ir560
21.7
4.1
0.47/0.48



Sol-D-Ir566
Ir566
21.9
4.1
0.46/0.53



Sol-D-Ir608
Ir608
19.1
3.9
0.38/0.57



Sol-D-Ir609
Ir609
20.9
4.2
0.42/0.54



Sol-D-Ir701
Ir701
19.8
4.0
0.41/0.56
220000







Green - cyan OLEDs of type 1












Sol-D-Ir-G3
Ir-G3
18.8
4.4
0.33/0.63
100000


Sol-D-Ir-G5
Ir-G5
18.3
4.6
0.34/0.62
 3000


Sol-D-Ir-G6
Ir-G6
21.3
4.7
0.33/0.63
 27000


Sol-D-Ir-G7
Ir-G7
21.6
4.7
0.33/0.63
 60000


Sol-D-Ir(LH1)3
Ir(LH1)3
22.2
4.6
0.33/0.65
190000


Sol-D-Ir(LH5)3
Ir(LH5)3
22.7
4.7
0.33/0.64
220000


Sol-D-Ir(LH12)3
Ir(LH12)3
21.9
4.6
0.34/0.62



Sol-D-Ir(LH13)3
Ir(LH13)3
21.8
4.6
0.44/0.52
220000


Sol-D-Ir(LH15)3
Ir(LH15)3
22.1
4.6
0.34/0.61
200000


Sol-D-Ir(LH20)3
Ir(LH20)3
19.3
4.6
0.22/0.42



Sol-D-Ir(LH21)3
Ir(LH21)3
19.1
4.7
0.21/0.43



Sol-D-Ir(LH37)3
Ir(LH37)3
21.1
4.6
0.36/0.61
190000


Sol-D-Ir(LH38)3
Ir(LH38)3
21.6
4.6
0.35/0.63



Sol-D-Ir(LH39)3
Ir(LH39)3
21.3
4.6
0.37/0.61



Sol-D-Ir(LH54)3
Ir(LH54)3
21.6
4.6
0.34/0.63
200000


Sol-D-Ir(LH56)3
Ir(LH56)3
21.7
4.7
0.35/0.62
210000


Sol-D-Ir514
Ir514
22.3
4.5
0.34/0.63
210000


Sol-D-Ir515
Ir515
22.1
4.6
0.34/0.63



Sol-D-Ir528
Ir528
21.5
4.7
0.35/0.62



Sol-D-Ir535
Ir535
21.8
4.7
0.36/0.61



Sol-D-Ir540
Ir540
22.2
4.6
0.34/0.63



Sol-D-Ir542
Ir542
22.5
4.6
0.34/0.63



Sol-D-Ir545
Ir545
21.4
4.6
0.28/0.49



Sol-D-Ir546
Ir546
20.5
4.5
0.23/0.46



Sol-D-Ir564
Ir564
21.8
4.6
0.33/0.64



Sol-D-Ir565
Ir565
21.3
4.5
0.45/0.52



Sol-D-Ir567
Ir567
22.3
4.7
0.33/0.63
180000


Sol-D-Ir568
Ir568
21.5
4.6
0.45/0.52



Sol-D-Ir600
Ir600
20.2
4.5
0.34/0.64



Sol-D-Ir601
Ir601
20.0
4.6
0.35/0.63



Sol-D-Ir604
Ir604
19.8
4.6
0.23/0.46



Sol-D-Ir605
Ir605
21.8
4.6
0.33/0.63



Sol-D-Ir606
Ir606
20.9
4.5
0.23/0.46



Sol-D-Ir607
Ir607
19.9
4.5
0.35/0.62



Sol-D-Ir702
Ir702
20.8
4.6
0.45/0.52



Sol-D-Ir703
Ir703
20.3
4.6
0.33/0.63



Sol-D-Ir704
Ir704
19.7
4.4
0.32/0.62



Sol-D-Ir800
Ir800
16.1
4.3
0.16/0.35



Sol-D-Ir801
Ir801
16.7
4.5
0.17/0.40



Sol-D-Ir803
Ir803
19.2
4.5
0.17/0.38











B: From Polymeric Functional Materials:


Production of the OLEDs as described under A: For the production of the emission layer, the polymers according to the invention are dissolved in toluene. The typical solids content of such solutions is between 10 and 15 g/l if, as here, the typical layer thickness of 80 nm for a device is to be achieved by means of spin coating. The said OLED examples have not yet been optimised, Table 5 summarises the data obtained.









TABLE 4







Results with solution-processed materials













EQE (%)
Voltage (V)
CIE x/y


Ex.
Polymer
1000 cd/m2
1000 cd/m2
1000 cd/m2










Yellow OLEDs











D-P3
P3
20.1
3.7
0.42/0.57







Green OLEDs











D-P1
P1
20.5
4.0
0.33/0.61


D-P2
P2
20.6
4.1
0.32/0.63










3) White-Emitting OLED9


A white-emitting OLED having the following layer structure is produced in accordance with the general processes from 1):









TABLE 5







Structure of the white OLEDs















EML
EML
EML





HTL2
Red
Blue
Green
HBL
ETL


Ex.
Thickness
Thickness
Thickness
Thickness
Thickness
Thickness





D-W1
HTM
EBM:Ir521
M1:M4:Ir(LH40)3
M3:Ir(LH1)3
M3
ETM1:ETM2



230 nm
(97%:3%)
(65%:30%:5%)
(95%:5%)
10 nm
(50%:50%)




10 nm
8 nm
7 nm

30 nm
















TABLE 6







Device results












EQE (%)
Voltage (V)
CIE x/y
LT50 (h)


Ex.
1000 cd/m2
1000 cd/m2
1000 cd/m2
1000 cd/m2





D-W1
20.9
5.7
0.42/0.38
5000
















TABLE 7





Structural formulae of the materials used









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image










Claims
  • 1. A compound of formula (1): M(L)n(L′)m  formula (1)comprising a moiety M(L)n of formula (2):
  • 2. The compound of claim 1, wherein the CyC is selected from the group consisting of structures of formulae (CyC-1) through (CyC-19), wherein CyC is in each case bonded to CyD at the position denoted by # and coordinated to M at the position denoted by *:
  • 3. The compound of claim 1, wherein CyC is selected from the group consisting of structures of formulae (CyC-1a) through (CyC-19a), wherein CyC is in each case bonded to CyD at the position denoted by # and coordinated to M at the position denoted by *:
  • 4. The compound of claim 1, wherein the group of formula (3), when p is 2, is selected from the group consisting of structures of formulae (4-A) and (4-B) and, when p is 3, is selected from the group consisting of structures of formulae (5-A), (5-B), and (5-C):
  • 5. The compound of claim 4, wherein R1 in formulae (3), (4-A), (4-B), (5-A), (5-B), and (5-C) is, identically or differently on each occurrence, H, D, or an alkyl group having 1 to 5 C atoms, wherein one or more H atoms are optionally replaced by F and wherein two or more adjacent radicals R1 optionally define an aliphatic ring system with one another.
  • 6. The compound of claim 1, wherein the compound is selected from the group consisting of compounds of formulae (6) through (11):
  • 7. The compound of claim 2, wherein L′ is a monoanionic bidentate ligand which is bonded to M via a neutral nitrogen atom and a negatively charged carbon atom or via a neutral carbon atom and a negatively charged carbon atom.
  • 8. The compound of claim 7, wherein L′ is a combination of two groups selected from the group consisting of structures of formulae (27) through (50):
  • 9. A formulation comprising one or more compounds of claim 1 and at least one further compound.
  • 10. The formulation of claim 9, wherein the at least one further compound is a solvent.
  • 11. An electronic device comprising, in at least one layer, at least one compound of claim 1.
  • 12. The electronic device of claim 11, wherein the device is selected from the group consisting of organic electroluminescent devices, organic integrated circuits, organic field-effect transistors, organic thin-film transistors, organic light-emitting transistors, organic solar cells, organic optical detectors, organic photoreceptors, organic field-quench devices, light-emitting electrochemical cells, and organic laser diodes.
  • 13. The electronic device of claim 12, wherein the electronic device is an organic electroluminescent device and the compound of claim 1 is employed as an emitting compound in one or more emitting layers.
  • 14. The electronic device of claim 13, wherein the emitting layer comprises one or more matrix materials selected from the group consisting of ketones, phosphine oxides, sulfoxides, sulfones, triarylamines, carbazoles, indolocarbazoles, indenocarbazoles, azacarbazoles, bipolar matrix materials, silanes, azaboroles, boronic esters, diazasiloles, diazaphospholes, triazines, zinc complexes, dibenzofurans, and bridged carbazoles.
Priority Claims (1)
Number Date Country Kind
14000417 Feb 2014 EP regional
PCT Information
Filing Document Filing Date Country Kind
PCT/EP2015/000043 1/13/2015 WO 00
Publishing Document Publishing Date Country Kind
WO2015/117718 8/13/2015 WO A
US Referenced Citations (10)
Number Name Date Kind
20060014047 Takiguchi Jan 2006 A1
20070231600 Kamatani Oct 2007 A1
20110282059 Baranoff Nov 2011 A1
20120068170 Pflumm Mar 2012 A1
20130082209 Stoessel et al. Apr 2013 A1
20140070180 Choi et al. Mar 2014 A1
20150263297 Stoessel et al. Sep 2015 A1
20150318498 Stoessel et al. Nov 2015 A1
20150333280 Stoessel et al. Nov 2015 A1
20150349277 Stoessel et al. Dec 2015 A1
Foreign Referenced Citations (12)
Number Date Country
1023939296 Feb 2013 CN
2007269734 Oct 2007 JP
2008075043 Apr 2008 JP
2013531652 Aug 2013 JP
2014055131 Mar 2014 JP
2016507490 Mar 2016 JP
2016507491 Mar 2016 JP
2016508127 Mar 2016 JP
2011157339 Dec 2011 WO
2014008982 Jan 2014 WO
WO-2014094960 Jun 2014 WO
WO-2014094962 Jun 2014 WO
Non-Patent Literature Citations (7)
Entry
Lee et al., Highly Efficient Green-Emitting Electrophosphorescent Iridium Complexes with Enhanced Steric Hindrance, Journal of Nanoscience and Nanotechnology, 2009, 9, 7099-7103. (Year: 2009).
Lee et al., “Highly Efficient Green-Emitting Electrophosphorescent Iridium Complexes with Enhanced Steric Hindrance”, J. Nanosci. Nanotechnol., vol. 9, No. 12, pp. 7099-7103 (2009).
Stoessel et al., “Transition metal cyclometalated 2-arylbenimidazole complexes as blue phosphorescent materials for organic light-emitting devices”, Chemical Abs. Service, 2011. XP002736158.
Stoessel et al., “Metal complexes with heterocyclic ligands and their preparation and use in electronic devices”, Chemical Abs. Service, 2014. XP002736159.
Lee et al., “Highly efficient green-emitting electrophosphorescent iridium complexes with enhanced steric hindrance”, Chemical Abs Service, 2009. XP002736160.
Office Action dated Sep. 7, 2018 in Japanese Patent Application No. 2016-550250 (4 pages).
Office Action dated Sep. 20, 2018 in Taiwanese Patent Application No. 104103451 (7 pages).
Related Publications (1)
Number Date Country
20170170413 A1 Jun 2017 US